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PREFACE 
 Why did we write this monograph, what are its contents, what is new, who is the intended 
audience, and how will readers benefit from it? 
Motivation 
 Non-communicable diseases have overtaken communicable diseases as the leading cause of 
global mortality.  There are myriad reasons for this trend.  As this monograph shows, the main reasons 
center around the implementation and inadequate regulation of modern technology in our economy.   
 Far more attention is given to "treatment" of these diseases than to prevention.  Discovery of new 
treatments for serious diseases, while both interesting and challenging, is presently insufficient to reverse 
or eliminate most non-communicable diseases.  Eliminating the actionable foundational causes of these 
diseases is at least as important as applying new treatments, if there is to be any hope for full or partial 
reversal of non-communicable diseases. 
 Toward that end, the first author developed a holistic medical principle that would form the 
bedrock of a healing protocol for diseases: At the present time, removal of cause is a necessary, but not 
necessarily sufficient, condition for restorative treatment to be effective (where "removal" encompasses 
"neutralization" in those cases where actual "removal" is not possible, and "restoration" encompasses 
restoration of health to the organ/tissue as well as restoration of function).  To prevent disease, the 
actionable foundational causes that underlie the disease symptoms need to be identified and removed as 
comprehensively, thoroughly, and rapidly as possible.  To reverse disease (if irreversible damage has not 
been done and genetic predisposition is not a dominant factor), the preventive steps above need to be 
implemented as well.  If the preventive protocols are inadequate for reversing disease progression, they 
need to be augmented by treatments.  The first step in either disease prevention or reversal is to identify 
the full spectrum of potential foundational causes, or contributing factors, for the disease(s) of interest. 
 It also became evident that much of the information required to identify and eliminate these 
foundational causes of disease is in the literature already, but is not being extracted and exploited 
adequately.  There is little financial incentive for much of the researcher and clinician community to focus 
on eliminating causes relative to instituting new treatments.  Additionally, the biomedical literatures for 
diseases such as Alzheimer's Disease (AD) are large, and extracting these AD foundational causes 
comprehensively from the literatures is a complex text mining problem.   
 About five years ago, the first author started a series of proof-of-principle demonstrations to show 
that foundational causes (and treatments) could be identified comprehensively and efficiently for single 
diseases using a novel text mining approach.  The initial application focused on preventing and treating 
chronic kidney disease (CKD).  The next application broadened the perspective by identifying potential 
contributing factors to ~4000 diseases that had a threshold level of commonality; i.e., those contributing 
factors/causes that could be viewed as "pervasive".  The book that resulted from this comprehensive study 
provided insights not possible from examining one disease only. 
 Based on the insights and lessons learned from these two initial studies, it was decided to initiate 
a larger detailed study on a single disease.  AD was selected because of 1) its debilitating nature, 2) 
projected increased prevalence due to an aging population, and 3) potentially increased future incidence 
because of the poorly regulated introduction of new technologies that have exhibited adverse effects on 
some AD surrogate endpoints.  The study focusing on identifying potential AD foundational contributing 
factors is the subject of the present monograph.  A monograph was selected as the communication vehicle 
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rather than a series of journal papers, since separate journal publications would have fragmented the text 
mining and biomedical results, and would have greatly decremented the value of an integrated 
interdisciplinary presentation.  Producing a monograph allowed a full exposition and integration of the 
study's results and conclusions, not constrained by journal limitations. 
Contents 
 The overall theme of this monograph is preventing and reversing AD based on the following 
holistic medical principle: At the present time, removal of cause is a necessary, but not necessarily 
sufficient, condition for restorative treatment to be effective.  The specific focus of this monograph is 
identifying, categorizing, and analyzing the foundational (tangible actionable) causes of AD, allowing 
these actionable causes to then be eliminated. 
 These AD foundational causes are based on analysis of many thousands of biomedical journal 
articles from the premier medical literature.  The AD foundational causes are categorized and analyzed by 
discipline, as well as by the underlying main sources of these causes. 
 There is a lengthy section describing the text mining/information technology advances that 
allowed the AD foundational causes to be extracted efficiently from the large numbers of biomedical 
journal articles retrieved. 
Novelty 
 While the individual direct AD foundational causes identified in this monograph are "known", in 
the sense that they exist scattered throughout the published literature, they have not been integrated 
previously to the extent they are integrated in this monograph.  The new "insights" in this monograph are:  
1) the sheer number of AD potential foundational causes that are possible;  
2) the sheer number of potential foundational causes that have to be eliminated for any person to prevent 
or reverse AD (assuming irreversible damage has not been done or overwhelming genetic predisposition 
is not operable);  
3) the sheer number of potential combinations of AD foundational causes that have to be identified and 
researched (many of whose individual components have not yet been identified); and  
4) the depth to which each potential AD foundational cause must be eliminated for AD prevention or 
reversal to occur. 
 Most papers addressing chronic disease take the form: here's a symptom(s); here's what my drug 
can do to suppress that symptom(s); and here are some of the other symptoms that can arise as a result of 
my drug.  They are using a 22-caliber handgun for a problem that requires a howitzer! 
Audience 
 There are two communities to whom this monograph is targeted.  First is the "AD prevention and 
reversal" community.  This encompasses the public health community, the AD research community, 
medical practitioners involved clinically with AD prevention and reversal, and individuals interested in 
what the present approach has to offer (they should heed the warnings in the Disclaimer).  The AD 
foundational cause taxonomies and discussions in Chapters 3 and 8 should be of particular interest to this 
community.   
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 Second is the text mining and information technology community.  This would cover the full 
spectrum of researchers interested in extraction of useful information from any type of text, since the 
techniques developed in this monograph can be readily adapted to extracting useful information from 
myriad types of text.  The concepts, algorithms, and discussions in Chapters 2 and 7 should be of special 
interest to this community. 
Benefits 
 The interested reader will gain a deeper understanding of the main causative factors that drive 
AD, and will also gain an understanding of the broad spectrum of rigorous actions required to prevent 
and/or reverse AD.  The reader will be able to see why there are no "magic bullets" to prevent or reverse 
AD, and will be able to understand why motivation, discipline, and hard work are required to achieve, or 
regain, good health.  Finally, the motivated reader will see that much of what is required to reverse AD 
may potentially be available in the here and now, for selected individuals! 
 
Ronald N. Kostoff, 15 April 2017, Gainesville, VA 
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EXECUTIVE SUMMARY 
ES-1. Overview 
 Recent small-scale clinical results by Dr. Dale Bredesen (UCLA) have shown that reversal of 
cognitive decline in patients with early Alzheimer's Disease (AD) or its precursors, MCI (mild cognitive 
impairment) and SCI (subjective cognitive impairment), is obtainable today [1, 2].  These results were 
generated by 1) eliminating a modest number of actionable foundational causes/contributing factors 
(tangible causes over which one has some control, such as poor diet, lack of exercise, use of recreational 
drugs, etc) in selected patients, 2) increasing health-promoting practices (e.g., adequate sleep, adequate 
exercise, stress-reduction practices, etc), and 3) providing myriad supplements to bring selected metabolic 
parameters into targeted ranges [1, 2].   
 His approach is founded on the assumptions that AD/dementia symptoms 1) are driven mainly by 
external factors, and 2) can be prevented/reversed by elimination of these external factors (excluding 
those cases where genetic deficiencies are overwhelming or irreversible damage has been done), possibly 
supplemented by other therapies.  If assumptions 1 and 2 are correct, then the effectiveness of this 
approach will be limited by the comprehensiveness of external factors that have been identified, 
addressed, and eliminated. 
               Our goal is to overcome these limitations by identifying as many of these external factors as 
possible.  Towards that end, we have developed a novel information technology approach that selects 
those biomedical literature articles identifying potential AD/dementia foundational contributing factors.  
The approach is based on the following holistic medical principle: At the present time, removal of cause 
is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective.   
 To prevent AD (or any chronic disease), the foundational causes that underlie the AD symptoms 
need to be identified and removed as comprehensively, thoroughly, and rapidly as possible. To reverse 
AD (if irreversible damage has not been done and strong genetic predisposition is not a dominant factor), 
the preventive steps above need to be implemented, and treatments to reverse AD progression (if 
necessary) need to be applied.   
 The first step in either AD prevention or reversal protocols is to identify the full spectrum of 
potential foundational causes (or contributing factors) for AD.  These contributions are either direct (the 
biomedical literature source article states the factor(s) contributes to AD/dementia) or indirect (the theme 
of the biomedical literature source article is AD/dementia, and the article states the factor(s) contributes to 
a surrogate endpoint of AD/dementia (e.g., tau hyperphosphorylation, neurofibrillary tangles, cognitive 
decline, amyloid-beta peptide (Abeta) generation)). 
ES-2. General Results 
 We have applied our novel methodology to the Medline database, and identified ~400-600 
potential contributing factors (the exact number depending on how these contributing factors are 
aggregated) to AD/dementia.  This represents an order of magnitude more AD potential actionable 
contributing factors than we have seen in any AD/dementia article in the published literature.  We have 
generated a hierarchical taxonomy consisting of five broad categories at the top level (Lifestyle, 
Iatrogenic, Biotoxic, Occupational/Environmental, Psychosocial/Socioeconomic) to categorize these 
potential AD foundational causes.  These categories and their sub-categories cover a far wider range of 
potential AD causes than those used by Bredesen in his study, or any other published study related to 
potential AD contributing factors.  We have also shown the linkages between AD contributing factors and 
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their impacts on four discrete areas relevant to the disease: 1) cellular-level mechanisms; 2) biomarkers; 
3) performance; and 4) AD precursor diseases. 
               Because of potential synergies among these myriad factors, we believe as many potential AD 
contributing factors as possible (applicable to any individual) must be eliminated as thoroughly and 
rapidly as possible in order to achieve maximal results.  We do not exclude supplements or drug (or other) 
therapies in conjunction with comprehensive potential AD cause elimination.  We hypothesize that the 
need for these other therapies may be reduced, or perhaps even eliminated, if comprehensive potential AD 
cause elimination is successful.  In other words, we do not exclude the possibility that the metabolic 
deficiencies addressed by Bredesen through providing supplements could be reduced or eliminated by 
removing a wider range of potential AD contributing factors! 
ES-3. Specific Results 
 A. Lifestyle AD contributing factors include:  
-excessive fat, salt, sugar, refined carbohydrates, calories, and meat, along with high temperature cooking;  
-deficient vitamin and mineral-laden fruits, vegetables, and fatty fish; 
-sedentary lifestyle and cognitive inactivity;  
-inadequate sleep;  
-substance abuse (cocaine, amphetamines/MDMA, phencyclidine, opioids, excessive smoking and 
alcohol).   
 B. Iatrogenic AD contributing factors include: drug side-effects, radiotherapy side effects, 
surgical complications, and diagnostics side-effects. 
 Drugs that produce AD-related side-effects include: anti-neoplastic agents, cardiovascular agents, 
the massive category of central nervous system agents, hematologic agents, steroids/hormones, 
antihypertensive agents, and gastrointestinal agents.  
 Radiotherapy involving the brain region was a contributing factor to cognition problems and AD. 
 Surgeries that produce AD-related side-effects tend to involve vessel occlusion, cerebral 
ischemia, broader cardiac surgery, estrogen depletion, and myriad forms of dialysis.  Since inhalation 
anesthesia seems to be a strong AD contributing factor, almost any major surgery employing this type of 
anesthesia would have to involve some potential risk for AD.   
 Diagnostics that could have been assigned to this category were placed in other more 
phenomenon-based categories; e.g., dental x-rays were placed under Radiation, and other diagnostic 
procedures requiring sedation were placed under Anesthetics.  More broadly, reference [3] implies that 
people who experience high doses of ionizing radiation to the brain (such as from CT scans in that general 
region) can end up with cognitive dysfunction. 
 C. Biotoxic contributing factors reflect mainly the biological substances to which we are exposed 
naturally, but sometimes accidentally, and sometimes by design.  This category is divided into five sub-
categories: Mycotoxins; Exotoxins; Bacteria/Fungi/Parasites; Viruses; Other.  Biotoxins contributing to 
AD include: 
Prevention and Reversal of Alzheimer's Disease               Copyright © 2017               Ronald N. Kostoff et al 
 
11 
 
-some mycotoxins (e.g., ochratoxin A, Fumonisin B1, macrocyclic trichothecenes, etc); 
-many exotoxins (e.g., excitotoxins, phosphatase inhibitors, excitatory amino acids, cyanobacteria, 
saporins, mitochondrial inhibitors);  
-large numbers of bacteria, fungi, and parasites; 
-large numbers of viruses;  
-plant-based contributing factors (e.g., 12-myristate 13-acetate, Forskolin, arecoline hydrobromide, 
quisqualate, etc); 
-a very substantial number of endogenous substances that were administered exogenously (e.g., 27-
hydroxycholesterol, acetylcholinesterase, Bradykinin, CD40, etc).   
 D. Occupational/Environmental contributing factors include:  
-Industrial and Household Chemicals  
--hydrocarbons (e.g. methylcholanthrene, polycyclic aromatic hydrocarbons, diesel fuel, kerosene, etc,); 
--solvents (e.g. petroleum-based solvents, chlorinated solvents, organic solvents, etc);  
--many other chemicals that emphasize chlorine, bromine, nitrogen, sodium, sulfur, and carbon 
compounds. 
-Materials 
--heavy metals (e.g., aluminum, arsenic, cadmium, cobalt, copper, iron, lead, manganese, mercury, 
selenium, zinc, manganese, etc); 
--particulates (e.g., air pollution, surgical smoke, dust, etc); 
--nanoparticles (e.g., iron nanoparticles, titanium dioxide nanoparticles, CdSe quantum dots, diesel 
exhaust nanoparticles, alumina nanoparticles, manganese oxide nanoparticles, copper nanoparticles, 
silicon dioxide nanoparticles, zinc oxide nanoparticles, silver nanoparticles, and nickel nanoparticles, etc). 
-Agricultural Chemicals 
--pesticides/herbicides/insecticides (e.g. Organochlorine Pesticides, Organophosphate Pesticides, 2,4,5-
trichlorophenoxyacetic acid, 2,4-Dichlorophenoxyacetic Acid, Agent Orange, Aldrin, 
Alkylphenolpolyethoxylates, APEOs, Arsenic, Beta-hexachlorocyclohexane/beta-HCH, Bipyridyles, 
Carbamates, Carbofuran, Chlorfenvinphos, Chlorpyrifos/CPF, Cycloheximide, Cypermethrin, 
Deltamethrin, Dichlorodiphenyldichloroethylene/DDE, Dichlorodiphenyltrichloroethane/DDT, 
Dichlorodiphenyldichloroethane/DDD, Dieldrin, Dimethyl parathion, Endosulfan, Famoxadone, 
Fenamidone, Glyphosate, Hexachlorobenzene, Hexachlorocyclohexane/HCH, Imidacloprid, Lindane, 
Maneb, Methamidophos, Methyl parathion, Neonicotinoids, Nonylphenol, Octylphenol, Paraquat, 
Parathion, Pyraclostrobin, Pyrethroids, Trans-nonachlor, Trichlorfon/TCF, Trifloxystrobin, etc).  
-Electromagnetic Radiation 
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--ionizing (e.g., gamma radiation (dental X-rays, gamma rays, etc), particle radiation (56Fe-particle 
radiation, cosmic radiation, HZE particle radiation), radionuclide pollutants (uranium, cesium, cobalt, 
radon), etc); 
--non-ionizing non-visible (e.g., electromagnetic fields at myriad frequencies, such as extremely low 
frequency/ELF-EMF, 900 MHz radiofrequency (RF), electromagnetic pulse/EMP, electroconvulsive 
shock/ECS, UV irradiation, etc);  
--non-ionizing visible (UV irradiation, photolysis of 1-(2-nitrophenyl)ethyl sulfate, etc).  
-Sound (e.g. short-lasting impulse noise, chronic noise exposure, night-time aircraft noise, ultrasound 
sonication, etc).  
-Temperature (e.g. cold water hypothermia, cold water stress, heat shock, heat stress, heating, 
hyperthermia, etc.). 
-Force (e.g. blasts, blast traumatic brain injury, hippocampal injury, accumulated mechanical stress, spinal 
cord injury, frequent strong Valsalva maneuvers, long hours of repetitive heavy lifting, sequences of 
blows during the playing of a wind instrument, forceful and repetitive cough, bearing-down efforts during 
parturition, history of head trauma, etc). 
 E. Psychosocial/Socioeconomic contributing factors include: 
-Psychological 
--chronic stress (e.g., repeated stress, chronic mild stress, chronic psychological stress, multiple chronic 
stresses, behavioral stress, childhood trauma, bereavement, chronic restraint stress, high job stress, etc); 
--low mental activity (e.g., low cognitively engaging activity, low purposeful activities, low leisure 
activities/low hobbies, low music/drawing/meditation,  low reading/arts/crafts, etc). 
-Sociological 
--social isolation (e.g., isolation, loneliness, living alone, unmarried, maternal separation, low social 
activity index, low social support at work, constricted life space, etc); 
--low education (e.g., illiteracy, etc). 
 Genetic causes were not addressed in this monograph.  The main focus of the monograph is on 
potential AD foundational causes that are somewhat actionable (action could, at least in theory, be taken 
to attenuate, neutralize, or eliminate them).  It is difficult to modify a person's genetic endowment 
presently, although that may not be true in the future.  Genetic manipulation is in its infancy, and may 
some day be the treatment of choice for genetically-based diseases. 
ES-4. Underlying Sources of AD Foundational Causes 
 There appear to be five main underlying sources of the ~400-600 potential AD foundational 
causes: Direct Technology, Indirect Technology, Inadequate Regulation, Individual Choice, Poverty. 
 A. Direct Technology (the degree of direct impact of technology on the foundational cause) plays 
a strong role in Lifestyle, Iatrogenic, and Occupational/ Environmental AD foundational causes. In 
addition, through its impact on the immune and other critical systems, modern technology may play a role 
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in whether exposure to bacteria and viruses results in AD and its associated symptoms. Modern 
technology impacts the growing, processing, and preparation of foods, and many of the adverse effects 
identified in the present study can be traced back to the use (misuse) of technology in the food cycle. The 
Iatrogenic adverse effects of modern technology result mainly from the high-technology-based drugs, 
surgery, diagnostics, and therapy that characterize much of modern medicine today. The Occupational/ 
Environmental adverse effects result mainly from the employment of modern technology in 1) commerce, 
2) the environment, and 3) the workplace. 
 B. Indirect Technology reflects those adverse health-impacting behaviors enabled by Direct 
Technology. One example is reduced labor because of modern technology, leading to today's highly 
damaging sedentary lifestyle that contributes to myriad diseases, including AD. Another example is large 
numbers of people being able to live in inhospitable northern climates because of modern transportation, 
food logistics, clothing, and shelter. This results in less exposure to sunlight and less Vitamin D 
production, contributing to diseases (such as AD) related in part to Vitamin D deficiency. 
 C. Inadequate Regulation is coupled strongly to the introduction of high technology in all aspects 
of life. Many of the problems with foods derive from relatively unregulated chemicals, materials, and 
other contaminants entering the food supply during agriculture and animal husbandry. Many of the 
Occupational/Environmental exposures arise from relatively unregulated harmful substances entering the 
workplace and the environment, especially in less developed countries, but in more developed countries 
as well. Many of the Iatrogenic problems could be traced to drugs, diagnostics, therapies, and other 
procedures entering practice with insufficient front-end long-term testing, and inadequate evaluation of 
side-effects. 
 Two major aspects of Inadequate Regulation revolve around insufficient safety: inadequate safety 
data gathering, and inadequate safety testing. Much of the adverse impact data gathering tends to be from 
passive surveillance systems, where response rates can be an order of magnitude (or more) less than real-
world incidence rates. Pre-market testing, in many cases, suffers from inadequate sample sizes, 
unrepresentative samples, insufficient long-term testing, and insufficient combination testing to identify 
potential synergistic effects. Insufficient long-term testing on humans is particularly troubling, since many 
serious diseases such as AD may have decadal latency periods from specific toxic stimuli. 
Transgenerational effects cannot  be excluded without appropriate long-term testing.  Additionally, results 
from animal testing (which could be long-term from the perspective of many short-lived animals used in 
testing) do not necessarily translate to human outcomes. 
 D. Individual Choice reflects decisions by people to choose unhealthy diets, sedentary activities, 
recreational drugs, elective drugs and surgery, unhealthy occupations, unhealthy residential environments, 
unhealthy relationships, etc. There is the unwritten corollary assumption that people have adequate 
knowledge about the consequences of these choices, and there are no other major factors that limit their 
choices. For many people, this is a highly unrealistic assumption. They have very limited knowledge 
about the consequences of these choices, either through 
1) accurate information not being available, or 
2) apathy in searching out this information, or, as implied in [4, 5], 
3) being provided incorrect information. 
 E. Poverty limits individual choices about diet, occupations, and environment. Poverty plays 
strong direct and indirect roles in malnutrition and the resulting diseases of deficiency. By limiting access 
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to modern medicine and modern technology, poverty avoids some of the adverse impacts ascribed to 
modern technology presented above, but at the same time, denies many of the benefits available from 
modern medicine and modern technology. 
ES-5. Near-Term Implementation of Findings 
 To gain operational experience with exploiting the findings in this monograph, clinical trials 
should be started in the near future.  Given the limitations in knowing exposures to many potential AD 
contributing factors outlined above, these trials could start with incorporating the "low-hanging fruit" 
contributing factors that have been identified in the present study.  These are potential AD contributing 
factors that could be estimated or measured relatively easily.  Initial elimination of these contributing 
factors would include:  
1) curbing the dietary excesses identified and removing the dietary deficiencies identified:   
-reducing the amounts of fat, salt, sugar, refined carbohydrates, calories, and meat strongly, along with 
reducing high cooking temperatures;   
-increasing the amounts of vitamin and mineral-laden fruits, vegetables, and fatty fish  substantially, 
along with increasing sun exposure for enhanced Vitamin D;  
2) eliminating food additives to the extent knowable and possible, including those dietary excesses that 
derive from food additives (excessive fat, sugar, salt);  
3) reversing the sedentary behavior patterns identified, and increasing physical and mental activity;  
4) removing the foundational impediments to better sleep;  
5) eliminating the use of "recreational" drugs, including smoking and excessive alcohol;  
6) eliminating the use of elective (not absolutely necessary) medicinal drugs shown to be potential AD 
contributing factors; 
7) eliminating any elective (not absolutely necessary) diagnostic or surgical procedures that involve 
inhalational anesthetics or high doses of ionizing radiation in head region (e.g., CT scans); 
8) minimizing exposures to some hydrocarbons such as diesel exhaust, kerosene, polycyclic aromatic 
hydrocarbons (including those found in smoke), etc; 
9) minimizing exposures to some solvents, especially petroleum-based solvents, chlorinated solvents, and 
organic solvents;  
10) minimizing exposures to pesticides, herbicides, insecticides, and fungicides, both inhalation and 
ingestion exposures;  
11) minimizing exposures to heavy metals in food, water, and air; 
12) minimizing exposures to particulates, especially air pollution;  
13) minimizing exposures to ionizing radiation, non-ionizing non-visible radiation (e.g., cell phones, cell 
towers, WiFi, smart meters, etc), non-ionizing visible radiation (e.g., excessive UV radiation), sound 
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radiation (e.g., high noise levels), extreme temperature fields (e.g., cold water hypothermia/stress, heat 
shock/hyperthermia), and extreme force fields (e.g., high impacts, especially to head region); 
14) minimizing chronic stress (mental/emotional/psychological), increasing mental and meaningful 
leisure-time activities; 
15) minimizing social isolation. 
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Chapter 1 
INTRODUCTION 
1A. Overview 
 Alzheimer's Disease (AD) is a brain disease, and the most common form of dementia.  Currently, 
it affects those 65 years old and above overwhelmingly; incidence increases with age.  The prevalence of 
AD in the USA was approximately 4.7 million people in 2010, and is projected to increase to 5.8 million 
in 2020, 8.4 million in 2030, and 11.6 million in 2040 [1].  
 These projections may be strong under-estimates.  AD has an environmental component, and 
there have been many high-technology additions to the environment in the past few decades (e.g., 
wireless radiation, vaccines, agricultural chemicals, etc, have expanded greatly).  Because of latency 
delays, inadequate time has elapsed to show linkages between these environmental additions and changes 
in the incidence of AD in human populations.  As will be shown in the present study, the impact of, e.g., 
recent environmental and dietary additions on AD surrogate endpoints offers the possibility of 
extrapolation to increased incidence and prevalence of AD in the future. 
 The mainstream medical approach to treating AD has been centered around drug therapy mainly.  
How effective has it been?  Bredesen states: "In the case of Alzheimer’s disease, there is not a single 
therapeutic that exerts anything beyond a marginal, un-sustained symptomatic effect, with little or no 
effect on disease progression. Furthermore, in the past decade alone, hundreds of clinical trials have been 
conducted for AD, at an aggregate cost of billions of dollars, without success. This has led some to 
question whether the approach taken to drug development for AD is an optimal one [2]."  Bredesen is an 
AD researcher who has shown that "reversal of cognitive decline in patients with early Alzheimer's 
disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment)" is 
obtainable today [2].  Basing his approach on optimizing metabolic parameters, Bredesen used a 
combination of 1) eliminating potential AD contributing factors, 2) substituting positive health practices, 
and 3) adding dietary supplements to achieve his AD/MCI/SCI reversal results.  
 His approach can be viewed as one "footprint" of a more general holistic medical principle for 
preventing or reversing disease developed by the first author over the time period 2012-2017: At the 
present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative 
treatment of disease to be effective. To prevent AD, or any disease, the foundational causes that underlie 
the disease symptoms need to be identified and removed as comprehensively, thoroughly, and rapidly as 
possible. To reverse AD (if irreversible damage has not been done and strong genetic predisposition is not 
a dominant factor), the preventive steps above need to be implemented, and treatments to reverse 
progression (if necessary) need to be applied. The first step in both AD prevention and reversal protocols 
is to identify the full spectrum of potential AD foundational causes/contributing factors.  The remainder 
of the monograph takes this first step, and addresses the full spectrum of AD actionable contributing 
factors. 
1B. Structure of Monograph 
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 Chapter 6 contains the Background for the present study.  Chapter 2 presents a summary of the 
methodology used to obtain the results; the detailed methodology can be found in Chapter 7.  Chapter 3 
presents a summary of the findings; the detailed findings can be found in Chapter 8.  Chapter 4 presents 
the discussion and conclusions, and Chapter 5 contains suggested further research.  Chapter 9 presents the 
most highly cited AD/dementia papers, and implications of the patterns in those papers.  The references 
for each chapter will be presented at the end of each chapter. 
1C. References - Chapter 1 
[1] Alzheimer's Association.  2016 Alzheimer’s Disease Facts And Figures.  
http://www.alz.org/documents_custom/2016-facts-and-figures.pdf. 
[2] Bredesen DE. Reversal of cognitive decline: A novel therapeutic program. Aging. 2014;6(9):707-17.  
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Chapter 2 
SUMMARY METHODOLOGY 
2A. Overview 
 The methodology employed in this monograph identifies actionable foundational causes (tangible 
items over which we have some control, such as smoking, food additives, pesticides, etc) linked directly 
to AD, or indirectly through surrogate endpoints for AD (surrogate endpoints are early/intermediate 
markers thought to predict longer-term clinical benefit, and are used by the FDA to accelerate drug 
approval [1]).   
 Why is the surrogate endpoint concept used as part of the present study?  Direct links between 
potential contributing factors and AD are established through satisfying conditions such as Koch's 
Postulates, Bradford Hill criteria, or other causation criteria.  However, for diseases that emerge late in 
life, such as AD, linking potential causes/contributing factors to the disease directly could require many 
decades to validate potential causes that occur early in life.  Therefore, to avoid the enhanced risk of 
populations being exposed to potentially harmful substances for many decades while waiting for 
definitive links between the potential causes and AD to be demonstrated, identifying links between the 
potentially harmful substances and shorter-term/intermediate markers of AD (surrogate endpoints) could 
lead to precautionary risk mitigation. 
2B. Approach 
 Two overlapping approaches were used to identify potential AD contributing factors.  First, a 
complex query (see Chapter 7 for full query) focused on potential causes linked directly to AD (e.g., 
"increased risk for AD"), or linked to its surrogate endpoints (e.g., "produced  hyperphosphorylated tau", 
"accelerated neurofibrillary tangles", "caused cognitive decline", "induced amyloid beta", etc), was 
applied to the ~100,000 Medline articles that had Alzheimer* as a Title or MeSH term.  The ~5,000 most 
recently published articles were read by the first three authors to identify potential AD contributing 
factors.   
 Second, cause-related MeSH and text terms (e.g., "exposed", "induced", etc) were generated (see 
Chapter 7 for these full queries) that would link to MeSH and text representations of potential AD 
actionable foundational causes in the ~100,000 Medline articles (e.g., "nerve agent exposure", "smoking-
induced").  The potential AD foundational causes ("nerve agent", "smoking") would then be separated 
from the cause-related linking terms ("exposure", "-induced").  Both factors that linked directly to AD 
(e.g., "risk factor for AD") and to surrogate endpoints (e.g., "risk factor for tau hyperphosphorylation") 
were included.  Surrogate endpoints for AD additional to those used in the complex query of the previous 
paragraph were identified over the course of the study (e.g., "impaired BBB integrity", "induced 
neurotoxicity", "produced cholinergic hypofunction and tissue lesions"), and could be useful for future 
studies of this type. 
2C. References - Chapter 2 
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Chapter 3 
SUMMARY RESULTS 
3A. Overview 
 A hierarchical taxonomy consisting of six broad categories at the top level (Lifestyle, Iatrogenic, 
Biotoxic, Occupational/Environmental, Psychosocial/Socioeconomic, and Genetics) was generated to 
categorize the potential AD foundational causes.  Contents of the first five categories will be summarized 
in the present chapter, and will be analyzed in more detail in Chapter 8. 
 AD genetic causes were not addressed in the findings because the main focus of this monograph 
is on AD foundational causes that are (by definition) somewhat actionable (action could, at least in 
theory, be taken to attenuate, neutralize, or eliminate these types of causes). It is difficult to modify a 
person's genetic endowment at the present time, although that may not be true in the future. Genetic 
manipulation is in its infancy, and may someday be the treatment of choice for genetically-based diseases. 
 The Psychosocial/Socioeconomic top-level category has reasonable overlap with the Lifestyle 
category.  It has two major components: "causes" over which the individual has some control and are 
therefore "actionable" (e.g., low hobby time, low reading time, low music time, unmarried, urban living, 
etc), and causes over which the individual has little, if any, control (e.g., bereavement, early life stress, 
chronic unpredictable stress, etc).  A potential AD cause like "high job strain" could be in either category.  
It is Lifestyle to the extent that the job is an individual choice, and one could always leave.  But, that line 
of reasoning could be extended to other categories.  Many of the Iatrogenic adverse effects result from 
one's choosing to 1) take drugs electively or 2) undergo certain types of elective surgeries.  They could be 
categorized Lifestyle as well.  It was decided to treat Psychosocial/Socioeconomic as a separate category. 
3B. Under-Reporting of AD Foundational Causes 
 Chapter 9 of reference [1], and reference [2], contain many caveats showing why the numbers of 
AD foundational causes presented here may be vast under-representations of the numbers of AD 
operational foundational causes.  Summarily, many adverse events are not reported and published in the 
literature (e.g., see references 70-125 of reference [1]), or, if they are reported and published, many are 
not accessed due to inadequate search algorithms.  The under-reporting occurs at the patient, doctor, 
researcher, journal, corporate, and Federal agency levels, mainly because of myriad incentives (and few 
disincentives) for under-reporting.  See Chapter 9 of reference [1], or reference [2], for further examples. 
 Over-reporting cannot be excluded as well.  As is also shown in Chapter 9 of reference [1], and 
reference [2], there are strong publication pressures (especially in academia), and, depending on the 
nature of the foundational cause, a finding not warranted by the data could be rushed into publication. 
3C. Top-Level Taxonomy of AD Foundational Causes  
 Table 3-1 reflects the top-level categories of the AD foundational causes   taxonomy.  It is 
followed by a more detailed description of the contents in each of the categories listed in Table 3-1.  The 
three columns in Table 3-1 reflect categorization by type of foundational cause (Lifestyle, Iatrogenic, 
Biotoxic Agents, Occupational/Environmental Exposures, Psychosocial/Socioeconomic, and Genetics); 
category assignments are not unique.  The findings in the first five categories will now be summarized by 
sub-category; more detailed findings, categorizations, and supporting reference links are shown in 
Chapter 8.  
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TABLE 3-1  Taxonomy of AD Foundational Causes  
CATEGORY SUB-CATEGORY SUB-SUB-CATEGORY 
I.  
Lifestyle 
I-A. Diet I-A1. Dietary Excesses 
I-A2. Dietary Deficiencies 
I-A3. Food Additives 
I-B. Activity 
I-C. Substance Abuse 
II.  
Iatrogenic 
II-A. Drugs 
II-B. Radiotherapy 
II-C. Surgery/Invasive Procedures 
II-D. Diagnostic Agents/Procedures 
III.  
Biotoxic Agents 
III-A. Mycotoxins 
III-B. Exotoxins 
III-C. Bacteria/Fungi/Parasites 
III-D. Viruses 
III-E. Other 
IV. 
Occupational/ 
Environmental 
Exposures 
IV-A. Chemicals/ 
Materials 
IV-A1.  Industrial/Household Chemicals/Materials 
IV-A2.  Agricultural Chemicals 
IV-A3.  Materials 
IV-B. Physical/ 
Mechanical 
IV-B1.  Electromagnetic Radiation 
IV-B2.  Sound 
IV-B3.  Temperature 
IV-B4.  Force/Pressure/Physical Trauma 
IV-B5.  Other 
V. 
Psychosocial/ 
V-A. Psychological 
V-B. Sociological 
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Socioeconomic V-C. Economic 
VI. 
Genetics 
VI-A. Polymorphism/Genotypes/Haplotypes  
VI-B. Mutations  
VI-C. Linkages  
VI-D. Risk Alleles  
VI-E.  Genotoxicity  
VI-F.  Familial  
VI-G. Congenital  
 
I. Lifestyle 
 Lifestyle includes choices mainly under individual control, and is divided arbitrarily into Diet, 
Activity, Substance Abuse, Other. 
I-A. Diet 
 Poor diet reflects the adverse effects of excesses and deficiencies of dietary components.  It has 
been used to induce myriad diseases in test animals, and it was a critical disease factor from many 
epidemiological and case studies.   
I-A1. Dietary Excesses 
 Dietary excesses include high-calories, high-fat, high-sugar, high-salt, high-meet, high-refined 
carbohydrates, high advanced glycation end products (AGEs); high-cholesterol; high-iron; high 
arachidonic acid; high methionine; high copper; high zinc; high unfermented soy, and high-temperature 
cooking that results in harmful products (e.g., AGEs, nitrosamines, polycyclic aromatic hydrocarbons, 
and acrylamides). 
I-A2. Dietary Deficiencies 
 Many deficiencies listed in the literature may be symptoms of metabolic problems, not 
foundational causes in the present sense.  Thus, a Vitamin A deficiency may be caused by 1) insufficient 
Vitamin A intake (foundational cause), or 2) a metabolic problem that results in reduced Vitamin A levels 
(symptom).   
 Dietary deficiencies include low: vitamins, especially Vitamins B (B2, B6, B12, folate/folic acid, 
thiamine), C, D, E; minerals, especially potassium, iron, zinc, magnesium, calcium, selenium; calories 
(starvation, malnutrition, early life nutrient restriction); water (dehydration); glucose; glutathione; linoleic 
acid; docosahexaenoic acid; tryptophan; alcohol (nondrinkers); flavonoids/flavanols (cocoa, coffee, 
acacetin, aminogenistein, apigenin,  kaempferol, 7,8-Dihydroxyflavone, anthocyanins, atriplex laciniata 
L, curcumin, cyanidin, datiscetin, delphinidin, EGCG, epicatechin, Epimedium brevicornum, fisetin, 
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genistein, ginkgo, glycitein, icariin,  isoscutellarein 7-O-[6'''-O-acetyl-beta-D-allopyranosyl-(12)]-beta-D-
glucopyranoside, isovitexin, morin, myricetin, nobiletin, pelargonidin, phloridzin, rutin, salvigenin, 
Scutellaria baicalensis Georgi, Sideritis flavonoids, vitexin, xanthomicrol, luteolin, morin, PD98059, 
quercetin,  taxifolin, β-naphthoflavone); fruit (blackberries, blueberries, strawberries, raspberries, 
cherries, oranges, plums, prunes, red grapes, pomegranates, date palm fruits); vegetables, especially 
cruciferous, dark and green leafy; fatty fish. 
 A very clear message about the dietary contribution to AD can be extracted from the above 
picture of dietary excesses and deficiencies.  From the macro perspective, the amounts of fat, salt, sugar, 
refined carbohydrates, calories, and meat need to be reduced strongly, along with cooking at high 
temperatures, and the amounts of vitamin and mineral-laden fruits, vegetables, and fatty fish need to be 
increased substantially to reduce the risk of AD and perhaps contribute to reversal of AD. 
I-A3. Food Additives 
 Many food additives are accompanied by adverse effects, and these effects may be under-
diagnosed and under-researched.  Many of the excesses and deficiencies mentioned above are the result of 
substances being added to, or removed from, the fresh whole food.   
 Additives include cysteine, diacetyl, and monosodium glutamate.  Depending on how one defines 
'food additives', those additives with the widest impacts tend to include the major items listed under 
excesses above, such as fat, sugar, and salt.  These components are typically added to foods for taste 
enhancement, not nutritional improvement. 
I-B. Activity 
 The main sub-categories of Activity are exercise, sedentary lifestyle, and sleep.  The sedentary 
lifestyle, including low exercise, low physical activity, low daily gardening, low walking, chronic 
immobilization was mentioned quite often, and cognitive inactivity also received some mention. The 
resultant low cardiovascular fitness was also emphasized. 
 Circadian disruption and poor sleep/sleep deprivation were also mentioned, although the main 
foundational components of poor sleep would be 1) choosing to sleep less or 2) not practicing good sleep-
preparation habits.  Other contributing factors to poor sleep, such as excessive pain, anxiety, etc, may be 
less under one's control, and are not regarded as foundational under the present definition. 
I-C. Substance Abuse 
 Substance abuse includes 'recreational' drugs of all types (cocaine, methamphetamine, etc), and 
especially excessive cigarette smoking and alcohol. The main substance abuse contributing factors were 
1) recreational drugs (especially cocaine, amphetamines/3,4-Methylenedioxyamphetamine [MDMA - 
Ecstacy], phencyclidine, opioids) and 2) excessive smoking and alcohol.  The bulk of the studies 
identified mainly the recreational drugs' contributions to AD surrogate endpoints, such as 
neurodegeneration markers and cognitive dysfunction. 
 The individual AD foundational causes identified with Lifestyle are usually studied in isolation, 
and synergistic effects are typically not identified.  Given the number of Lifestyle component 
combinations that could potentially be synergistic, and adding in  
1) the foundational causes from the remaining categories (identified in Table 8-3) to the potential 
combinations, and  
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2) potential foundational causes that surface only when operating in synergy but which have not yet been 
identified in Table 8-3 as individual foundational causes, 
it is clear that only the tip of AD foundational causes iceberg is being identified in this study. 
II. Iatrogenic 
 Iatrogenic reflects diseases, symptoms, and injuries resulting from medical treatment, and is 
divided into four sub-categories: Drugs; Radiotherapy; Surgeries/Invasive Procedures; Diagnostic 
Agents/Procedures.  Iatrogenic is a substantial category, due mainly to the large numbers of drugs and 
surgeries that have side-effects and complications.  The main categories are presented in this section, and 
more detailed drugs and surgeries are presented in Table 8-3.  While the drug categories have some 
overlap, each drug in Table 8-3 is listed in one category only for purposes of brevity when populating the 
drug categories, 
 The more frequently drugs, radiotherapy, surgeries, or diagnostics are used, the more opportunity 
for side-effects and complications, and the more opportunity for publications describing these side-effects 
and complications.  This study does not provide an indication of how often such side-effects and 
complications would occur as a percentage of use. 
II-A. Drugs 
 There were eighteen major drug categories identified in Table 8-3.  Only those with substantial 
entries are discussed in Chapter 8, including anti-neoplastic agents, cardiovascular agents, the massive 
category of central nervous system agents, hematologic agents, steroids/hormones, antihypertensive 
agents, and gastrointestinal agents. 
 Table 8-3 does not show the effect of drug-drug combinations, or drug-other toxic agent 
combinations.  The effects of these combinations could be important, but might not surface in some types 
of studies.   
 A study on drug-drug combinations concluded that, of approximately 11,000 drug products on the 
US market, trillions of clinical trials would be required to provide an evidentiary basis of safety for all 
combinations of ten drugs [3] .  Even for all combinations of only three drugs, approximately one million 
clinical trials would be required to evaluate safety, or lack thereof, for all these possible three drug 
combinations.  These numbers go far beyond what is practical in real-world laboratory, clinical, and field 
studies. 
 Thus, there are many ways that 1) a drug shown to contribute to AD or its surrogate endpoints in 
isolation, when combined with two other drugs not shown to contribute to AD or its surrogate endpoints 
in isolation, could in aggregate have a much stronger contribution to AD or its surrogate endpoints, and/or 
2) three drugs that have been shown to have a modest contribution to AD in isolation, when combined, 
could in aggregate have a much stronger contribution to AD, and/or 3) three drugs that have been shown 
to have negligible contribution to AD in isolation, when combined, could in aggregate have a strong 
contribution to AD.  Even if there are small numbers for any one combination of three drugs, when they 
are aggregated over the one million potential combinations, this could add up to a large number of strong 
contributions.  This effect might not surface in any epidemiological study because 1) it would fall beneath 
the statistical radar screen, 2) temporal variation in the combinations would be difficult to assess, and 3) 
the numbers of clinical trials required to assess the impact of drug combinations are astronomical and 
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would be impractical.  For combinations of drugs larger than three, which increase for people as they age 
[3], the numbers of combinations and clinical trials to demonstrate safety increase rapidly. 
II-B. Radiotherapy 
 Radiotherapy that involved the brain region was a contributing factor to cognition problems and 
AD. 
II-C. Surgery/Invasive Procedures 
 The sub-categorization for II-C is not unique.  Some procedures could be assigned to multiple 
categories.  Surgeries/invasive procedures that contribute to AD tend to involve vessel occlusion, cerebral 
ischemia, broader cardiac surgery, estrogen depletion, and myriad forms of dialysis.  Since inhalation 
anesthesia seems to be a strong contributing factor, almost any major surgery employing this type of 
anesthesia would have to involve some potential risk for AD.  As in the case of drugs, these absolute 
numbers of complications from all surgical and invasive procedures must be considered in light of the 
numbers of procedures performed. 
II-D. Diagnostic Agents/Procedures 
 Items that could have been assigned to this category were placed in other more phenomenon-
based categories.  For example, dental x-rays were placed under  Radiation, and other diagnostic 
procedures requiring sedation were placed under under Anesthetics.  More broadly, people who 
experience high doses of ionizing radiation to the brain (such as from CT scans in that general region) can 
end up with cognitive dysfunction [4]. 
III. Biotoxic Agents 
 Biotoxic Agents reflect mainly the biological substances to which we are exposed naturally, but 
sometimes accidentally, and sometimes by design.  This category is divided into five sub-categories: 
Mycotoxins; Exotoxins; Bacteria/Fungi/Parasites; Viruses; Other.  Biotoxins contributing to AD include 
some mycotoxins, but mainly exotoxins, bacteria, and viruses. 
III-A. Mycotoxins 
 Only a few mycotoxins were identified, including ochratoxin A, Fumonisin B1, and macrocyclic 
trichothecenes. 
III-B. Exotoxins 
 Many exotoxins were identified, including excitotoxins (kainic acid/kainate, quisqualic acid, 
ibotenic acid, domoic acid, quinolinic acid/quinolinate), phosphatase inhibitors (okadaic acid), excitatory 
amino acids, malonate, annonaceaeous  acetogenins, cyanobacteria (beta-N-methylamino-L-
alanine/BMAA, saxitoxin, anatoxin-a, blue-green algae, microcystin), diphtheria toxin, pseudomonas 
aeruginosa exotoxin Y, saporins (192 IgG-saporin, p75-saporin), cycad plant 
(cycasin/methylazoxymethanol), glutamate/glutamine synthetase, mitochondrial inhibitors (rotenone, 3-
NPA, antimycin, KCN, oligomycin).  Some substances in the Other category could have been assigned to 
the Exotoxin category. 
III-C. Bacteria/Fungi/Parasites 
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 Myriad bacteria/fungi/parasites are contained in this sub-category.  The bacteria/bacterial 
infections include bacterial endotoxins, bacterial lipopolysaccharide, gram-negative bacterium, 
spirochetes, Chlamydophyla pneumoniae, Helicobacter pylori, Escherichia coli, Treponema pallidum, 
Tannerella forsythia, Treponema denticola, T. socranskii, T. pectinovorum, T. medium, T. amylovorum, 
T. maltophilum, Fusobacterium nucleatum, Prevotella intermedia, Chlamydia pneumoniae, 
Porphyromonas gingivalis, propionibacterium acnes, Treponemas, T. lecithinolyticum, and Borrelia 
burgdorferi.  Bacteria are somewhat ubiquitous, so the flexibility of cause removal for items in this sub-
category is much less than for items in the Lifestyle and Iatrogenic categories.   
 The fungi/fungal infections include Cryptococcus, Coccidioides, Aspergillus, Histoplasma, 
Blastomyces, C. famata, C. parapsilosis, C. glabrata, C. krusei, Candida albicans, Candida ortholopsis, 
Candida tropicalis, Cladosporium, Malassezia globosa, Malassezia restricta, Neosartorya hiratsukae, 
Phoma, Sacharomyces cerevisae, and Sclerotinia borealis.   
 The parasites include Trypanosoma brucei rhodesiense, Trypanosoma brucei gambiense, 
Acanthamoeba, Balamuthia mandrillaris, Toxoplasma gondii, Taenia solium, Toxocara canis, T. cati, 
Toxocara ova, and Leishmania amazonensis. 
III-D. Viruses 
 Myriad viruses are contained in this sub-category, and are shown in detail in Chapter 8.   
III-E. Other 
 The category named Other contains myriad substances, which are listed in detail in Chapter 8.  It 
includes some plant-based contributing factors (e.g., 12-myristate 13-acetate, Forskolin, arecoline 
hydrobromide, quisqualate, etc), and a very substantial number of endogenous substances that were 
administered exogenously (e.g., 27-hydroxycholesterol, acetylcholinesterase, Bradykinin, CD40, etc).  
 Ordinarily, endogenous substances are not foundational causes, but intermediate causes, since 
their harmful effects typically are driven by other foundational causes.  However, for consistency, if an 
endogenous substance was administered exogenously for purposes of experimentation or trial, it was 
considered as an exotoxin or other foundational cause for the purposes of this monograph.  Thus, amyloid 
beta, an endogenous substance, could be viewed as an endotoxin when internal processes are being 
discussed, but also as an exotoxin when administered in laboratory experiments.   
IV. Occupational/Environmental Exposures 
 Occupational/Environmental Exposures are those typically man-made substances and radiations 
to which we are exposed in our jobs and larger environment.  This category is divided into 
chemicals/materials and physical/mechanical, and the further divisions of these major categories are also 
shown.  This category is also massive, due mainly to the substantial numbers of chemicals and materials 
in our larger environment.   
IV-A. Chemicals/Materials 
IV-A1. Industrial and Household Chemicals/Materials 
 This sub-category, which includes hydrocarbons, solvents, chemical compounds, and Other, is 
very broad.  There is overlap among the next level  taxonomy elements; for example, some of the solvents 
are hydrocarbons and some of the chemical compounds are hydrocarbons.   
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 The hydrocarbons sub-category includes, e.g., methylcholanthrene, polycyclic aromatic 
hydrocarbons, diesel fuel, kerosene, etc. 
 The solvents sub-category includes, e.g., petroleum-based solvents (mineral turpentine, diesel 
fuel, fuel oil, kerosene, etc), chlorinated solvents (trichloroethylene, perchlorethylene, trichloroethane, 
dichloromethane, benzene), organic solvents (benzene, toluene, phenols, alcohols, ketones, 
methylmethacrylate), dimethyl sulfoxide/DMSO, etc.  The impacts from the members of this sub-
category, as reported in the references selected, tended to focus on performance and disease.  This was 
due to a number of epidemiology studies of occupational impacts, which tend to focus on higher level 
impacts. 
 The chemical compounds/Other sub-categories include a full spectrum of chemical compounds 
covering myriad sub-categories, especially chlorine, bromine, nitrogen, sodium, sulfur, and carbon 
compounds.  Members of these sub-categories include, e.g., Neurotoxins (6-hydroxydopamine/6-OHDA, 
5,6-dihydroxytryptamine/5,6-DHT, -5,7-dihydroxytryptamine/5,7-DHT, Type-2 Alkenes/Reactive 
aldehydes (Acrolein, 4-Hydroxynonenal/HNE, Acrylamide, Methyl glyoxal), Nitrosamine/N-
nitrosodiethylamine, Adenosine, 3', 5'-cyclic monophosphate/cAMP, Carbon tetrachloride, Chemical 
warfare agents/nerve agents (organophosphates, soman, sarin, ethyl S-2-di-isopropylaminoethyl-
phosphonothiolate, VX, tabun), Cyanide (Potassium cyanide, Sodium cyanide), Formaldehyde, Hydrogen 
peroxide/H2O2, Lipophilic chemicals (persistent organic pollutants, bisphenol A, phthalates, low 
molecular weight hydrocarbons, polynuclear aromatic hydrocarbons, endocrine disruptors), Sulfur 
dioxide/SO2, Phthalates (Di-(2-ethylhexyl)-phthalate/DEHP, mono-2-ethylhexyl phthalate/MEHP, DEHP 
metabolites), Brominated flame retardants (hexabromocyclo-dodecane/HBCD, tetrabromobisphenol-
Al/TBBPA, decabromodiphenyl ether/DBDE, polybrominated diphenyl ethers/PBDEs), Ammonia, 
Hypochlorous acid/HOCl, Methanol, Peroxynitrite, Sodium azide, Acetaldehyde, 3-Bromopyruvate, 
Vehicular emission oxides (nitrogen dioxide/NO2, carbon monoxide/CO), Sodium fluoride, Membrane-
mimicking detergents (sodium dodecyl sulfate, lithium dodecyl sulfate), Nitric oxide donors (sodium 
nitroprusside, DETA NONOate), Amorphous aluminosilicates, Sodium nitrite, Tert-butyl 
hydroperoxide/t-BHP, Alloxan, Ammonium chloride, Anionic dyes (Congo Red, Thiazine Red, 
Thioflavin S), Aroclor 1254, Cobalt chloride, Magnesium chloride, 2,2'-azobis(2-methylpropionamidine) 
dihydrochloride/AAPH, Methylglyoxal/Glyoxal, Disuccinimidyl suberate, Naphthazarin/5,8-dihydroxy-
1,4-naphthoquinone/ 5,8-dihydroxy-1,4-naphthalenedione, Pyrithiamine, Pyrogallol, Glyceraldehyde-3-
phosphate/GAPDH, Ethylcholine mustard aziridinium ion/AF64A, 1-methyl-4-phenylpyridinium ion, 
2,2'-dithiodipyridine, Aftin-4, Kaolin, Ozone, 2;3;7;8-tetrachlorodibenzo-p-dioxin. 
IV-A2. Agricultural Chemicals 
 This sub-category emphasizes pesticides, herbicides, insecticides, and fungicides, and includes, 
e.g., Organochlorine Pesticides, Organophosphate Pesticides, 2,4,5-trichlorophenoxyacetic acid, 2,4-
Dichlorophenoxyacetic Acid, Agent Orange, Aldrin, Alkylphenolpolyethoxylates, APEOs, Arsenic, Beta-
hexachlorocyclohexane/beta-HCH, Bipyridyles, Carbamates, Carbofuran, Chlorfenvinphos, 
Chlorpyrifos/CPF, Cycloheximide, Cypermethrin, Deltamethrin, Dichlorodiphenyldichloroethylene/DDE, 
Dichlorodiphenyltrichloroethane/DDT, Dichlorodiphenyldichloroethane/DDD, Dieldrin, Dimethyl 
parathion, Endosulfan, Famoxadone, Fenamidone, Glyphosate, Hexachlorobenzene, 
Hexachlorocyclohexane/HCH, Imidacloprid, Lindane, Maneb, Methamidophos, Methyl parathion, 
Neonicotinoids, Nonylphenol, Octylphenol, Paraquat, Parathion, Pyraclostrobin, Pyrethroids, Trans-
nonachlor, Trichlorfon/TCF, Trifloxystrobin, etc.   These chemicals impact the larger population 
through the food supply, and have devastating effects on the agricultural workforce.  Given the ubiquitous 
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nature of agricultural chemicals and industrial/household chemicals in daily life, eliminating them will be 
challenging. 
IV-A3. Materials 
 The materials/particulates that constitute this category are broadly-based, and in many cases have 
become part of the average lifestyle.  Some examples include: 
-heavy metals (e.g., aluminum, arsenic, cadmium, cobalt, copper, iron, lead, manganese, mercury, 
selenium, zinc, manganese, etc) 
-particulates (e.g., air pollution, surgical smoke, dust, etc) 
-nanoparticles (e.g., iron nanoparticles, titanium dioxide nanoparticles, CdSe quantum dots, diesel exhaust 
nanoparticles, alumina nanoparticles, manganese oxide nanoparticles, copper nanoparticles, silicon 
dioxide nanoparticles, zinc oxide nanoparticles, silver nanoparticles, and nickel nanoparticles, etc) 
IV-B. Physical/Mechanical 
 This sub-category includes ionizing radiation, non-ionizing non-visible radiation, non-ionizing 
visible radiation, sound radiation, temperature fields, and force fields.   
IV-B1. Electromagnetic Radiation 
IV-B1a. Ionizing 
 The ionizing radiation component includes, e.g., gamma radiation (dental X-rays, gamma rays, 
etc), particle radiation (56Fe-particle radiation, cosmic radiation, HZE particle radiation), radionuclide 
pollutants (uranium, cesium, cobalt, radon).   
IV-B1b. Non-Ionizing 
IV-B1b1. Non-Visible 
 The non-ionizing non-visible radiation component includes, e.g.,  electromagnetic fields at 
myriad frequencies, such as extremely low frequency/ELF-EMF, 900 MHz radiofrequency (RF), 
electromagnetic pulse/EMP, electroconvulsive shock/ECS, UV irradiation, etc.   
IV-B1b2. Visible 
 The non-ionizing visible radiation component includes, e.g., UV irradiation, photolysis of 1-(2-
nitrophenyl)ethyl sulfate, etc. 
IV-B2. Sound 
 The sound radiation component includes, e.g., short-lasting impulse noise, chronic noise 
exposure, night-time aircraft noise, ultrasound sonication, etc.   
IV-B3. Temperature; Heat/Cold 
 The thermal component includes, e.g., cold water hypothermia, cold water stress, heat shock, heat 
stress, heating, hyperthermia, etc.  
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IV-B4. Force/Pressure/Physical Trauma 
 The physical force component includes, e.g., blasts, blast traumatic brain injury, hippocampal 
injury, accumulated mechanical stress, spinal cord injury, frequent strong Valsalva maneuvers, long hours 
of repetitive heavy lifting, sequences of blows during the playing of a wind instrument, forceful and 
repetitive cough, bearing-down efforts during parturition, history of head trauma, etc.    
 The main components of this sub-category, the different types of physical fields with which we 
interact (electromagnetic, sound, temperature, pressure, force) are ubiquitous.  Avoiding exposure to these 
emissions/interactions would require a major change in lifestyle (and possibly location) for most people.   
IV-C. Other 
The 'Other' category is small, and contains adverse effects from over- and under-exposure to oxygen. 
V. Psychosocial/Socioeconomic 
 Psychosocial/Socioeconomic are those foundational causes that reflect personal problems, social 
interactions, larger societal interactions, and economic relationships.  Psychological and sociological 
stress were major causative factors; economic types of stress seemed to play less of a direct role.   
V-A. Psychological 
 This sub-category includes, e.g., chronic stress (repeated stress, chronic mild stress, chronic 
psychological stress, multiple chronic stresses, behavioral stress, childhood trauma, bereavement, chronic 
restraint stress, high job stress), low mental activity (low cognitively engaging activity, low purposeful 
activities, low leisure activities/low hobbies, low music/drawing/meditation/reading/arts/crafts), etc. 
V-B. Sociological 
 This sub-category includes, e.g., social isolation (isolation, loneliness, living alone, unmarried, 
maternal separation, low social activity index, low social support at work, constricted life space), low 
education (illiteracy), etc. 
V-C. Economic 
 This sub-category includes, e.g., economic stress (childhood socioeconomic circumstance), etc. 
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Chapter 4 
DISCUSSION AND CONCLUSIONS 
4A. Contributing Factors Identified 
 Approximately 400-600 AD foundational causes are identified in this monograph (depending on 
how one aggregates). Given the myriad disincentives for reporting adverse medical events [1, 2], this 
number should be viewed as a 'floor'.   
 These foundational causes are divided into six traditional categories for clarity of presentation 
(Lifestyle, Iatrogenic, Biotoxic Agents, Occupational/ Environmental Exposures, 
Psychosocial/Socioeconomic, Genetics).  The latter category, Genetics, was not addressed in the findings 
because the main focus of this monograph is on foundational causes that are (by definition) somewhat 
actionable (action could, at least in theory, be taken to attenuate, neutralize, or eliminate them). It is 
difficult to modify a person's genetic endowment at the present time, although  that may not be true in the 
future. 
4A1. Latent Variables 
 To gain an understanding of the deeper commonality among these foundational causes, they can 
be re-categorized manually according to a few main latent variables [1]: Direct Technology, Indirect 
Technology, Inadequate Regulation, Individual Choice, Poverty. Each of these five major themes (latent 
variables) will be discussed now. 
4A1a.  Direct Technology 
 Direct Technology (the degree of direct impact of technology on the foundational cause) plays a 
strong role in Lifestyle, Iatrogenic, and Occupational/ Environmental foundational causes. In addition, 
through its impact on the immune and other critical systems, modern technology may play a role in 
whether exposure to bacteria and viruses results in symptoms and diseases. Modern technology impacts 
the growing, processing, and preparation of foods, and many of the adverse effects identified in the 
present study can be traced back to the use (mis-use) of technology in the food cycle. The Iatrogenic 
adverse effects of modern technology result mainly from the high-technology-based drugs, surgery, 
diagnostics, and therapy that characterize much of modern medicine today. The 
Occupational/Environmental adverse effects result mainly from the employment of modern technology in 
1) commerce, 2) the environment, and 3) the workplace. 
4A1b. Indirect Technology 
 Indirect Technology reflects those adverse health-impacting behaviors enabled by Direct 
Technology. One example is reduced labor because of modern technology, leading to today's highly 
damaging sedentary lifestyle that contributes to myriad diseases, including AD. Another example is large 
numbers of people being able to live in inhospitable northern climates because of modern transportation, 
Prevention and Reversal of Alzheimer's Disease               Copyright © 2017               Ronald N. Kostoff et al 
 
32 
 
food logistics, clothing, and shelter. This results in less exposure to sunlight and less Vitamin D 
production, contributing to diseases (such as AD) related in part to Vitamin D deficiency. 
4A1c, Inadequate Regulation 
 Inadequate Regulation is coupled strongly to the introduction of high technology in all aspects of 
life. Many of the problems with foods derive from relatively unregulated chemicals, materials, and other 
contaminants entering the food supply during agriculture and animal husbandry. Many of the 
Occupational/ Environmental exposures arise from relatively unregulated harmful substances entering the 
workplace and the environment, especially in less developed countries, but in more developed countries 
as well. Many of the Iatrogenic problems could be traced to drugs, diagnostics, therapies, and other 
procedures entering practice with insufficient front-end long-term testing, and inadequate evaluation of 
side-effects. 
 Two major aspects of Inadequate Regulation revolve around insufficient safety: inadequate safety 
data gathering, and inadequate safety testing. Much of the adverse impact data gathering tends to be from 
passive surveillance systems, where response rates can be an order of magnitude (or more) less than real-
world incidence rates. Pre-market testing, in many cases, suffers from inadequate sample sizes, 
unrepresentative samples, insufficient long-term testing, and insufficient combination testing to identify 
potential synergistic effects. Insufficient long-term testing on humans is particularly troubling, since many 
serious diseases such as AD may have decadal latency periods from specific toxic stimuli. 
Transgenerational effects could not be excluded without appropriate long-term testing.  Additionally, 
results from animal testing (which could be long-term from the perspective of many short-lived animals 
used in testing) do not necessarily translate to human outcomes. 
4A1d.  Individual Choice 
 Individual Choice reflects decisions by people to choose unhealthy diets, sedentary activities, 
recreational drugs, elective drugs and surgery, unhealthy occupations, unhealthy residential environments, 
unhealthy relationships, etc. There is the unwritten corollary assumption that people have adequate 
knowledge about the consequences of these choices, and there are no other major factors that limit their 
choices. For many people, this is a highly unrealistic assumption. They have very limited knowledge 
about the consequences of these choices, either through 
1) accurate information not being available, or 
2) apathy in searching out this information, or,  
3) being provided incorrect information [1, 2]. 
4A1e. Poverty 
 Poverty limits individual choices about diet, occupations, and environment. Poverty plays a 
strong role in malnutrition and the diseases of deficiency resulting therefrom, directly and indirectly. By 
limiting access to modern medicine and modern technology, poverty avoids some of the adverse impacts 
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ascribed to modern technology presented in this monograph, but at the same time, denies many of the 
benefits available from modern medicine and modern technology.  
4B.  Synergies/Combination Effects/Additional Contributing Factors 
4B1. Under-Reporting of Combinations of Potential Contributing Factors 
 Many, if not most, people are exposed to at least tens of the ~400-600 potential foundational 
causes identified in this monograph, and perhaps tens more of the foundational causes that remain under-
reported. Given the potential synergistic effects of these causes acting in concert, whereby the potential 
damage from the combinations exceeds the damage of the causes acting in isolation, the opportunity for 
developing AD is significant.  
 However, while ~400-600 potential foundational causes appears to be a large number, it may be 
the tip of the iceberg of the real number of potential foundational causes.  If two or more substances do 
not show an adverse effect for AD when each is studied in isolation, then they would probably not be 
examined in combination in the lab or clinic, even though some could produce an adverse effect in 
combination.  So, a large number of combinations would have to be examined, to cover both 1) the case 
where each member of the combination showed no adverse effect when studied in isolation, and 2) the 
case where each member of the combination would have a very slight effect on AD when studied in 
isolation, but the combination would produce a large effect.  While some of these combinations would 
have been reported in the present study, those reported would probably be a very small fraction of all 
potential combinations. 
 The targeted literature studies in particular tend to select substances of interest for the 
experiments, then look for biomarkers of interest.  Unless there is good reason to select a combination for 
study, it probably would not get chosen. 
4B2. Numerical Estimates of Potential Combinations 
 The reason few combinations are selected for study derives from combinatorics.  Consider the 
number of possible combinations of two and three items.  For n variables, and possible combinations of a 
subset of n consisting of r variables, the number of combinations is: C(n,r)=n!/(r!*(n-r)!), where [!] 
denotes the factorial function.  For large n, and r small compared to n, C(n,r)~=n
r
/r!  For large n, C 
becomes a large number.  How large?  Consider the following.   
 It would be useful to identify those substances that, in isolation or in combination, could 
potentially impact AD or its surrogate endpoints, but have not been studied yet.  There are many tens of 
thousands of items that could be potential candidates for study.  Is there any way to narrow those down? 
 Reference [1] considered ~4,000 diseases, and identified factors that contributed to 1) any of 
these diseases and 2) a threshold number of diseases.  In reference [1], on the order of 800 substances that 
contributed to at least a threshold number of the ~4,000 diseases were identified.  These 800 pervasive 
causes constituted about ten percent of the total number of causes (90% of which impacted less than the 
threshold number of diseases) identified for the ~4,000 diseases.  The total number of causes identified 
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for all diseases (~8,000) might be a good starting point for identifying additional potential AD causes.  
Why is this a reasonable assumption? 
 The various systems in the body are inter-related.  The immune system, neural system, endocrine 
system, circulatory system, etc, are linked.  There are research disciplines devoted to study of these linked 
systems (e.g., neuroimmunology, neuroimmunoendocrinology, etc).  Most of the ~8,000 causes identified 
in reference [1] impacted one or more of these inter-related systems.  Many of the studies focused on the 
impact of the test substance on (typically) one system only.  It would be reasonable to expect that a 
substance impacting one of the systems above would have some level of impact on the other systems 
above, with some impacts being more significant than others. 
 Thus, the ~8,000 potential causes identified in reference [1], minus those that were identified in 
the present AD study, would be candidates for evaluation as potential AD causes.  Subtracting the ~500 
AD causes identified in the present study from the ~8,000 causes leaves on the order of ~7,500 items to 
be examined in isolation.  Assume there were another 500 items evaluated for potential impacts on AD in 
other studies but were shown not to have an effect (in isolation, although we may want to examine them 
as part of a combination).  We are then left with on the order of  1) ~7,500 substances to study in 
combination, and 2) ~7,000 of the initial ~7,500 substances to study in isolation.  This would include the 
case where the ~500 identified contributing factors in isolation could have a stronger effect in 
combination, for those cases where the combinations have not been studied.   
 The numbers of combinations of two and three for 7,500 test items, C(7500,2), C(7500,3), are, 
according to the formula above for small r: 
C(7500,2)=~28 million 
C(7500,3)=~70 billion 
 These numbers are astronomical in any of the cases shown.  Research on each of these 
combinations is a major resource and time effort, in the lab and/or in the field/clinic.  There's no way all 
the combinations, or even the most relevant ones, can be run.  Unfortunately, the combinations of 
potentially toxic stimuli mirror the real world, not the potentially toxic stimuli acting in isolation.  And, 
which combinations are important to a specific individual would be a function of that person's unique 
characteristics, such as genetic makeup. 
4B3. Synergy Effects on Dose Rates 
 Dose rates may also be affected by synergy.  When two or more items with adverse health effects 
(in isolation) are combined, smaller doses of each in combination can produce an equal or greater adverse 
health effect (this synergy is also true for the case of positive health effects). 
 As an example, assume hypothetically that heavy cell tower radiofrequency (RF) exposure could 
be a strong contributing factor to AD, and high-fat diet could be a strong contributor.  If people are 
exposed simultaneously to cell towers and fat-containing diets, then perhaps only modest levels of cell 
tower exposure and modest fat diets could in combination have an adverse effect equivalent to that from 
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high levels of exposure of each in isolation.  Thus, if the initial tests in isolation were at low doses of the 
stimuli, the results could be misleading.  So, each of the combination experiments would have to cover a 
wide parametric range to be credible. 
 These conclusions reflect the challenge of preventing or reversing not only  AD, but all other 
chronic diseases that have a wide spectrum of causative factors.  The only glimmer of hope for true 
prevention or reversal is that, for any complex system characterized by many variables, there are typically 
a few main variables that drive performance and need to be addressed with high priority.  That may 
explain why Dale Bredesen was able to get positive results for his treatment of AD/MCI [3]  and Terri 
Wahls was able to reverse her multiple sclerosis (as summarized in Chapter 9, sub-section D of [1]).  
Unfortunately, given the rapidly increasing number of potentially harmful exposures to advanced and 
untested technologies in our biosphere, identifying and eliminating these hazards may become  
increasingly difficult.  This is especially true for those diseases with long latency periods (like AD). 
4C. Health Policy 
4C1. Health Policy Framework 
 While the main objective of this monograph is identification of potential contributing factors to 
AD, some brief statements about the health policy that could exploit these findings might prove useful.  
The health policy that derives from the above findings would contain two main components: persuasion 
and mandates. Persuasion would be applied to influence Lifestyle/Individual Choice, which is the "low-
hanging fruit" of foundational causes. Mandates would be applied to alter  Inadequate Regulation, the 
next level up on the "fruit tree". Effective persuasion and mandates depend strongly on the most 
scientifically accurate biomedical information being placed in the biomedical literature, and then 
communicated to the public in a straight-forward manner. 
 This monograph has taken a large step in identifying the voluminous potential AD foundational 
causes that need to be eliminated for AD prevention or possible AD reversal. A better resourced study 
would be able to 1) sample more Abstracts for analysis, and 2) examine phrases further down the 
frequency spectrum, to identify additional potential foundational causes for AD. 
 However, while the addition of more AD foundational causes obtainable with an expanded study 
would provide a more complete picture of such causes, the elimination of the specific and categorical 
causes identified in this monograph may be adequate to prevent or (alone or in concert with treatments) 
reduce/halt/reverse AD progression in selected cases.  
4C2. Health Policy Implementation 
4C2a.  Eliminating Potential AD Contributing Factors 
 There are three key issues in implementing elimination of any potential AD contributing factor 
for any person.  First, what is the exposure level (duration, strength) of this individual to a given 
contributing factor, and is this exposure level in the toxic range?  For some types of contributing factors, 
exposures can be estimated readily.  These types of contributing factors include some aspects of diet, 
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some drugs, and perhaps some occupational exposures.  For most contributing factors for most people, 
the exposure levels at both any point in time and as a function of time are unknown.  To obtain that data, 
myriad exposure meters measuring radiation (ionizing, non-ionizing), chemicals ingested, inhaled, 
entering the body through the skin, etc, would be required on a continual basis.  For the foreseeable 
future, many  exposures relevant to AD contributing factors will be unknown because of the absence of 
these critical measurement systems on a continuing basis. 
 Second, assuming a particular individual's exposure to a given contributing factor is known and 
potentially harmful, its elimination needs to be placed in some priority order.  If one examines the 
research papers on potential causes, almost every researcher believes his/her findings are a critical 
contribution to AD.  Not many, if any, papers emphasize prioritization among potential contributing 
factors.   
 Third, assuming a particular individual's exposure to a given contributing factor is known and 
harmful, and its priority for elimination is known and high, then determination of the individual's 
motivation to eliminate the potential contributing factor is required.  Having motivation to eliminate 
contributing factors to which one is effectively "addicted" may be the most difficult step in the above 
process. 
 A parallel issue is understanding what is meant in practice by "elimination".  What is the speed, 
breadth, and depth with which a potential contributing factor has to be removed for it to be considered 
"eliminated", in order to halt/reverse the progression of AD or any disease?  For example, does a poor diet 
have to be improved by 50% to be effective in disease reversal?  90%?  In the multiple sclerosis  reversal 
study summarized in Chapter 9, sub-section D of [1], Dr. Terri Wahls was shown to have reversed her 
MS.  Dr. Wahls' symptom removal and especially damage reversal were not effective until her diet 
achieved near-"pristine" status. There is no reason to believe that: 
1) similar dietary improvement would not be required to reverse AD (for those cases where the damage 
may not yet be irreversible or genetic predisposition is not overly dominant), or 
2) similar improvement in other types of cause removal would not be required to reverse AD. 
 The degree of cause removal required for reversal (with or without the requirement for additional 
treatments) would probably be different among patients. The major roadblock would be individual choice. 
It would require high discipline and compliance on the part of the patient. For those patients who are 
willing to do whatever it takes to reverse AD (like Dr. Wahls' motivations to reverse multiple sclerosis), 
and who have no intrinsic limitations based on strong genetic predisposition or irreversible damage, the 
findings in this monograph offer a starting point for an effective protocol. 
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Chapter 5 
SUGGESTED FURTHER RESEARCH 
5A. Additional AD Contributing Factors 
 The present study, while more comprehensive than any of its predecessors with respect to 
identifying potential contributing factors for AD based on the premier biomedical literature, has identified 
only the tip of the iceberg of potential AD contributing factors.  As shown in Chapter 4, section 4B, many 
other potentially toxic stimuli, and their combinations, have yet to be addressed.  As shown in [1], the 
adverse effects of many potentially toxic stimuli have not entered the biomedical literature for myriad 
reasons.  Many of the AD studies on potential contributing factors have been narrowly focused; only a 
few sub-levels in the taxonomy of impacts in Chapter 8 were targeted in any research project. 
 One straight-forward way of identifying additional potential AD contributing factors is with use 
of the discovery component of the literature-related discovery and innovation (LRDI) approach.  Some 
examples of how this could be done were presented in the CKD LRDI study [2].  An adequately 
resourced study could identify many more of these contributing factors for AD.  
5B. Develop Measurement Devices for Potential AD Contributing Factor Exposures 
 In the brief discussion of health policy implementation above, it was shown that a key deficiency 
in implementation is lack of knowledge of the myriad toxic stimuli to which one is being exposed 
continually.  What is the full spectrum of potentially toxic chemicals in 1) our drinking water, 2) the air 
we breathe, 3) the food we eat, 4) contact with our skin, and what is the full spectrum of ionizing and non-
ionizing, visible and non-visible, radiations to which we are exposed as a function of time?  To answer 
these questions, we need devices that can measure the full range of these toxic stimuli and are convenient 
and portable.  Producing such devices would require an extensive research and development effort, 
especially devices in a form that people would be motivated to wear and use. 
5C. Institute Clinical Trials Removing Potential AD Contributing Factors 
 Finally, to gain operational experience with exploiting the findings in the present monograph, 
clinical trials should be started in the near future.  Given the limitations in knowing exposures to many 
contributing factors outlined above, these trials could start with incorporating the "low-hanging fruit" 
contributing factors that have been identified in the present study.  These would include:  
1) curbing the dietary excesses identified and removing the dietary deficiencies identified;  
2) eliminating food additives to the extent knowable and possible, including those dietary excesses that 
derive from food additives (excessive fat, sugar salt);  
3) reversing the sedentary behavior patterns identified;  
4) removing the foundational impediments to better sleep;  
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5) eliminating the use of 'recreational' drugs, including smoking and excessive alcohol;  
6) eliminating the use of medicinal drugs shown to be potential contributing factors,  unless where these 
drugs are absolutely necessary; 
7) eliminating any elective (not absolutely necessary) diagnostic or surgical procedures that involve 
inhalational anesthetics or high doses of ionizing radiation in head region (e.g., CT scans); 
8) minimizing exposures to some hydrocarbons such as diesel exhaust, kerosene, polycyclic aromatic 
hydrocarbons (including those found in smoke), etc; 
9) minimizing exposures to some solvents, especially petroleum-based solvents, chlorinated solvents, and 
organic solvents;  
10) minimizing exposures to pesticides, herbicides, insecticides, and fungicides, both inhalation and 
ingestion exposures;  
11) minimizing exposures to heavy metals in food, in water, and in the air; 
12) minimizing exposure to particulates, especially air pollution;  
13) minimizing exposures to ionizing radiation, non-ionizing non-visible radiation (such as cell phones, 
cell towers, WiFi, smart meters, etc), non-ionizing visible radiation (such as excessive UV radiation), 
sound radiation (high noise levels), temperature fields (such as cold water hypothermia/stress, heat 
shock/hyperthermia), and force fields (high impacts, especially to head region); 
14) minimizing chronic stress (mental/emotional/psychological), increasing mental activities; 
15) minimizing social isolation. 
 Most of the other sub-category members in Table 8-3 are unknown to the average person (both in 
name and level of exposure), and would require (mainly) portable instrumentation to determine exposure 
levels and potential concerns. 
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Chapter 6 
BACKGROUND 
6A. Overview 
 Alzheimer's Disease (AD) is a brain disease, and the most common form of dementia [1-3].  
Presently, it affects overwhelmingly those 65 years old and above; incidence increases with age.  
According to reference [4], 'A growing number of studies indicate that the age-specific risk of 
Alzheimer’s and other dementias in the United States and other higher-income Western countries may 
have declined in the past 25 years, though results are mixed.  These declines have largely been attributed 
to increasing levels of education and improved control of cardiovascular risk factors.'  That positive 
assessment of declining incidence was questioned somewhat in a recent comprehensive meta-analysis [5]: 
"We found no evidence to suggest that the current assumption of constant age-specific prevalence of 
dementia over time is ill-founded".  The prevalence of AD in the USA was approximately 4.7 million 
people in 2010, and is projected to increase to 5.8 million in 2020, 8.4 million in 2030, and 11.6 million 
in 2040 [4].   
 Thus, these studies referenced conclude that age-adjusted AD incidence is either declining 
slightly or remaining approximately level.  Projected prevalence is increasing rapidly, since the number of 
elderly is projected to increase rapidly. 
 The incidence projections may be highly misleading.  They are based mainly on extrapolations 
from the past, estimating the adverse effects of established technologies.  The main body of the present 
monograph identifies many new technologies that could potentially contribute to AD.  The growth in 
implementation of technologies (over the last couple of decades) potentially contributing to AD (or many 
other chronic diseases) portends ominously for the future.  These new technologies have not been 
operational for sufficient time to display direct impacts on AD (or myriad other chronic diseases) in 
humans, because of potential decadal latency periods before serious diseases emerge.   
 Thus, the appropriate future projection of AD incidence and prevalence should consist of 
superposition of 1) declining/flat incidence trend line due to past personal health advances and 2) 
increasing incidence due to implementation of new harmful technologies with decadal latency periods.  
The Precautionary Principle dictates that the impacts of these newer technologies on surrogate endpoints 
be considered when developing future incidence projections, especially in the longer-term. 
 Additional details on AD can be found in the following books [6-15] and review articles [16-21]. 
 This Background section consists of two parts: studies to identify a broad spectrum of causes for 
AD, and text mining approaches for identifying potential contributing factors to disease. 
6B. AD Contributing Factors Studies 
 As shown in Chapter 8, there are many published studies focusing on identifying one or a few 
contributing factors to AD.  There are many fewer studies identifying a broad spectrum of AD 
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contributing factors, as was done in the present monograph.  The focus in the present section is to 
summarize the results from credible broad spectrum or meta analysis studies indentifying myriad AD 
contributing factors.  
 Hazar et al [22] concluded: "Diabetes mellitus (DM) type 2, smoking, physical inactivity, 
overweight and obesity were significantly associated with increased risk of AD".  Grant [23-24] focused 
on dietary factors, and concluded that advanced glycation end products associated with high-temperature 
cooking, meat consumption,  eggs, high-fat dairy, and low 25-hydroxyvitamin D concentrations are 
associated with increased risk of AD.  Li et al [25] concluded: "Patients with MCI with APOEepsilon4, 
abnormal CSF tau level, hippocampal and medial temporal lobe atrophy, entorhinal atrophy, depression, 
diabetes, hypertension, older age, female gender, lower MMSE score and higher ADAS-cog score, had a 
high risk for the progression to AD".  Xu et al [26] concluded that hyperhomocysteine, depression, frailty, 
carotid atherosclerosis, hypertension, low diastolic blood pressure, type 2 diabetes mellitus (Asian 
population), low education, and high body mass index (BMI) in mid-life increased AD risk.  Barnes and 
Yaffe [27] concluded that up to half the worldwide cases of AD can be attributed to seven "modifiable" 
risk factors: diabetes, midlife hypertension, midlife obesity, smoking, depression, cognitive inactivity, 
low educational attainment, and physical inactivity.  Meng et al [28]  concluded that high blood pressure, 
hypercholesterolemia, obesity, diabetes mellitus in midlife, smoking, and hyperhomocysteinemia are AD 
risk factors.  Srisuwan [29]  concluded that reducing dementia risk through "modifiable" risk factors 
requires cognitive activity, higher education, mentally demanding occupations, participation in mentally 
challenging leisure activities, more active socially, low saturated fat diet, high fruit and vegetable diet, 
smoking cessation,  prevention of head injury with loss of consciousness, reduce high blood pressure, 
especially at midlife, reduce diabetes, reduce high serum cholesterol especially at midlife, and reduce 
depression. 
 There is a thread of common risk factors running through the above full spectrum surveys and 
meta-analyses.  These include hypertension, diabetes, obesity, smoking, depression, physical inactivity, 
low education, and cognitive inactivity.  Quasi-common risk factors include high meat diet, high saturated 
fat diet, high cholesterol, and hyperhomocysteine. 
 Superficially, this is a relatively low number of "modifiable" risk factors (the authors of these 
review articles view them as "modifiable").  However, this "low number" is deceptive.  If we view the 
foundational causes as independent variables (those over which we have direct control, at least in theory), 
there are very few that have been identified in the studies above.  These include smoking, physical 
activity, cognitive activity, educational level, and the dietary factors of high fat, high meat, low fruit and 
vegetables. 
 The non-foundational risk factors/contributing factors are in fact dependent variables, and include 
hypertension, diabetes, obesity, depression, hypercholesterolemia, and hyperhomocysteinemia. As shown 
in Chapter 8, there are many hundreds of foundational causes/contributing factors for AD that can be 
identified from the published literature alone.   
 As was shown in the precursor study identifying foundational causes for chronic kidney disease 
(CKD) [30], there were also many hundreds of potential CKD foundational causes that could be 
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identified.  Additionally, in the first author's book on pervasive causes of disease [31], it was shown that 
there are many chronic diseases for which hundreds of potential foundational causes could be identified.  
It is reasonable to assume that hundreds of potential foundational causes could be identified for each of 
the above dependent variables/diseases (hypertension, diabetes, obesity, depression, 
hypercholesterolemia, and hyperhomocysteinemia).  The surveys above, while valuable in their own right, 
do not work in the actionable coordinate system of foundational contributing factors, and cannot lead to a 
protocol whereby action could be taken to prevent or reverse AD in selected cases.  The approach in the 
present monograph does indeed lead to such an actionable protocol! 
6C. Text Mining to Identify Contributing Factors to Disease 
6C1. Overview 
 The two main literature-based approaches for identifying potential contributing factors to AD (or 
any other disease) are "direct" and "indirect", where "direct" can be viewed as analogous to Innovation, 
and "indirect" can be viewed as analogous to Discovery [30].  The direct approach identifies contributing 
factors that appear in the same article as AD (e.g., smoking increases the risk for AD) and link directly to 
AD.  The indirect approach identifies potential contributing factors to some disease/symptom other than 
AD, then links this disease/symptom to AD (e.g., high-salt diet increases the risk for hypertension, 
hypertension is strongly linked to AD).   
 The bulk of the present monograph focuses on direct contributing factors to AD, and includes 
conceptual discussion, but not examples, of indirect contributing factors.  The latter are of two types: 1) 
linkages between a potential contributing factor and a disease/symptom where AD is mentioned in the 
article as being related to the disease/symptom, and 2) linkages between a potential contributing factor 
and a disease/symptom where AD is not mentioned in the article.  Case 1) is, e.g., typical of surrogate 
endpoint papers.  In case 2), identifying another article where the disease/symptom is linked to AD is 
required to close the loop.  Case 2) is usually described in the text-mining literature as literature-based 
discovery or literature-related discovery.  Case 1) could also be viewed as "soft" discovery, and case 2) as 
"hard" discovery [30].  Case 2) examples are not provided in the present monograph because of length 
considerations, but, based on past experience, voluminous discoveries of potential contributing factors for 
disease are possible (e.g., [30]).  
6C2. Literature Survey 
 The published text mining approach related most closely to that used in the present monograph 
can be found in [30-31].  In the more recent of these two [31], three approaches were used to develop 
queries for identifying foundational causes for all diseases.  The first approach used MeSH Qualifiers 
relevant to identifying foundational causes of disease (e.g., adverse effects, toxicity, pathogenicity, 
poisoning) to retrieve records from Pubmed for analysis.  The second approach used generic MeSH terms 
related relatively unambiguously to foundational causes (e.g., "Drug-Related Side Effects AND Adverse 
Reactions"; Abnormalities, Drug Induced; Air Pollutants, Occupational; Amphetamine Related 
Disorders; Carcinogens; Chemical Warfare Agents; Chemically-Induced Disorders, etc) to retrieve the 
records from Pubmed for analysis.  The third approach used text terms (applied to the Title field) to 
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retrieve the records from Pubmed for analysis.  This Title query consisted of two parts: standalone terms 
(e.g., cardiotoxic*, genotoxic*, mutagenic, adverse-outcome, adverse-metabolic-effect*, etc) and terms 
that are intersected with diseases (e.g., (expos* OR induc*) AND (cancer* OR dermatitis)). 
 Other text mining approaches have been developed for generating literature-based discovery.  
They have been used mainly for identifying potential new treatments for disease, but the approaches used 
for identification of new treatments  could be easily modified for identification of potential new 
foundational causes as well (e.g., [30]).  In the past decade, a number of these semantic relation-based 
approaches have been promulgated.  
 Cohen et al [32] use semantic indexing to identify empirically sequences of relationships known 
as 'discovery patterns', such as "drug x INHIBITS substance y, substance y CAUSES disease z" that link 
pharmaceutical substances to diseases they are known to treat. These sequences are derived from 
semantic predications extracted from the biomedical literature, and subsequently utilized to direct the 
search for known treatments for a held out set of diseases. Hu et al [33] present a biomedical semantic-
based association rule system that significantly reduces spurious/useless/biologically irrelevant 
connections (the B terms in the ABC approach) through semantic filtering. Miller et al [34] advance the 
hypothesis of "cortisol as part of a mechanistic link elucidating the observed correlation between 
decreased testosterone in aging men and diminished sleep quality". Hristovski et al [35] overview myriad 
approaches to literature-based discovery, emphasizing semantic relations, especially 'discovery patterns'.  
Sang et al [36] develop a supervised learning based approach to generate hypotheses from biomedical 
literature, splitting the traditional processing of hypothesis generation with classic ABC model into AB 
model and BC model.  Cameron et al [37] implement a context-driven, automatic subgraph creation 
method that captures multifaceted complex associations between biomedical concepts; given a pair of 
concepts, the method automatically generates a ranked list of subgraphs, which provide informative and 
potentially unknown associations between such concepts.  Kastrin et al [38] mimic the process of 
literature-based discovery as a classification problem on a graph of MeSH terms, using unsupervised and 
supervised link prediction methods for predicting previously unknown connections between biomedical 
concepts.   
 These approaches achieve neither the breadth nor the volume of Innovation and Discovery found 
in references [30-31, 39]. 
 Other information technology approaches have been used to identify potential risk 
factors/contributing factors for specific diseases.  They differ from the Discovery approaches above 
because of their focus on identifying the direct causes of disease as defined above.  Examples of these 
information technology approaches include training neural networks to identify risk factors for specific 
diseases/ conditions [40-43], machine learning-based methods to quantify risk factors for 
diseases/conditions [44-45], data based clustering and rule based prediction to identify risk factors for 
diseases/conditions [46-48], Bayesian networks to identify risk factors [49-54], association rules to 
identify risk factors [55-57], decision trees to identify risk factors [58-62], and text/data mining 
approaches [63-65]. Additionally, there is a substantial literature on information technology approaches 
for identifying adverse events resulting from drugs and surgery [66-78]. 
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6D. Foundational Cause Definition 
 The myriad causes of AD reported in this monograph are termed "foundational".  A foundational 
cause is a tangible stimulus or behavior that can contribute to a symptom.  Thus, excesses of calcium, 
water, exercise, drugs, environmental exposures, etc, can contribute to a symptom(s), and severe 
deficiencies of calcium, water, or exercise can contribute to a symptom(s) as well.  Abuse, poverty, 
educational status, etc, can contribute to symptoms, even though categorizations into excesses and 
deficiencies may be less applicable.   
 A symptom(s)/disease(s) is the result of imbalance between the strength of the toxic stimuli and 
the person's innate ability to neutralize the effects of the toxic stimuli, including the genetic factors that 
were not included in this monograph.  The two are not independent; the toxic stimuli can affect the 
capabilities of the defensive system to neutralize incoming toxic stimuli.  Thus, the incoming toxic stimuli 
can be viewed as a "signature" of individual toxic stimuli, with different weightings assigned to each 
toxic stimulus, and the defense can also be viewed as a "signature", with different weightings assigned to 
the health of the body's defensive mechanisms.  Whether a symptom will materialize as a result of one or 
more toxic stimuli depends on whether the defensive "signature" is able to neutralize the "signature" of 
the incoming toxic stimuli. 
 Thus, not every person who eats a high-fat diet or undergoes surgery with inhalation anesthetics 
develops AD, but some (more than expected randomly) do.  There were a number of cases in the literature 
where relatively few people were reported to have adverse reactions to a given toxic stimulus.  Identifying 
the offensive-defensive "signature" relationships that allow toxic stimuli to translate into symptoms 
(within the context of understanding genetic polymorphisms and the resulting variations in biological 
pathways) will play a significant role in explaining why some people develop a disease and others do not 
when exposed to the same agent.  Understanding the complex web of gene-environment interactions is the 
central challenge of modern medicine; our identification of myriad individual toxic stimuli and defensive 
system deficiencies is the first step in this long journey. 
 For purposes of this monograph, we term a toxic stimulus a (foundational) cause if  
1) the research author stated/implied/inferred the toxic stimulus was a cause and  
2) the information presented supported the research author's conclusion.   
We recognize, however, that this toxic stimulus was in all probability one component of a more complex 
offensive-defensive "signature" imbalance that resulted in the symptom(s) of interest. 
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Chapter 7 
DETAILED METHODOLOGY 
7A. Methodology for Identifying AD Foundational Causes 
7A1. Overview 
 This study focuses on identifying direct (and some indirect) AD foundational causes.  It 
extrapolates and extends the identification techniques used in the chronic kidney disease (CKD) study [1] 
and in the eBook on identifying foundational causes for "all" diseases [2]. In the CKD study, 
approximately 900 direct and indirect potential foundational causes of CKD were identified (as well as 
direct and indirect treatments), and in the eBook, approximately 800 potential pervasive foundational 
causes of disease were identified ('pervasive' meant that the foundational cause listed contributed to some 
threshold number of different diseases). 
 The present study had two main components, with a different approach and different search 
engine for each component.  The earlier component involved 1) using a novel targeted query to retrieve 
records with high probability of containing AD foundational causes, and then 2) performing a visual 
inspection (reading) of the retrieved records.  The later component involved retrieving all the records in 
the AD core literature, then using advanced text mining techniques to extract phrases from text fields (and 
MeSH terms from the MeSH field) that had high probability of being foundational causes. 
7A2. Database/Search Engine Selection 
 The first step in designing and developing a specific query for retrieving records is identifying the 
databases(s) and search engine(s) that will be used in the retrieval process, since the query format has to 
be tailored to the database and search engine characteristics. Medline was selected as the database to be 
used, since it is the main repository of records from the premier biomedical journals. The Thomson 
Reuters version of the Medline search engine was used for the initial visual inspection component of the 
AD study, since the Thomson search engine had the proximity search capability compatible with query 
terms.  The Pubmed version of the Medline search engine was used for the later "streamlined" component 
of the AD study, since the phrase extraction approach did not require proximity searching.  
7A3. Visual Inspection Component 
 To define candidate query terms, an AD core literature consisting of about 100,000 Medline 
records was downloaded and examined.  The higher frequency MeSH terms associated with the AD core 
literature records were examined manually, and those MeSH terms that appeared to relate to foundational 
causes were evaluated for relevance. Nominally, ten records that contained each candidate causes MeSH 
term were examined, and if relevance was about 70% or beyond, the MeSH term was selected. In 
borderline cases, more MeSH terms were sampled until definitive conclusions could be drawn. Relevant 
does not mean unanimity or consensus was achieved for causes. Non-agreement with the majority could 
have been attributable to poor research, research with a pre-determined agenda (e.g., [1, 2]), or selection 
of a "window" in parameter space different from where the cause was operable. But, if cause was found 
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operable in a few of the sampled papers for a given MeSH term, the term was deemed sufficiently 
important to select for the query. 
 These higher frequency MeSH terms were then matrixed with all MeSH terms in the retrieval.  
Lower frequency MeSH term candidates were identified through strong co-occurrence with the higher 
frequency terms, and the lower frequency terms were subsequently validated. Then, a separate database 
was generated consisting of all the records that included these high and low frequency selected MeSH 
terms. In this new database, the higher frequency Abstract phrases were examined, and those that 
appeared to relate to potential causes were evaluated for relevance. A similar procedure to that used for 
causes MeSH term selection was followed. The higher frequency Abstract phrases, and some generic 
Abstract phrases related to causes (e.g., expos*, induc*, etc), were matrixed with all Abstract phrases to 
identify lower frequency phrase candidates through strong co-occurrence. 
 Eventually, all the MeSH terms were read and examined, and a few low frequency terms that 
were missed with the co-occurrence procedure were added to the list. The same was not possible with the 
Abstract phrases. While there were thousands of MeSH terms (readable, although visually intensive), 
there were millions of Abstract phrases.  
 As stated in the Introduction, only foundational causes were evaluated in this study. There were 
six main types of foundational causes: Lifestyle, Iatrogenic, Biotoxic, Occupational/Environmental, 
Psychosocial/Socioeconomic, and Genetics. Since the purpose of this study is to identify specific causes 
to eliminate in order to prevent/halt/reverse AD, and since relatively little can be done at this time to alter 
the genetics foundational causes, the genetics causes were not included in the final queries. 
 The overall query structure was of the generic form [Cause][Produces][Symptom]. Two of the 
three would be specified in the query, directly or implicitly, and the retrieval would provide the third. 
Examples from causes query: 
a. Cause near Produces: steroid-induc* or diet-induc* OR antibiotic near/1 cause*. These are generic or 
specific members of classes of potential causes in proximity to Produces-type terms. The classes tend to 
be drugs, diets, chemicals, radiation sources, etc. The Produces-type terms are necessary since drugs, 
diets, etc can be either beneficial or harmful, depending on circumstances (e.g., a chemotherapeutic drug 
can be helpful for treating cancer, but may also produce cognitive decline). 
b. Produces near Symptom: cause* near/5 "cognitive decline" NOT "cognitive decline cause*" 
c. Cause near Symptom: *Bacterium or pentachloro* in Title, with either Symptom in Title or in MeSH. 
If Abstracts are searched, stronger proximity conditions are required; e.g., *Bacterium near/5 Symptom. 
Unlike case a) above, in this case the causes are specific members of classes of potential causes that 
usually don't have beneficial effects, and therefore don't require proximity to causes-like terms; the 
causative nature is implied by the substance. 
 Note on the above. The model used was [cause-produce-symptom], but a somewhat broader form 
could be: [cause-produce-adverse effects], of which Symptom is one way of describing an adverse effect. 
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Thus, "toxic*" or "adverse effect*", or "harm*" in the Title by itself, along with the Symptom in the Title 
or MeSH tends to be accompanied by the cause and the effect it has. 
 Additionally, many research articles addressing causes use the language [cause-
activates/inhibits/blocks-signaling pathway(s)] (e.g., "MicroRNA-222 promotes tumorigenesis via 
targeting DKK2 and activating the Wnt/beta-catenin signaling pathway"). The signaling pathways were 
not used as part of the queries in this study, but a future more comprehensive and well-resourced study 
could include the signaling pathways in the queries; their incorporation would be straight-forward. Many 
research papers, especially at the more fundamental biological level, may not mention diseases or 
symptoms, but are written in the language of effects on signaling pathways, and these papers could be 
accessed by the appropriately-written queries.  To close the loop in this case, the link between altered 
signalling pathway and either AD or its surrogate endpoints would have to be established. 
 The final query used is shown in section 7A - Appendix 1.  The Thomson Medline AD core 
literature (from 1994-2014) consisted of 76663 records, and intersection of the query terms with this 
literature yielded 10,733 records.  The most recent 5,000 were inspected visually, and the relevant 
foundational causes were extracted. 
7A4. Streamlined Component 
7A4a. Overview 
 An AD core literature consisting of 99,610 records was downloaded from Pubmed on 25 April 
2015.  Three streamlined sub-components were applied to this downloaded literature to extract AD 
foundational causes.   
 The first sub-component used only MeSH Qualifiers to filter downloaded records and extract 
potential foundational causes.  The second sub-component used  MeSH terms (relatively unambiguously 
related to foundational causes) to filter downloaded records and extract potential foundational causes.  
The third sub-component used text terms (applied to the Title and Abstract fields) to filter downloaded 
records and extract potential foundational causes. The results of the Visual Inspection component and the 
Streamlined component were integrated to produce the final AD foundational causes, as shown in the 
taxonomy of Table 8-3. 
7A4b. MeSH-Based Approach 
7A4b1.  MeSH Qualifiers Approach 
 An offshoot of the MeSH Qualifier concept was used for identifying foundational causes. MeSH 
Headings have a number of Qualifiers associated with them to allow focus on items of interest. Thus, the 
MeSH term Cadmium/toxicity allows records to be retrieved related to the toxicity of Cadmium. These 
MeSH Qualifiers may be perceived as linking terms to the MeSH Headings, allowing for "surgical" 
extraction of MeSH Headings that meet desired criteria. Thus, if MeSH Qualifiers strongly related to 
foundational causes can be identified, they can be used to identify MeSH Headings that are potential 
foundational causes of disease. 
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 There were 83 topical MeSH Qualifiers (in Pubmed) used for indexing and cataloging in 
conjunction with MeSH Heading descriptors when this concept was developed. All 83 were examined in 
more or less detail for applicability to identifying foundational causes of disease. For the initial Visual 
Inspection approach query, three were selected as producing  relevant results when used in isolation: 
chemically induced, toxicity, poisoning.   
 The Streamlined approach was performed one year after the Visual Inspection approach, with one 
year's experience working with the selected MeSH Qualifiers.  The MeSH Qualifiers were re-examined 
for the Streamlined approach, and four were selected (after extensive validation) as producing highly 
relevant results when used in isolation: adverse effects, toxicity, pathogenicity, poisoning. A few limited 
combinations of the remaining MeSH Qualifiers were examined for the Streamlined approach, but none 
were deemed to have sufficient relevance.  
 All MeSH terms that contained at least one of these Qualifiers were extracted, and the related 
records examined for potential foundational causes.  While this MeSH Qualifier linking approach was 
developed for, and applied to, potential foundational causes, it can be easily modified for identifying 
potential treatments, identifying potential biomarkers, identifying potential mechanisms, etc. 
7A4b2. MeSH Headings Approach 
 MeSH Headings related relatively unambiguously to foundational causes were identified two 
ways. First, results from past studies were examined, especially [1, 2], and relevant MeSH Headings were 
extracted. Second, a few of the most unambiguous MeSH terms identified from past studies were entered 
into Pubmed as query terms, and all the MeSH terms in the resultant retrieval (i.e., those that co-occurred 
with the entry MeSH terms) were examined for relevance.  The final list of relevant MeSH terms (7A - 
Appendix 2) was intersected with the total list of MeSH terms in the retrieved database, and the resulting 
records were examined for potential AD foundational causes.  Again, while this focused MeSH Heading 
approach was developed for identifying potential foundational causes, it could (with some work) be 
adapted to identifying potential treatments, potential biomarkers, potential mechanisms, etc. 
7A4c. Text-Based Approach 
7A4c1. Title Linking Phrases Approach 
 Because of MeSH terms' limitations (not all Medline records have MeSH descriptors, not all 
MeSH terms are included in those records that have MeSH terms, not all MeSH descriptors used have 
appropriate Qualifiers attached. etc), a text-based approach for identifying causes was added to the 
analysis. Because of 1) the large number of phrases in a record's Abstract compared to the Title, and 2) 
computer storage and software limitations, the bulk of the analysis was performed on the Title phrases.  A 
more limited analysis was performed on the Abstract phrases, and is shown in Section 7A4c3 - Abstract 
Linking Phrases Approach. 
 There were millions of Title phrases that had to be evaluated for potential causes. Only the 
highest frequency phrases could be inspected visually. To access the lower frequency terms, a number of 
linking terms were identified. 
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 The linking terms were generated through visually inspecting many records containing 
foundational causes in the Titles, and identifying those terms that appeared frequently with the 
foundational causes. These linking terms include: -induced; caused by; induced by; -contaminated; 
exposure to; exposure(s) [at end of phrase]; exposed to; poisoning [at end]; -exposed [at end]; -related; -
associated; -infected; abuse*; toxicity. The phrases that included the linking terms eventually had to be 
separated from the linking terms to identify the specific foundational causes. Other linking terms were 
virus* and generic bacterial headings, but these did not have to be separated from the phrases. 
7A4c2. Title Dot Product Approach 
 Finally, potential foundational causes from myriad other sources (including past foundational 
causes studies, government-approved lists of toxic substances, MeSH-derived causes, etc) were 
intersected with the full list of Title phrases, and added to the potential foundational causes identified in 
the Linking Phrases approach. 
 While the Title phrase linking terms were developed specifically for identifying causes, a similar 
approach could be used to develop linking terms for identifying potential treatments, potential 
biomarkers, or potential mechanisms. Moreover, there could be substantial benefits gained by using 
Abstracts for phrase generation rather than Titles, and even full-text rather than Abstracts. While use of 
proximity queries with the linking terms in the Title were not required, they would be required for use in 
Abstracts or full-text. Adding proximity capability would be a minor modification to the form of the 
query developed below. The major issue would be switching to a database search engine that had the 
capability of proximity searching. 
7A4c3 - Abstract Linking Phrases Approach 
 Given the size and breadth of Abstracts relative to Titles, most of the linking terms used to extract 
causes from the Title were relatively inefficient in extracting foundational causes from the Abstract.  
Variants of induc* and expos* were used to link to potential foundational causes in Abstract records, and 
these extracted terms received the same treatment as those from the Title. 
 The myriad potential foundational causes from the Visual Inspection component and the 
Streamlined component were combined. 
7A5 - Validation of Potential Foundational Causes 
 There were 9427 potential foundational causes that resulted from combination of the above 
sources.  Each of these terms had to be validated before inclusion in the final AD potential foundational 
causes taxonomy.  The validation process was as follows. 
 The Thomson Medline search engine was the main vehicle used for validation, although in some 
cases Thomson Science Citation Index Expanded (SCI) had to be used, and in a very few cases, Pubmed 
was used.  A query consisting of two components was entered into the search engine.  The first 
component covered the core AD literature: Alzheimer* OR dementia in Title or MeSH.  The second 
component was the potential foundational cause to be validated (e.g., smoking).  The two components 
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were intersected (e.g., (Alzheimer* OR dementia) AND smoking), and some/all of the records retrieved 
were read.  The evidence for linkages between the potential foundational cause and Alzheimer's Disease 
directly or surrogate endpoints was evaluated critically.  This was a difficult process, compounded by the 
fact that adverse effects of toxic stimuli may be under-reported/mis-reported [1]. 
 Because of the presence of duplicate terms and concepts, not all the 9427 potential foundational 
cause terms had to be read with the same level of certainty.  Many could be eliminated by inspection, as 
long as the duplication was perceived. 
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7A - Appendix 1 - AD Causes Query - Visual Inspection Approach 
I. Core Literature Retrieval Thomson Medline (76,663 records retrieved - core only) 
TOPIC 
Alzheimer* 
OR 
MESH HEADING  
Alzheimer Disease 
NOT 
TOPIC 
(streptozotocin OR scopolamine OR colchicine OR LPS-induc* OR polymorphism* OR Abeta-induc* 
OR "beta-amyloid-induc*" OR "amyloid-beta-induc*" OR "beta-amyloid peptide-induc*" OR "Abeta25-
35-induc*" OR "Abeta25-35 peptide-induc*" OR Abeta40-induc* OR nontoxic OR non-toxic)  
AND 
Remainder of Query Intersected with Core Literature 
II. TEXT FIELD TERMS 
IIA. NON-LIFESTYLE-SPECIFIC COMPONENT - TOPIC 
 ("2,4,6- triiodobenzoic acid" OR "3-deazaneplanocin A" OR "5AZA" OR "5-aza-deoxycytidine" OR "5-
fluorouracil" OR "9-alpha fluorocortisol" OR "9-alpha fluoroprednisolone" OR "9-hydroxy-2-
methylellipticinium" OR "acarbose" OR "ACE inhibitor*" OR "acetaminophen" OR "acetazolamide" OR 
"acetylsalicylic acid" OR "acyclovir" OR "adalimumab" OR "adefovir" OR "adriamycin" OR 
"alclofenac" OR "aliskiren" OR "alizapride" OR "allopurinol" OR "all-trans-retinoic acid" OR "alpha-
mercaptopropionylglycine" OR "amikacin" OR "Aminoglycoside*" OR "Amiodarone" OR 
"amitriptyline" OR "amlodipine" OR "amoxicillin" OR "amphetamine*" OR "amphotericin b" OR 
"ampicillin" OR "ampiroxicam" OR "anabolic steroid*" OR "Anaesthetic*" OR "Analgesic*" OR 
"anasthesia" OR "androgen deprivation therapy" OR "anesthetic*" OR "anthracycline" OR 
"antiadrenergic agent*" OR "anti-adrenergic agent*" OR "antiadrenergic drug*" OR "anti-adrenergic 
drug*" OR "antiallergic agent*" OR "Anti-Allergic agent*" OR "antiallergic drug*" OR "Anti-Allergic 
drug*" OR "antiandrogen* agent*" OR "anti-androgen* agent*" OR "antiandrogen* drug*" OR "anti-
androgen* drug*" OR "antianginal agent*" OR "anti-anginal agent*" OR "antianginal drug*" OR "anti-
anginal drug*" OR "antiangiogenesis agent*" OR "anti-angiogenesis agent*" OR "antiangiogenesis 
drug*" OR "anti-angiogenesis drug*" OR "antiarrhythmic agent*" OR "antiarrhythmic drug*" OR "anti-
arrythmatic agent*" OR "anti-arrythmatic drug*" OR "antiasthmatic agent*" OR "anti-asthmatic agent*" 
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OR "antiasthmatic drug*" OR "anti-asthmatic drug*" OR "antibacterial agent*" OR "Anti-bacterial 
agent*" OR "antibacterial drug*" OR "Anti-bacterial drug*" OR "antibiotic*" OR "antibone-loss agent*" 
OR "Anti-Bone-Loss agent*" OR "antibone-loss drug*" OR "Anti-Bone-Loss drug*" OR "anticholinergic 
agent*" OR "anti-cholinergic agent*" OR "anti-cholinergic drug*" OR "anticholinergic* drug*" OR 
"anticoagulant*" OR "Anti-coagulant*" OR "anticonvulsant*" OR "anti-convulsant*" OR 
"antidepressant*" OR "anti-depressant*" OR "Antidiabetic agent*" OR "anti-diabetic agent*" OR 
"Antidiabetic drug*" OR "anti-diabetic drug*" OR "antidiarrheal agent*" OR "anti-diarrheal agent*" OR 
"antidiarrheal drug*" OR "anti-diarrheal drug*" OR "anti-emetic" OR "antiemetic*" OR "antifungal 
agent*" OR "anti-fungal agent*" OR "antifungal drug*" OR "anti-fungal drug*" OR "antigonadotropic 
agent*" OR "anti-gonadotropic agent*" OR "antigonadotropic drug*" OR "anti-gonadotropic drug*" OR 
"antigout agent*" OR "anti-gout agent*" OR "antigout drug*" OR "anti-gout drug*" OR "antihistamine 
agent*" OR "anti-histamine agent*" OR "antihistamine drug*" OR "anti-histamine drug*" OR 
"Antihypertensive agent*" OR "anti-hypertensive agent*" OR "Antihypertensive drug*" OR "anti-
hypertensive drug*" OR "antiinfective agent*" OR "Anti-Infective agent*" OR "antiinfective drug*" OR 
"Anti-Infective drug*" OR "anti-infective*" OR "antiinflammatory agent*" OR "Anti-Inflammatory 
agent*" OR "antiinflammatory drug*" OR "Anti-Inflammatory drug*" OR "antimalarial agent*" OR 
"anti-malarial agent*" OR "antimalarial drug*" OR "anti-malarial drug*" OR "antimetabolite agent*" OR 
"anti-metabolite agent*" OR "antimetabolite drug*" OR "anti-metabolite drug*" OR "antimigraine 
agent*" OR "anti-migraine agent*" OR "antimigraine drug*" OR "anti-migraine drug*" OR 
"Antineoplastic Agent*" OR "anti-neoplastic agent*" OR "Antineoplastic drug*" OR "anti-neoplastic 
drug*" OR "antiparkinson agent*" OR "anti-parkinson agent*" OR "antiparkinson drug*" OR "anti-
parkinson drug*" OR "antiplatelet agent*" OR "anti-platelet agent*" OR "antiplatelet drug*" OR "anti-
platelet drug*" OR "antipseudomonal agent*" OR "anti-pseudomonal agent*" OR "antipseudomonal 
drug*" OR "anti-pseudomonal drug*" OR "antipsoriatic agent*" OR "anti-psoriatic agent*" OR 
"antipsoriatic drug*" OR "anti-psoriatic drug*" OR "Antipsychotic Agent*" OR "Anti-psychotic agent*" 
OR "Antipsychotic drug*" OR "Anti-psychotic drug*" OR "Antiretroviral Agent*" OR "Anti-retroviral 
Agent*" OR "Antiretroviral drug*" OR "Antiretroviral drug*" OR "antiretroviral therapy" OR 
"Antirheumatic Agent*" OR "anti-rheumatic agent*" OR "Antirheumatic drug*" OR "anti-rheumatic 
drug*" OR "antiseptic agent*" OR "anti-septic agent*" OR "antiseptic drug*" OR "anti-septic drug*" OR 
"antispasmodic agent*" OR "anti-spasmodic agent*" OR "antispasmodic drug*" OR "anti-spasmodic 
drug*" OR "anti-thymocyte serum" OR "Antithyroid Agent*" OR "Anti-thyroid Agent*" OR 
"Antithyroid drug*" OR "Anti-thyroid drug*" OR "antitoxin*" OR "anti-toxin*" OR "antituberculosis 
agent*" OR "anti-tuberculosis agent*" OR "antituberculosis drug*" OR "anti-tuberculosis drug*" OR 
"antitussive agent*" OR "anti-tussive agent*" OR "antitussive drug*" OR "anti-tussive drug*" OR 
"antivenin*" OR "antivertigo agent*" OR "anti-vertigo agent*" OR "antivertigo drug*" OR "anti-vertigo 
drug*" OR "Antiviral agent*" OR "Anti-viral agent*" OR "Antiviral drug*" OR "Anti-viral drug*" OR 
"aprotinin" OR "aspirin" OR "AT1 receptor antagonists" OR "atazanavir" OR "atorvastatin" OR 
"axitinib" OR "azacitadine" OR "azathioprine" OR "azithromycin" OR "Azole*" OR "Barbiturate*" OR 
"bardoxolone methyl" OR "benfluorex" OR "benoxaprofen" OR "beta-lactam" OR "bevacizumab" OR 
"bezafibrate" OR "bisacodyl" OR "Bisphosphonate*" OR "Bleomycin" OR "bortezomib" OR 
"bucillamine" OR "bupivacaine" OR "buspirone" OR "caffeine" OR "calcineurin inhibitor*" OR 
"calcitriol" OR "Calcium Channel Blocker" OR "Calcium channel blocker*" OR "capecitabine" OR 
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"captopril" OR "carbamazepine" OR "carbenoxolone" OR "carbimazole" OR "carboplatin" OR 
"Cardiovascular Agent*" OR "carmustine" OR "C-arylsuccinimides" OR "cediranib" OR "cefdinir" OR 
"cefoxitin" OR "ceftriaxone" OR "cefuroxime" OR "celecoxib" OR "Central Nervous System Agent*" 
OR "cephaloridine" OR "cephalosporins" OR "Cephems" OR "cetuximab" OR "chlorambucil" OR 
"Chloramphenicol" OR "chlormezanone" OR "chloroquine" OR "Chlorpromazine" OR "chlorprothixene" 
OR "chlorthalidone" OR "cidofovir" OR "cimetidine" OR "ciprofibrate" OR "ciprofloxacin" OR 
"cisplatin" OR "clarithromycin" OR "clometacin" OR "clomipramine" OR "clopentixol" OR 
"clopidogrel" OR "cloxacillin" OR "clozapine" OR "colchicine" OR "colistin" OR "contrast medium" OR 
"coronary artery bypass" OR "corosolic acid" OR "Corticosteroid*" OR "cyclophosphamide" OR 
"cycloserine" OR "cyclosporine" OR "cytarabine" OR "cytosine arabinoside" OR "dasatinib" OR 
"daunomycin" OR "daunorubicin" OR "decitabine" OR "deferasirox" OR "deferoxamine" OR 
"demeclocycline" OR "deoxycorticosterone acetate" OR "desipramine" OR "dexamethasone" OR 
"dexfenfluramine" OR "dexmethylphenidate" OR "dextran" OR "diaziquone" OR "diclofenac" OR 
"didecyldimethylammonium chloride" OR "diethyacetylurea" OR "diflunisal" OR "Digitalis" OR 
"diltiazem" OR "diphenylhydantoin" OR "diphosphonates" OR "dipivalyl adrenaline hydrochloride" OR 
"dipyrone" OR "disopyramide" OR "Diuretic*" OR "doxepin" OR "doxorubicin" OR "doxycycline" OR 
"d-penicillamine" OR "dRK6" OR "efavirenz" OR "enoxaparin" OR "epoetin" OR "erythromycin" OR 
"erythropoietin" OR "esomeprazole" OR "etanercept" OR "ethambutol" OR "ethosuximide" OR 
"famotidine" OR "fenbufen" OR "fenclofenac" OR "fenfluramine" OR "fenofibrate" OR "fenoldopam" 
OR "fenoprofen" OR "Fibrate therapy" OR "flubiprofen" OR "flucloxacillin" OR "fluindione" OR 
"Fluoroquinolones" OR "flupenthixol" OR "fluphenazine" OR "flurbiprofen" OR "flurithromycin" OR 
"fondaparinux sodium" OR "foscarnet" OR "furantoin" OR "furosemide" OR "fusidic acid" OR "FYX-
051" OR "gabapentin" OR "gadodiamide" OR "Gadolinium" OR "gadopentetate dimeglumine" OR 
"Gastrointestinal Agent*" OR "gatifloxacin" OR "GBCA" OR "GCCA" OR "gefitinib" OR "gemcitabine" 
OR "gemfibrozil" OR "gentamicin" OR "germicide*" OR "Glucocorticoid*" OR "glycyrrhizinic acid" OR 
"Haloperidol" OR "Halothane" OR "Hematologic Agent*" OR "heparin" OR "hetastarch" OR "high 
insulin" OR "hydralazine" OR "hydrochlorothiazide" OR "hydroxychloroquine" OR "hydroxyethylstarch" 
OR "hydroxymethylglutaryl-CoA reductase inhibitor*" OR "hylan G-F 20" OR "Hypnotic Agent*" OR 
"iatrogenic" OR "ibuprofen" OR "ifosfamide" OR "IGF-1" OR "iloprost" OR "imatinib" OR 
"imipramine" OR "imiquimod" OR "Immunosuppressive Agent*" OR "indinavir" OR "indomethacin" 
OR "infliximab" OR "Interferon*" OR "intravenous immunoglobulin*" OR "Iodine" OR "iodixanol" OR 
"iohexol" OR "ionizing radiation" OR "iopamidol" OR "ioxilan" OR "iron sucrose" OR "iron-induced" 
OR "iron-overload" OR "isocarboxazid" OR "isoniazid" OR "isoprenaline" OR "ketamine" OR 
"Ketoconazole" OR "ketoprofen" OR "ketorolac" OR "lansoprazole" OR "lapatinib" OR "leflunomide" 
OR "levetiracetam" OR "levofloxacin" OR "Lipid Regulating Agent*" OR "lithium" OR "lopinavir" OR 
"loratadine" OR "loxapine" OR "mannitol" OR "maprotiline" OR "mefanamic acid" OR "meropenem" 
OR "mesalamine" OR "mesalazine" OR "mesoridazine" OR "metamizole" OR "metformin" OR 
"methicillin" OR "methimazole" OR "methocarbamol" OR "methotrexate" OR "methotrimeprazine" OR 
"methoxyflurance" OR "methyldopa" OR "methylphenidate" OR "methysergide" OR "metolazone" OR 
"metoprolol" OR "Metronidazole" OR "midecamycin acetate" OR "Mineralcorticoid*" OR "minocycline" 
OR "mirtazapine" OR "mitomycin" OR "Mood Stabilizer*" OR "morphine" OR "Movement Stabilizer*" 
OR "moxifloxacin" OR "Muscle Relaxant*" OR "Mustard gas" OR "muzolimine" OR "nafcillin" OR 
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"naphazoline hydrochloride" OR "naproxen" OR "N-arylsuccinimides" OR "Nasal decongestant*" OR 
"nelfinavir" OR "neomycin" OR "Niacin" OR "nifedipine" OR "niflumic acid" OR "nimesulide" OR 
"nitrendipine" OR "nitrofurantoin" OR "nitrogen mustard" OR "Nitroglycerin" OR "nitrosureas" OR 
"nomifensine" OR "Nonsteroidal anti-inflammatory drug*" OR "norepinephrine" OR "norfloxacin" OR 
"nortriptyline" OR "NSAID*" OR "NVP-BKM120" OR "ofloxasin" OR "olanzapine" OR "olmetin" OR 
"olsalazine" OR "omeprazole" OR "orlistat" OR "oxaliplatin" OR "oxymetazoline hydrochloride" OR 
"oxytetracycline" OR "ozurdex" OR "paliperidone" OR "pamidronate" OR "panitumumab" OR 
"pantoprazole" OR "papaverine" OR "paracetamol" OR "paroxetine" OR "pazopanib" OR "pefloxacin" 
OR "Penams" OR "penicillamine" OR "penicillin" OR "pentamidine" OR "pentazocine" OR 
"pericyazine" OR "perphenazine" OR "phenacetin" OR "phenindione" OR "phenobarbital" OR 
"phenylbutazone" OR "phenylephrine" OR "phenylpropanolamine" OR "phenytoin" OR 
"phosphatidylinositol-3-kinase inhibitor*" OR "physostigmine" OR "pimozide" OR "piperacillin" OR 
"piroxicam" OR "pirprofen" OR "platalet aggregation inhibitor*" OR "polymyxin B" OR "pranlukast" 
OR "prednisolone" OR "Primaquine" OR "probenecid" OR "procainamide" OR "prochlorperazine" OR 
"propoxyphene" OR "propylthiouracil" OR "protamine" OR "Proton pump inhibitor*" OR "prulifloxacin" 
OR "pseudoephedrine hydrochloride" OR "ptu-induced" OR "puromycin" OR "quetiapine" OR 
"quinacrine" OR "quinidine" OR "quinine" OR "quinolone" OR "rabeprazole" OR "radiofrequency-
induced cosmetic volume reduction" OR "ranitidine" OR "rapamycin" OR "rhuepo-induced" OR 
"rifampicin" OR "rifampin" OR "risperidone" OR "Ritalin" OR "ritodrine hydrochloride" OR "ritonavir" 
OR "rofecoxib" OR "rosuvastatin" OR "scopolamine" OR "selegiline" OR "sibutramine" OR 
"simvastatin" OR "sodium barbital" OR "sodium valproate" OR "sorafenib" OR "spirapril" OR 
"spironolactone" OR "Statin*" OR "Steroid*" OR "Stimulant*" OR "streptomycin" OR "streptozocin" 
OR "streptozotocin" OR "Succinimide derivative*" OR "sulfadiazine" OR "sulfamethoxazole" OR 
"sulfasalazine" OR "Sulfonamide*" OR "sulfonylureas" OR "sulfur mustard" OR "sulindac" OR 
"sulphinpyrazone" OR "sulpiride" OR "sunitinib" OR "superdrol" OR "tacrolimus" OR "Tamoxifen" OR 
"tazobactam" OR "telazol" OR "telithromycin" OR "tenofovir" OR "testosterone" OR "tetrabenazine" OR 
"Tetracycline*" OR "tetrahydrozoline hydrochloride" OR "tetrandrine" OR "thiazides" OR 
"thiopropazate" OR "thioproperazine" OR "Thioridazine" OR "thiothixene" OR "thrombolytic therapy" 
OR "ticlopidine" OR "tiletamine" OR "tiopronin" OR "tobramicin" OR "triamterene" OR "trichostatin A" 
OR "Tricyclics" OR "trimethadione" OR "trimethoprim" OR "trimipramine" OR "tripelennamine" OR 
"valdecoxib" OR "Valproic Acid" OR "valpromide" OR "vancomycin" OR "venlafaxine" OR "verapamil" 
OR "verteporfin" OR "warfarin" OR "whole-body irradiation" OR "wortmannin" OR "yohimbine" OR 
"zoledronate" OR "zopiclone" OR "zotepine" OR "zuclopenthixol" OR "4-HNE" OR "7-Ketocholesterol" 
OR "aflatoxin" OR "Aipysurus laevis venom" OR "amorimia exotropica" OR "anti-mouse-GBM sera" 
OR "AOPP-modified rat serum albumin" OR "apoferritin" OR "bee sting*" OR "beta-conglycinin" OR 
"bovine serum albumin" OR "cantharidin" OR "ceramide" OR "citrinin" OR "concanavalin A" OR 
"connective tissue growth factor" OR "cow milk processing" OR "CTGF" OR "cylindrospermopsin" OR 
"deoxynivalenol" OR "D-fructofuranosyl" OR "Endotoxin*" OR "Exotoxin*" OR "fumonisin B1" OR 
"homopolysaccharide" OR "indican" OR "indoxyl sulfate" OR "levan" OR "lipopolysaccharide" OR 
"lipopolysaccharide-induced" OR "L-NAME" OR "L-NNA" OR "lps-induced" OR "monocrotaline" OR 
"monosodium urate crystal" OR "mycobacterial infection*" OR "Mycotoxin*" OR "nephritogenoside" 
OR "NG-nitro-L-arginine methyl ester" OR "Nitroarginine" OR "nivalenol" OR "Nω-nitro-L-arginine" 
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OR "oak toxicosis" OR "ochratoxin A" OR "Ochratoxin*" OR "O-glycosylated IgA rheumatoid factor" 
OR "p-Cresyl sulfate" OR "PDGF-BB" OR "penicillic acid" OR "Platelet-derived growth factor-BB" OR 
"pufferfish tetrodotoxin" OR "quercus calliprinos" OR "scorpion sting*" OR "sea anemone Phyllodiscus 
semoni" OR "sea snake venom" OR "snake bite" OR "stinging insect venom" OR "tetrodotoxin" OR 
"Tityus serrulatus scorpion venom" OR "Tricothecene*" OR "U1-70-kDa small nuclear 
ribonucleoprotein/snRPN70" OR "viper snake venom" OR "vomitoxin" OR "wasp sting*" OR "yew" OR 
"*Bacteri*" OR "*Chia" OR "*Ococcus" OR "*Omonas" OR "adenine" OR "Aspergillus " OR 
"Bartonella henselae" OR "beta-hemolysin " OR "Brucella" OR "Burkholderia pseudomallei" OR "C. 
difficile toxin A" OR "C. difficile toxin B" OR "Campylobacter jejuni" OR "Campylobacter jejuni" OR 
"Candida albicans" OR "Candida tropicalis" OR "Candidemia" OR "Capillaria hepatica" OR "Chlamydia 
pneumoniae" OR "Chlamydia" OR "Chlamydophila" OR "Citrobacter rodentium" OR "Clostridium" OR 
"Corynebacterium diphtheriae" OR "diphtheria toxin" OR "Corynebacterium renale" OR "Dirofilaria 
immitis" OR "Echinococcus" OR "Ehrlichia canis" OR "Enterococcus faecalis" OR "Escherichia coli" 
OR "e. coli" OR "falciparum malaria" OR "malaria" OR "Fusarium graminearum" OR "Gemella 
haemolysans" OR "Haemophilus" OR "Helicobacter pylori" OR "Klebsiella pneumoniae" OR "leprosy" 
OR "Mycobacterium leprae" OR "Mycobacterium lepromatosis" OR "Leptospirosis" OR "leptospira" OR 
"marcescens" OR "Mycoplasma" OR "Neisseria" OR "Nematode*" OR "Parasite*" OR "Penicillium 
aurantiogriseum" OR "Penicillium aurantiogriseum" OR "Plasmodium brasilianum" OR 
"Propionibacterium acnes" OR "Proteus mirabilis" OR "Pseudomonas aeruginosa" OR "Rickettsia" OR 
"Rochalimaea" OR "salmonella" OR "Schistosoma haematobium" OR "Schistosoma mansoni" OR 
"Serratia marcescens" OR "staphylococcal infection*" OR "Staphylococcus aureus" OR "Streptococcus 
agalactiae" OR "Streptococcus mutans" OR "Streptococcus pyogenes" OR "streptococcal pyrogenic 
exotoxin B" OR "Thy-1.1 monoclonal antibody" OR "Toxocara canis" OR "Treponema" OR "Trichinella 
spiralis" OR "Trypanosoma brucei" OR "Tyrophagus putrescentiae" OR "Vibrio" OR "Yersinia" OR 
"*OBACTER" OR "*nitrophenol*" OR "*benzene" OR "*ethane" OR "*phthalate" OR "*toluene" OR 
"1,1,1-trichloroethane" OR "12-O-tetradecanoylphorbol-13-acetate " OR "1-methyl-4-phenylpyridinium" 
OR "2,3,5-triiodobenzoic acid" OR "2,3,7,8-tetrachlorodibenzo-p-dioxin" OR "2-Amino-4-
(ethylthio)butyric acid) " OR "acetaldehyde" OR "acrolein" OR "Air pollutant*" OR "air pollution" OR 
"aldrin" OR "alloxan" OR "alpha-Naphthylisothiocyanate" OR "aluminium" OR "aluminum" OR 
"ammonium perchlorate" OR "anti-trinitrophenol switch variant mAbs" OR "arsenic" OR "asbestos" OR 
"asphalt" OR "atrazine" OR "beryllium" OR "Bis(2-ethylhexyl) phthalate" OR "bismuth" OR "bitumen" 
OR "bromodichloromethane" OR "bromoform" OR "cadmium" OR "carbon tetrachloride" OR "cedar 
dust" OR "cerium oxide nanoparticles" OR "chloroform" OR "chlorpyrifos" OR "chromic acid " OR 
"chromium" OR "copper sulphate " OR "copper" OR "cotton pellets" OR "cyromazine" OR "decabrom*" 
OR "DEHP" OR "diazinon" OR "dibromochloromethane" OR "dichloro*" OR "diesel" OR "diethylene 
glycol" OR "dimethylnitrosamine " OR "dinitro*" OR "dinitrochlorobenzene" OR "dioxane" OR "dioxin 
" OR "domestic gas" OR "ethionine " OR "ethylene dibromide " OR "ethylene glycol" OR "fiberglass" 
OR "fibreglass" OR "fluoro-10-methyl-1-2-benzanthracene " OR "formaldehyde" OR "gasoline" OR 
"germanium" OR "glycerol" OR "grain dust" OR "halomethane* " OR "hcy-induced " OR "Heavy 
metal*" OR "Herbicide*" OR "hexabrom*" OR "hexachloro*" OR "hgcl2" OR "homocysteine" OR 
"house dust mite" OR "Hydrocarbons" OR "Insecticide*" OR "isopropyl alcohol" OR "jatropha curcas 
phorbol ester" OR "ketones" OR "malathion" OR "maleic vinyl ether anhydride " OR "Maneb" OR 
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"melamine" OR "menadione sodium bisulfite" OR "mercuric chloride" OR "Mercury" OR "methyl 
tertiary-butyl ether " OR "methylene chloride" OR "methylglyoxal" OR "multiwalled carbon nanotube*" 
OR "N,N′-dimethyl-4,4′-bipyridinium dichloride" OR "N,N'-diacetylbenzidine " OR "N-3-5-
dichlorophenyl-succinimide" OR "nanocopper" OR "n-methyl-n 1-nitro-n-nitroso guanidine " OR 
"nonylphenol" OR "octylphenol" OR "oxalates" OR "oxidant-induced" OR "p-Aminophenol" OR 
"parachloro*" OR "paraphenylenediamine" OR "paraquat " OR "Particulates" OR "pb" OR 
"pentachloro*" OR "pentachlorophenol" OR "perchloroethylene" OR "perfluor*" OR "perfluoroalkyl 
chemicals" OR "perfluorooctane sulfonate" OR "perfluorooctanoic acid" OR "Pesticide*" OR "Phenols" 
OR "phenylenediamine " OR "picric acid" OR "plant growth regulator* " OR "polybrom*" OR 
"polychlor*" OR "polychlorinated organic compound* " OR "polyfluor*" OR "polymethyl methacrylate " 
OR "potassium bichromate " OR "pristane" OR "p-xylene" OR "pyrinuron" OR "pyruvaldehyde " OR 
"silane " OR "silica" OR "silicon dioxide" OR "single wall carbon nanotube*" OR "styrene" OR 
"tetrabrom*" OR "tetrachloro*" OR "tetrachloroethylene" OR "thioacetamide " OR "titanium dioxide 
nanoparticles" OR "toluene" OR "trichloro*" OR "trichloroethylene" OR "trimethylpentane" OR 
"trinitrobenzenesulfonic acid " OR "Trinitrophenol" OR "uranium" OR "uranyl nitrate" OR "vacor" OR 
"wood dust" OR "wood preservatives" OR "xylene" OR "zinc phosphide" OR "sediment-associated" OR 
"particle-associated" OR "traffic-related" OR "work-related" OR EMF) near/20 ("poison*" OR 
"ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental OR "induc*" OR 
"damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" OR "treat*-caus*" OR 
"anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR "surg*-caus*" OR "radiation-
caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* progression" OR "caus* 
accumulation" OR "caus* * accumulation" OR "progression of" OR expos* OR contamina* OR 
chemicals OR abuse* OR induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR 
aggregation OR accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" 
OR "activat* microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR "adverse 
reaction*" OR "adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR "adverse * effect*" 
OR hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR "caus* *toxi*" OR "increas* *toxi" 
OR "produc* *toxi*" OR "enhanc* *toxi*" OR "stimulat* *toxi*" OR "accelerat* *toxi*" OR "caus* 
degrad*" OR "increas* degrad*" OR "caus* damag*" OR "increas* damag*" OR "caus* * *toxi*" OR 
"increas* * *toxi" OR "produc* * *toxi*" OR "enhanc* * *toxi*" OR "stimulat* * *toxi*" OR 
"accelerat* * *toxi*" OR "caus* * degrad*" OR "increas* * degrad*" OR "caus* * damag*" OR 
"increas* * damag*" OR "*toxi* caus* by" OR "*toxi* increas* by" OR "*toxi* produc* by" OR "*toxi* 
enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* accelerat* by" OR "damag* caus* by" OR "*damag* 
increas* by" OR deleterious OR deteriorat* OR trigger* OR  worsen* OR harm* OR hazard* OR "side-
effect*" OR dangerous OR destructive OR injurious OR unsafe OR "increas* amyloid-beta" OR 
"increas* beta-amyloid" OR "increas* Abeta" OR "increas* senile plaque*" OR "increas* tau aggregat*" 
OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR "increas* phospho-tau" OR 
"increas* tau protein*" OR "increas* hyperphosphorylated tau" OR "increas* neurofibrillary tangle*" OR 
"enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* Abeta" OR "enhanc* senile plaque*" 
OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR "enhanc*total tau" OR 
"enhanc* phospho-tau" OR "enhanc* tau protein*" OR "enhanc* hyperphosphorylated tau" OR "enhanc* 
neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR "stimulat* beta-amyloid" OR "stimulat* Abeta" 
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OR "stimulat* senile plaque*" OR "stimulat* tau aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" 
OR "stimulat*total tau" OR "stimulat* phospho-tau" OR "stimulat* tau protein*" OR "stimulat* 
hyperphosphorylated tau" OR "stimulat* neurofibrillary tangle*" OR "elevat* amyloid-beta" OR "elevat* 
beta-amyloid" OR "elevat* Abeta" OR "elevat* senile plaque*" OR "elevat* tau aggregat*" OR "elevat* 
T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR "elevat* phospho-tau" OR "elevat* tau protein*" OR 
"elevat* hyperphosphorylated tau" OR "elevat* neurofibrillary tangle*" OR "induc* amyloid-beta" OR 
"induc* beta-amyloid" OR "induc* Abeta" OR "induc* senile plaque*" OR "induc* tau aggregat*" OR 
"induc* T-tau" OR "induc* P-tau" OR "induc*total tau" OR "induc* phospho-tau" OR "induc* tau 
protein*" OR "induc* hyperphosphorylated tau" OR "induc* neurofibrillary tangle*" OR "produc* 
amyloid-beta" OR "produc* beta-amyloid" OR "produc* Abeta" OR "produc* senile plaque*" OR 
"produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-tau" OR "produc*total tau" OR "produc* 
phospho-tau" OR "produc* tau protein*" OR "produc* hyperphosphorylated tau" OR "produc* 
neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR "accelerat* beta-amyloid" OR "accelerat* 
Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau aggregat*" OR "accelerat* T-tau" OR 
"accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* phospho-tau" OR "accelerat* tau protein*" 
OR "accelerat* hyperphosphorylated tau" OR "accelerat* neurofibrillary tangle*" OR "amyloid-beta 
induc* by" OR "beta-amyloid induc* by" OR "Abeta induc* by" OR "senile plaque* induc* by" OR "tau 
aggregat* induc* by" OR "T-tau induc* by" OR "P-tau induc* by" OR "total tau induc* by" OR 
"phospho-tau induc* by" OR "tau protein* induc* by" OR "hyperphosphorylated tau induc* by" OR 
"neurofibrillary tangle* induc* by" OR "amyloid-beta produc* by" OR "beta-amyloid produc* by" OR 
"Abeta produc* by" OR "senile plaque* produc* by" OR "tau aggregat* produc* by" OR "T-tau produc* 
by" OR "P-tau produc* by" OR "total tau produc* by" OR "phospho-tau produc* by" OR "tau protein* 
produc* by" OR "hyperphosphorylated tau produc* by" OR "neurofibrillary tangle* produc* by" OR 
"caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive decline" OR "caus* brain* decline" OR 
"caus* functional decline" OR "caus* memory decline" OR "caus* cognitive deficit*" OR "caus* 
language deficit*" OR "caus* memory deficit*" OR "caus* plasticity deficit*" OR "caus* behavioral 
deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR "caus* neuropsychological 
deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR "caus* memory impair*" OR 
"caus* neurogenesis impair*" OR "caus* neuropsychological impair*" OR "caus* mind impair*" OR 
"caus* functional impair*" OR "caus* learning impair*" OR "caus* executive function impair*" OR 
"caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* synaptic loss*" OR "caus* memory loss*" 
OR "caus* loss of memory" OR "caus* hearing loss*" OR "caus* volume loss*" OR "caus* Impair* face 
recognition" OR "caus* Impair* reasoning" OR "caus* Impair* judgment" OR "caus* Impair* problem 
solving" OR "caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" OR "caus* 
diabetes" OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* hypercholesterolemia" OR 
"caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR "induc* dementia" OR 
"induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional decline" OR "induc* 
memory decline" OR "induc* cognitive deficit*" OR "induc* language deficit*" OR "induc* memory 
deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral deficit*" OR "induc* saccade deficit*" 
OR "induc* learning deficit*" OR "induc* neuropsychological deficit*" OR "induc* cognitive impair*" 
OR "induc* vascular impair*" OR "induc* memory impair*" OR "induc* neurogenesis impair*" OR 
"induc* neuropsychological impair*" OR "induc* mind impair*" OR "induc* functional impair*" OR 
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"induc* learning impair*" OR "induc* executive function impair*" OR "induc* cognitive loss*" OR 
"induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss of 
memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face recognition" 
OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* Impair* problem solving" 
OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* neuropathology" OR "induc* diabetes" 
OR "induc* hypertension" OR "induc* high cholesterol" OR "induc* hypercholesterolemia" OR "induc* 
obesity" OR "induc* metabolic syndrome" OR "produc* Alzheimer*" OR "produc* dementia" OR 
"produc* cognitive decline" OR "produc* brain* decline" OR "produc* functional decline" OR "produc* 
memory decline" OR "produc* cognitive deficit*" OR "produc* language deficit*" OR "produc* memory 
deficit*" OR "produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade 
deficit*" OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* 
cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* 
neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" OR 
"produc* functional impair*" OR "produc* learning impair*" OR "produc* executive function impair*" 
OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* synaptic loss*" OR "produc* 
memory loss*" OR "produc* loss of memory" OR "produc* hearing loss*" OR "produc* volume loss*" 
OR "produc* Impair* face recognition" OR "produc* Impair* reasoning" OR "produc* Impair* 
judgment" OR "produc* Impair* problem solving" OR "produc* inflamm*" OR "produc* oxidative 
stress" OR "produc* neuropathology" OR "produc* diabetes" OR "produc* hypertension" OR "produc* 
high cholesterol" OR "produc* hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic 
syndrome" OR "increas* Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR 
"increas* brain* decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* 
cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR "increas* 
plasticity deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" OR "increas* 
learning deficit*" OR "increas* neuropsychological deficit*" OR "increas* cognitive impair*" OR 
"increas* vascular impair*" OR "increas* memory impair*" OR "increas* neurogenesis impair*" OR 
"increas* neuropsychological impair*" OR "increas* mind impair*" OR "increas* functional impair*" 
OR "increas* learning impair*" OR "increas* executive function impair*" OR "increas* cognitive loss*" 
OR "increas* neuronal loss*" OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* 
loss of memory" OR "increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face 
recognition" OR "increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* 
problem solving" OR "increas* inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" 
OR "increas* diabetes" OR "increas* hypertension" OR "increas* high cholesterol" OR "increas* 
hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* 
Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* 
decline" OR "exacerbat* functional decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive 
deficit*" OR "exacerbat* language deficit*" OR "exacerbat* memory deficit*" OR "exacerbat* plasticity 
deficit*" OR "exacerbat* behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning 
deficit*" OR "exacerbat* neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR 
"exacerbat* vascular impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" 
OR "exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional 
impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* 
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cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* 
memory loss*" OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume 
loss*" OR "exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* 
Impair* judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR 
"exacerbat* oxidative stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* 
obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR 
"trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* 
memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory 
deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade 
deficit*" OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* 
cognitive impair*" OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* 
neurogenesis impair*" OR "trigger* neuropsychological impair*" OR "trigger* mind impair*" OR 
"trigger* functional impair*" OR "trigger* learning impair*" OR "trigger* executive function impair*" 
OR "trigger* cognitive loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* 
memory loss*" OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" 
OR "trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" 
OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* oxidative stress" OR 
"trigger* neuropathology" OR "trigger* diabetes" OR "trigger* hypertension" OR "trigger* high 
cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* obesity" OR "trigger* metabolic 
syndrome" OR "accelerat* Alzheimer*" OR "accelerat* dementia" OR "accelerat* cognitive decline" OR 
"accelerat* brain* decline" OR "accelerat* functional decline" OR "accelerat* memory decline" OR 
"accelerat* cognitive deficit*" OR "accelerat* language deficit*" OR "accelerat* memory deficit*" OR 
"accelerat* plasticity deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR 
"accelerat* learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive 
impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* 
neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind impair*" OR 
"accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* executive function 
impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR "accelerat* synaptic loss*" 
OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR "accelerat* hearing loss*" OR 
"accelerat* volume loss*" OR "accelerat* Impair* face recognition" OR "accelerat* Impair* reasoning" 
OR "accelerat* Impair* judgment" OR "accelerat* Impair* problem solving" OR "accelerat* inflamm*" 
OR "accelerat* oxidative stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR 
"accelerat* hypertension" OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR 
"accelerat* obesity" OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia 
caused by" OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline 
caused by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* 
caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral deficit* 
caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR "neuropsychological 
deficit* caused by" OR "cognitive impair* caused by" OR "vascular impair* caused by" OR "memory 
impair* caused by" OR "neurogenesis impair* caused by" OR "neuropsychological impair* caused by" 
OR "mind impair* caused by" OR "functional impair* caused by" OR "learning impair* caused by" OR " 
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executive function impair* caused by" OR "cognitive loss* caused by" OR "neuronal loss* caused by" 
OR "synaptic loss* caused by" OR "memory loss* caused by" OR "loss of memory caused by" OR 
"hearing loss* caused by" OR "volume loss* caused by" OR "Impair* face recognition caused by" OR 
"Impair* reasoning caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused 
by" OR "inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR 
"diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR 
"hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" OR 
"Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" OR "brain* 
decline induced by" OR "functional decline induced by" OR "memory decline induced by" OR "cognitive 
deficit* induced by" OR "language deficit* induced by" OR "memory deficit* induced by" OR "plasticity 
deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* induced by" OR "learning 
deficit* induced by" OR "neuropsychological deficit* induced by" OR "cognitive impair* induced by" 
OR "vascular impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced 
by" OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional impair* 
induced by" OR "learning impair* induced by" OR " executive function impair* induced by" OR 
"cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* induced by" OR 
"memory loss* induced by" OR "loss of memory induced by" OR "hearing loss* induced by" OR 
"volume loss* induced by" OR "Impair* face recognition induced by" OR "Impair* reasoning induced 
by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR "inflamm* 
induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes induced 
by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia induced 
by" OR "obesity induced by" OR "metabolic syndrome induced by")  
OR 
IIB. LIFESTYLE-SPECIFIC COMPONENT 
IIB1. LIFESTYLE-SPECIFIC COMPONENT - TOPIC 
("2,3-Pentanedione" OR "acidogenic diet*" OR "acrylamide" OR "activity restriction" OR "acute stress" 
OR "additives" OR "advanced glycation end product*" OR "Advanced glycosylation end product*" OR 
"adverse food" OR "alcohol abuse*" OR "alcohol consum*" OR "alcohol intake" OR "alcoholic*" OR 
"alcohol-induc*" OR "alcoholism" OR "Amanita phalloides" OR "amphetamine*" OR "anabolic 
steroid*" OR "areca nut chewing" OR arnica OR "aspartame" OR "betel nut chewing" OR "binge eating" 
OR "biomass fuel for cooking" OR "bitter orange"   OR "caffeine" OR "childhood adversity" OR 
"chinese herb*" OR "chlorogenic acid" OR "cholesterol-induced" OR "cigarette*" OR "cocaine" OR 
"cola" OR "competitive strength exercise training" OR cortinarius OR "dehydration" OR "depression-
caus*" OR "depression-induc*" OR dextrose OR diet* near/1 effect* OR diet*-caus* OR diet*-induc* 
OR dietborne OR "djenkol beans" OR "early-life abuse" OR "eating fast" OR "effort-reward imbalance" 
OR "emotional abuse" OR ephedra OR "exercise-caus*" OR "folic acid-induc*" OR "food additive" OR 
"food poisoning" OR "free-fatty-acid-induced" OR "fructose" OR "germ-free" OR "glucose-induc*" OR 
"glucose-peaks-short-term" OR "gluten" OR glycerin OR guarana OR "heat stroke" OR "heroin" OR 
"high home temperature" OR "high insulin" OR "high meat" OR "high selenium diet" OR "high-fat-diet*" 
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OR "high-glucose-induc*" OR "High-glycemic-load diet*" OR "high-phosphate" OR "high-phosphorous-
diet*" OR "high-protein-diet*" OR "high-protein-induc*" OR "high-protein-intake*" OR "high-salt-
diet*" OR "high-salt-intake*" OR "high-saturated-fat diet*" OR "high-sodium-diet*" OR "high-sodium-
intake*" OR "high-soybean oil" OR "high-sucrose-diet*" OR "high-sugar-diet*" OR "high-tryptophan-
diet*" OR "Highway proximity" OR hypothermia OR "hypoxia-induced" OR "insufficient sleep" OR "job 
strain" OR "laxative abuse" OR "low fiber diet*" OR "low fiber intake" OR "low legumes intake" OR 
"low manganese intake" OR "low melatonin" OR "low potassium intake" OR "low pulses intake" OR 
"low-Vitamin D intake" OR "meat" OR "milk processing" OR "morphine" OR mothball* OR 
"mushrooms" OR noise OR "overfeeding" OR palmitate OR "palmitic acid" OR "parental hypertension" 
OR "parental occupation*" OR "parental sucrose" OR "persistent organic pollutants" OR "phosphorus 
additive*" OR "physical inactivity" OR "prenatal hypoxia" OR "preserved food*" OR "preserved meat*" 
OR "prolonged sitting" OR "psychogenic polydipsia" OR "psychological trauma" OR "refined 
carbohydrate*" OR "refined cereal*" OR "refined grain*" OR "refined flour" OR "residential remoteness" 
OR "salt-induced" OR "saturated fat*" OR "sedentary" OR "short sleep duration" OR "sitting time" OR 
"sleep deprivation" OR "smoking" OR "social environment" OR "sodium additive*" OR "soft drink*" OR 
"soybean oil heated repeatedly" OR "soy-rich diet" OR "star fruit" OR "sucralose" OR "sunflower oil" 
OR "tobacco" OR "trans-fat*" OR "water-borne" OR "zinc-deficient diet" OR low near/2 sunlight OR 
waterborne)  
OR 
IIB2. LIFESTYLE-SPECIFIC COMPONENT - TITLE 
(diet* near/1 effect* OR "adverse food" OR "additives" OR exercise-induc* OR diet*-induc* OR 
exercise-caus*  OR diet*-caus* OR waterborne OR "water-borne" OR dietborne OR "acidogenic diet*" 
OR "activity restriction" OR "advanced glycation end product*" OR "Advanced glycosylation end 
product*" OR "alcohol abuse*" OR "alcohol consum*" OR "alcohol intake" OR "alcoholic*" OR 
"alcohol-induc*" OR "alcoholism" OR "amphetamine*" OR "anabolic steroid*" OR "areca nut chewing" 
OR "betel nut chewing" OR "binge eating" OR "caffeine" OR "childhood adversity" OR "chinese herb*" 
OR "cholesterol-induced" OR "cigarette*" OR "cocaine" OR "cola" OR "milk processing" OR 
"dehydration" OR "depression-induc*" OR "depression-caus*" OR "effort-reward imbalance" OR 
"emotional abuse" OR "Exercise-induced" OR "folic acid-induc*" OR "free-fatty-acid-induced" OR 
"fructose" OR "germ-free" OR "glucose-induc*" OR "glucose-peaks-short-term" OR "gluten" OR "heat 
stroke" OR "heroin" OR "high-fat-diet*" OR "high-glucose-induc*" OR "High-glycemic-load diet*" OR 
"high home temperature" OR "high insulin" OR "high meat" OR "high-phosphate" OR "high-
phosphorous-diet*" OR "high-protein-diet*" OR "high-protein-intake*" OR "high-protein-induc*" OR 
"high-salt-diet*" OR "high-salt-intake*" OR "high-saturated-fat diet*" OR "high selenium diet" OR 
"high-sodium-intake*" OR "high-sodium-diet*" OR "high-soybean oil" OR "high-sucrose-diet*" OR 
"high-tryptophan-diet*" OR "job strain" OR "laxative abuse" OR "psychological trauma" OR 
"competitive strength exercise training" OR "low fiber diet*" OR "low fiber intake" OR "low legumes 
intake" OR "low manganese intake" OR "low melatonin" OR "low potassium intake" OR "low pulses 
intake" OR "low-Vitamin D intake" OR "meat" OR "morphine" OR "mothball abuse" OR "mushrooms" 
OR "parental sucrose" OR "phosphorus additive*" OR "physical inactivity" OR "refined cereal*" OR 
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"residential remoteness" OR "salt-induced" OR "sedentary" OR "short sleep duration" OR "sitting time" 
OR "sleep deprivation" OR "smoking" OR "social environment" OR "sodium additive*" OR "soybean oil 
heated repeatedly" OR "soy-rich diet" OR "star fruit" OR "stress-induced" OR "sunflower oil" OR 
"tobacco" OR "overfeeding" OR "zinc-deficient diet" OR "TRANS-FAT*" OR "2,3-Pentanedione" OR 
"acute stress" OR "biomass fuel for cooking" OR "early-life abuse" OR "Highway proximity" OR 
"parental occupation*" OR "Sugar" OR "Refined Carbohydrate*" OR "Acrylamide" OR "Aspartame" OR 
"Sucralose" OR "Preserved Meat*" OR "Refined Flour" OR "Saturated Fat*" OR "Soft Drink*" OR 
"Preserved Food*" OR "Insufficient Sleep") 
OR 
  
III. MESH FIELD TERMS 
RUN 3A1 AND 3B1 AS ONE QUERY 
IIIA. MESH QUALIFIERS - MESH HEADING 
IIIA1. NON-LIFESTYLE-SPECIFIC COMPONENT 
(/"chemically induced" OR /toxicity OR /poisoning)  
OR 
IIIB. MESH GENERIC TERMS - MESH HEADING NO EXPLODE  
IIIB1. NON-LIFESTYLE-SPECIFIC COMPONENT - MESH HEADING NO EXPLODE 
Abnormalities, Drug-Induced OR Aids Related Opportunistic Infections OR Air Pollutants, Occupational 
OR Bacterial Infections OR Congenital Abnormalities OR Congenital Disorders Of Glycosylation OR 
Dermatitis, Occupational OR Drug Eruptions OR Drug Hypersensitivity OR Drug Toxicity OR 
Environmental Exposure OR Environmental Illness OR Environmental Monitoring OR Environmental 
Pollutants OR Fossil Fuels OR Hazardous Substances OR Herbicides OR Household Products OR HTLV 
I Infections OR Iatrogenic Disease OR Inhalation Exposure OR Insecticides OR Marine Toxins OR 
Maternal Exposure OR Mutagens OR Mycotoxins OR Neurotoxins OR Nonprescription Drugs OR 
Occupational Diseases OR Occupational Exposure OR Occupations OR Opportunistic Infections OR 
Organic Chemicals OR Paternal Exposure OR Pesticides OR Plant Poisoning OR Plants, Toxic OR 
Poisoning OR Poisons OR Prenatal Exposure Delayed Effects OR Simplexvirus OR Soil Pollutants OR 
Solvents OR Streptococcal Infections OR Vehicle Emissions OR Water Pollutants, Chemical OR 
Welding 
OR 
IIIB2. LIFESTYLE-SPECIFIC COMPONENT - MESH HEADING NO EXPLODE 
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Alcohol Drinking OR Alcoholic Intoxication OR Alcoholism OR Alcohol-Related Disorders OR 
Amphetamine-Related Disorders OR Amphetamines OR Appetite Depressants OR Carbonated Beverages 
OR Cocaine OR Cocaine-Related Disorders OR Cola OR Contraceptive Agents OR Contraceptives, Oral 
OR Cooking And Eating Utensils OR Cosmetics OR Diet, High-Fat OR Fast Foods OR Food Additives 
OR Food Contamination OR Food Habits OR Food Preservatives OR Fructose OR Glycemic Index OR 
Glycosylation End Products, Advanced/adverse effects OR Hair Dyes OR Hallucinogens OR Hazardous 
Substances OR Heat Stroke OR Heroin OR Heroin Dependence OR Laxatives OR Leisure Activities OR 
Marijuana Abuse OR Methadone OR Mushroom Poisoning OR Narcotics OR Nonprescription Drugs OR 
Plant Poisoning OR Plants, Toxic OR Prenatal Exposure Delayed Effects OR Smoking OR Sodium 
Chloride, Dietary OR Sodium, Dietary OR Street Drugs OR Substance-Related Disorders OR Sweetening 
Agents OR Tattooing OR Tobacco OR Tobacco Smoke Pollution OR Tobacco Use Disorder OR 
Substance Withdrawal Syndrome OR Obesity OR Meat OR Foodborne Diseases OR Food Handling OR 
Dietary Fats OR Dietary Carbohydrates OR Plants Genetically Modified OR Sucrose OR Behavior 
Addictive OR Meat Products OR Poverty OR Maternal Exposure OR Flavoring Agents OR Diet High Fat 
OR Coffee OR Dairy Products OR Nutrition Disorders OR Prenatal Care OR Child Abuse OR Television 
OR Hygiene OR Doping In Sports OR Maternal Behavior OR Dietary Sucrose OR Thiamine Deficiency 
OR Folic Acid Deficiency OR Vitamin D Deficiency OR Cholesterol Dietary OR Lifestyle OR Sedentary 
Lifestyle OR Eating Disorders OR Sleep Disorders OR Paternal Exposure  
OR 
MESH TERMS DRUGS 
IIIB3a. TITLE 
("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental 
OR "induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" OR 
"treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR "surg*-caus*" 
OR "radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* progression" OR 
"caus* accumulation" OR "caus* * accumulation" OR "progression of" OR expos* OR contamina* OR 
abuse* OR induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR aggregation 
OR accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" OR "activat* 
microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR "adverse reaction*" OR 
"adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR "adverse * effect*" OR 
hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR "caus* *toxi*" OR "increas* *toxi" OR 
"produc* *toxi*" OR "enhanc* *toxi*" OR "stimulat* *toxi*" OR "accelerat* *toxi*" OR "caus* 
degrad*" OR "increas* degrad*" OR "caus* damag*" OR "increas* damag*" OR "caus* * *toxi*" OR 
"increas* * *toxi" OR "produc* * *toxi*" OR "enhanc* * *toxi*" OR "stimulat* * *toxi*" OR 
"accelerat* * *toxi*" OR "caus* * degrad*" OR "increas* * degrad*" OR "caus* * damag*" OR 
"increas* * damag*" OR "*toxi* caus* by" OR "*toxi* increas* by" OR "*toxi* produc* by" OR "*toxi* 
enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* accelerat* by" OR "damag* caus* by" OR "*damag* 
increas* by" OR deleterious OR deteriorat* OR trigger* OR  worsen* OR harm* OR hazard* OR "side-
effect*" OR dangerous OR destructive OR injurious OR unsafe) 
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AND 
MESH HEADING NO EXPLODE 
Antineoplastic Agents OR Anticoagulants OR Antineoplastic Combined Chemotherapy Protocols OR 
Anti-Inflammatory Agents, Non-Steroidal OR Hypoglycemic Agents OR Anti-Bacterial Agents OR 
Antipsychotic Agents OR Immunosuppressive Agents OR Anticonvulsants OR Platelet Aggregation 
Inhibitors OR Glucocorticoids OR Analgesics, Opioid OR Drug-Related Side Effects and Adverse 
Reactions OR Warfarin OR Analgesics OR Doxorubicin OR Cisplatin OR Protein Kinase Inhibitors OR 
Fibrinolytic Agents OR Fluorouracil OR Antirheumatic Agents OR Antihypertensive Agents OR 
Pyridines OR Cyclophosphamide OR Bone Density Conservation Agents OR Antiviral Agents OR 
Bleomycin OR Antidepressive Agents OR Serotonin Uptake Inhibitors OR Thiophenes OR Antibiotics, 
Antineoplastic OR Angiogenesis Inhibitors OR Drug Hypersensitivity OR Proton Pump Inhibitors OR 
Deoxycytidine OR Ticlopidine OR Organoplatinum Compounds OR Anti-Arrhythmia Agents OR 
Angiotensin-Converting Enzyme Inhibitors OR Anti-HIV Agents OR Paclitaxel OR Chemotherapy, 
Adjuvant OR Acetaminophen OR Quinazolines OR Taxoids OR Vasodilator Agents OR Pilocarpine OR 
Triazoles OR Benzodiazepines OR Anti-Infective Agents OR Estrogens OR Thiazolidinediones OR 
Antineoplastic Agents, Hormonal OR Antineoplastic Agents, Phytogenic OR Cyclooxygenase 2 
Inhibitors OR  Anti-Ulcer Agents OR Cyclosporine OR Vasoconstrictor Agents OR Anthracyclines OR 
Anticarcinogenic Agents OR Convulsants OR Calcium Channel Blockers OR Cardiotonic Agents OR 
Dermatologic Agents OR Isoproterenol OR Antifungal Agents OR Ribavirin OR Antiparkinson Agents 
OR Clozapine OR Carboplatin OR Tamoxifen OR Antiretroviral Therapy, Highly Active OR Vincristine 
OR Cholinesterase Inhibitors OR Antidepressive Agents, Second-Generation OR Antitubercular Agents 
OR Hypolipidemic Agents OR Antineoplastic Agents, Alkylating OR Gastrointestinal Agents OR 
Aromatase Inhibitors OR Antithyroid Agents OR Organophosphonates OR Cyclooxygenase Inhibitors 
OR Antidepressive Agents, Tricyclic OR Antimanic Agents OR Phosphodiesterase 5 Inhibitors OR 
Dipeptidyl-Peptidase IV Inhibitors OR Anti-Retroviral Agents OR Methyl Ethers OR Chelating Agents 
OR Anticholesteremic Agents OR Contraceptive Agents, Female OR Anti-Asthmatic Agents OR 
Dopamine Uptake Inhibitors OR HIV Protease Inhibitors OR N-Methyl-3,4-methylenedioxyamphetamine 
OR Mycophenolic Acid OR Bronchodilator Agents OR Hydroxychloroquine OR Neurotransmitter 
Agents OR Anti-Obesity Agents OR Anabolic Agents OR Anesthetics OR Cardiovascular Agents OR 
Histone Deacetylase Inhibitors OR Alkylating Agents OR Chloroquine OR Antifibrinolytic Agents OR 
Benzoxazines OR Protease Inhibitors OR Fertility Agents, Female OR Dopamine Agents OR Anti-
Infective Agents, Local OR Reverse Transcriptase Inhibitors OR Neuromuscular Agents OR Anti-
Allergic Agents OR Monoamine Oxidase Inhibitors OR Neuromuscular Nondepolarizing Agents OR 
Nootropic Agents OR Photosensitizing Agents OR 5-alpha Reductase Inhibitors OR Sweetening Agents 
OR Sensory System Agents OR Adrenergic Agents OR Adrenergic Uptake Inhibitors OR Indicators and 
Reagents OR Antitussive Agents OR Surface-Active Agents OR Antimutagenic Agents 
OR 
IIIB3b. TOPIC 
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("increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* Abeta" OR "increas* senile plaque*" 
OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR 
"increas* phospho-tau" OR "increas* tau protein*" OR "increas* hyperphosphorylated tau" OR "increas* 
neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* Abeta" 
OR "enhanc* senile plaque*" OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR 
"enhanc*total tau" OR "enhanc* phospho-tau" OR "enhanc* tau protein*" OR "enhanc* 
hyperphosphorylated tau" OR "enhanc* neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR 
"stimulat* beta-amyloid" OR "stimulat* Abeta" OR "stimulat* senile plaque*" OR "stimulat* tau 
aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-
tau" OR "stimulat* tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary 
tangle*" OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* Abeta" OR "elevat* senile 
plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR 
"elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" OR "elevat* 
neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR "induc* Abeta" OR 
"induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR "induc* P-tau" OR 
"induc*total tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR "induc* hyperphosphorylated 
tau" OR "induc* neurofibrillary tangle*" OR "produc* amyloid-beta" OR "produc* beta-amyloid" OR 
"produc* Abeta" OR "produc* senile plaque*" OR "produc* tau aggregat*" OR "produc* T-tau" OR 
"produc* P-tau" OR "produc*total tau" OR "produc* phospho-tau" OR "produc* tau protein*" OR 
"produc* hyperphosphorylated tau" OR "produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" 
OR "accelerat* beta-amyloid" OR "accelerat* Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau 
aggregat*" OR "accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* 
phospho-tau" OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* 
neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "Abeta induc* 
by" OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" OR "P-tau 
induc* by" OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* induc* by" OR 
"hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR "amyloid-beta produc* 
by" OR "beta-amyloid produc* by" OR "Abeta produc* by" OR "senile plaque* produc* by" OR "tau 
aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* by" OR "total tau produc* by" OR 
"phospho-tau produc* by" OR "tau protein* produc* by" OR "hyperphosphorylated tau produc* by" OR 
"neurofibrillary tangle* produc* by" OR "caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive 
decline" OR "caus* brain* decline" OR "caus* functional decline" OR "caus* memory decline" OR 
"caus* cognitive deficit*" OR "caus* language deficit*" OR "caus* memory deficit*" OR "caus* 
plasticity deficit*" OR "caus* behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning 
deficit*" OR "caus* neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular 
impair*" OR "caus* memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological 
impair*" OR "caus* mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" OR 
"caus* executive function impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* 
synaptic loss*" OR "caus* memory loss*" OR "caus* loss of memory" OR "caus* hearing loss*" OR 
"caus* volume loss*" OR "caus* Impair* face recognition" OR "caus* Impair* reasoning" OR "caus* 
Impair* judgment" OR "caus* Impair* problem solving" OR "caus* inflamm*" OR "caus* oxidative 
stress" OR "caus* neuropathology" OR "caus* diabetes" OR "caus* hypertension" OR "caus* high 
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cholesterol" OR "caus* hypercholesterolemia" OR "caus* obesity" OR "caus* metabolic syndrome" OR 
"induc* Alzheimer*" OR "induc* dementia" OR "induc* cognitive decline" OR "induc* brain* decline" 
OR "induc* functional decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* 
language deficit*" OR "induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral 
deficit*" OR "induc* saccade deficit*" OR "induc* learning deficit*" OR "induc* neuropsychological 
deficit*" OR "induc* cognitive impair*" OR "induc* vascular impair*" OR "induc* memory impair*" 
OR "induc* neurogenesis impair*" OR "induc* neuropsychological impair*" OR "induc* mind impair*" 
OR "induc* functional impair*" OR "induc* learning impair*" OR "induc* executive function impair*" 
OR "induc* cognitive loss*" OR "induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* 
memory loss*" OR "induc* loss of memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR 
"induc* Impair* face recognition" OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR 
"induc* Impair* problem solving" OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* 
neuropathology" OR "induc* diabetes" OR "induc* hypertension" OR "induc* high cholesterol" OR 
"induc* hypercholesterolemia" OR "induc* obesity" OR "induc* metabolic syndrome" OR "produc* 
Alzheimer*" OR "produc* dementia" OR "produc* cognitive decline" OR "produc* brain* decline" OR 
"produc* functional decline" OR "produc* memory decline" OR "produc* cognitive deficit*" OR 
"produc* language deficit*" OR "produc* memory deficit*" OR "produc* plasticity deficit*" OR 
"produc* behavioral deficit*" OR "produc* saccade deficit*" OR "produc* learning deficit*" OR 
"produc* neuropsychological deficit*" OR "produc* cognitive impair*" OR "produc* vascular impair*" 
OR "produc* memory impair*" OR "produc* neurogenesis impair*" OR "produc* neuropsychological 
impair*" OR "produc* mind impair*" OR "produc* functional impair*" OR "produc* learning impair*" 
OR "produc* executive function impair*" OR "produc* cognitive loss*" OR "produc* neuronal loss*" 
OR "produc* synaptic loss*" OR "produc* memory loss*" OR "produc* loss of memory" OR "produc* 
hearing loss*" OR "produc* volume loss*" OR "produc* Impair* face recognition" OR "produc* Impair* 
reasoning" OR "produc* Impair* judgment" OR "produc* Impair* problem solving" OR "produc* 
inflamm*" OR "produc* oxidative stress" OR "produc* neuropathology" OR "produc* diabetes" OR 
"produc* hypertension" OR "produc* high cholesterol" OR "produc* hypercholesterolemia" OR 
"produc* obesity" OR "produc* metabolic syndrome" OR "increas* Alzheimer*" OR "increas* 
dementia" OR "increas* cognitive decline" OR "increas* brain* decline" OR "increas* functional 
decline" OR "increas* memory decline" OR "increas* cognitive deficit*" OR "increas* language 
deficit*" OR "increas* memory deficit*" OR "increas* plasticity deficit*" OR "increas* behavioral 
deficit*" OR "increas* saccade deficit*" OR "increas* learning deficit*" OR "increas* 
neuropsychological deficit*" OR "increas* cognitive impair*" OR "increas* vascular impair*" OR 
"increas* memory impair*" OR "increas* neurogenesis impair*" OR "increas* neuropsychological 
impair*" OR "increas* mind impair*" OR "increas* functional impair*" OR "increas* learning impair*" 
OR "increas* executive function impair*" OR "increas* cognitive loss*" OR "increas* neuronal loss*" 
OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" OR "increas* 
hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" OR "increas* Impair* 
reasoning" OR "increas* Impair* judgment" OR "increas* Impair* problem solving" OR "increas* 
inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" OR "increas* diabetes" OR 
"increas* hypertension" OR "increas* high cholesterol" OR "increas* hypercholesterolemia" OR 
"increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* Alzheimer*" OR "exacerbat* 
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dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* decline" OR "exacerbat* functional 
decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive deficit*" OR "exacerbat* language 
deficit*" OR "exacerbat* memory deficit*" OR "exacerbat* plasticity deficit*" OR "exacerbat* 
behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning deficit*" OR "exacerbat* 
neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR "exacerbat* vascular impair*" OR 
"exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" OR "exacerbat* 
neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional impair*" OR 
"exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* cognitive 
loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* memory loss*" 
OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR 
"exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* 
judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* 
oxidative stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* 
obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR 
"trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* 
memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory 
deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade 
deficit*" OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* 
cognitive impair*" OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* 
neurogenesis impair*" OR "trigger* neuropsychological impair*" OR "trigger* mind impair*" OR 
"trigger* functional impair*" OR "trigger* learning impair*" OR "trigger* executive function impair*" 
OR "trigger* cognitive loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* 
memory loss*" OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" 
OR "trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" 
OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* oxidative stress" OR 
"trigger* neuropathology" OR "trigger* diabetes" OR "trigger* hypertension" OR "trigger* high 
cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* obesity" OR "trigger* metabolic 
syndrome" OR "accelerat* Alzheimer*" OR "accelerat* dementia" OR "accelerat* cognitive decline" OR 
"accelerat* brain* decline" OR "accelerat* functional decline" OR "accelerat* memory decline" OR 
"accelerat* cognitive deficit*" OR "accelerat* language deficit*" OR "accelerat* memory deficit*" OR 
"accelerat* plasticity deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR 
"accelerat* learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive 
impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* 
neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind impair*" OR 
"accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* executive function 
impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR "accelerat* synaptic loss*" 
OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR "accelerat* hearing loss*" OR 
"accelerat* volume loss*" OR "accelerat* Impair* face recognition" OR "accelerat* Impair* reasoning" 
OR "accelerat* Impair* judgment" OR "accelerat* Impair* problem solving" OR "accelerat* inflamm*" 
OR "accelerat* oxidative stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR 
"accelerat* hypertension" OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR 
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"accelerat* obesity" OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia 
caused by" OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline 
caused by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* 
caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral deficit* 
caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR "neuropsychological 
deficit* caused by" OR "cognitive impair* caused by" OR "vascular impair* caused by" OR "memory 
impair* caused by" OR "neurogenesis impair* caused by" OR "neuropsychological impair* caused by" 
OR "mind impair* caused by" OR "functional impair* caused by" OR "learning impair* caused by" OR " 
executive function impair* caused by" OR "cognitive loss* caused by" OR "neuronal loss* caused by" 
OR "synaptic loss* caused by" OR "memory loss* caused by" OR "loss of memory caused by" OR 
"hearing loss* caused by" OR "volume loss* caused by" OR "Impair* face recognition caused by" OR 
"Impair* reasoning caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused 
by" OR "inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR 
"diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR 
"hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" OR 
"Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" OR "brain* 
decline induced by" OR "functional decline induced by" OR "memory decline induced by" OR "cognitive 
deficit* induced by" OR "language deficit* induced by" OR "memory deficit* induced by" OR "plasticity 
deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* induced by" OR "learning 
deficit* induced by" OR "neuropsychological deficit* induced by" OR "cognitive impair* induced by" 
OR "vascular impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced 
by" OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional impair* 
induced by" OR "learning impair* induced by" OR " executive function impair* induced by" OR 
"cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* induced by" OR 
"memory loss* induced by" OR "loss of memory induced by" OR "hearing loss* induced by" OR 
"volume loss* induced by" OR "Impair* face recognition induced by" OR "Impair* reasoning induced 
by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR "inflamm* 
induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes induced 
by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia induced 
by" OR "obesity induced by" OR "metabolic syndrome induced by") 
AND 
MESH HEADING NO EXPLODE 
Antineoplastic Agents OR Anticoagulants OR Antineoplastic Combined Chemotherapy Protocols OR 
Anti-Inflammatory Agents, Non-Steroidal OR Hypoglycemic Agents OR Anti-Bacterial Agents OR 
Antipsychotic Agents OR Immunosuppressive Agents OR Anticonvulsants OR Platelet Aggregation 
Inhibitors OR Glucocorticoids OR Analgesics, Opioid OR Drug-Related Side Effects and Adverse 
Reactions OR Warfarin OR Analgesics OR Doxorubicin OR Cisplatin OR Protein Kinase Inhibitors OR 
Fibrinolytic Agents OR Fluorouracil OR Antirheumatic Agents OR Antihypertensive Agents OR 
Pyridines OR Cyclophosphamide OR Bone Density Conservation Agents OR Antiviral Agents OR 
Bleomycin OR Antidepressive Agents OR Serotonin Uptake Inhibitors OR Thiophenes OR Antibiotics, 
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Antineoplastic OR Angiogenesis Inhibitors OR Drug Hypersensitivity OR Proton Pump Inhibitors OR 
Deoxycytidine OR Ticlopidine OR Organoplatinum Compounds OR Anti-Arrhythmia Agents OR 
Angiotensin-Converting Enzyme Inhibitors OR Anti-HIV Agents OR Paclitaxel OR Chemotherapy, 
Adjuvant OR Acetaminophen OR Quinazolines OR Taxoids OR Vasodilator Agents OR Pilocarpine OR 
Triazoles OR Benzodiazepines OR Anti-Infective Agents OR Estrogens OR Thiazolidinediones OR 
Antineoplastic Agents, Hormonal OR Antineoplastic Agents, Phytogenic OR Cyclooxygenase 2 
Inhibitors OR  Anti-Ulcer Agents OR Cyclosporine OR Vasoconstrictor Agents OR Anthracyclines OR 
Anticarcinogenic Agents OR Convulsants OR Calcium Channel Blockers OR Cardiotonic Agents OR 
Dermatologic Agents OR Isoproterenol OR Antifungal Agents OR Ribavirin OR Antiparkinson Agents 
OR Clozapine OR Carboplatin OR Tamoxifen OR Antiretroviral Therapy, Highly Active OR Vincristine 
OR Cholinesterase Inhibitors OR Antidepressive Agents, Second-Generation OR Antitubercular Agents 
OR Hypolipidemic Agents OR Antineoplastic Agents, Alkylating OR Gastrointestinal Agents OR 
Aromatase Inhibitors OR Antithyroid Agents OR Organophosphonates OR Cyclooxygenase Inhibitors 
OR Antidepressive Agents, Tricyclic OR Antimanic Agents OR Phosphodiesterase 5 Inhibitors OR 
Dipeptidyl-Peptidase IV Inhibitors OR Anti-Retroviral Agents OR Methyl Ethers OR Chelating Agents 
OR Anticholesteremic Agents OR Contraceptive Agents, Female OR Anti-Asthmatic Agents OR 
Dopamine Uptake Inhibitors OR HIV Protease Inhibitors OR N-Methyl-3,4-methylenedioxyamphetamine 
OR Mycophenolic Acid OR Bronchodilator Agents OR Hydroxychloroquine OR Neurotransmitter 
Agents OR Anti-Obesity Agents OR Anabolic Agents OR Anesthetics OR Cardiovascular Agents OR 
Histone Deacetylase Inhibitors OR Alkylating Agents OR Chloroquine OR Antifibrinolytic Agents OR 
Benzoxazines OR Protease Inhibitors OR Fertility Agents, Female OR Dopamine Agents OR Anti-
Infective Agents, Local OR Reverse Transcriptase Inhibitors OR Neuromuscular Agents OR Anti-
Allergic Agents OR Monoamine Oxidase Inhibitors OR Neuromuscular Nondepolarizing Agents OR 
Nootropic Agents OR Photosensitizing Agents OR 5-alpha Reductase Inhibitors OR Sweetening Agents 
OR Sensory System Agents OR Adrenergic Agents OR Adrenergic Uptake Inhibitors OR Indicators and 
Reagents OR Antitussive Agents OR Surface-Active Agents OR Antimutagenic Agents 
OR 
MESH TERMS CHEMICALS 
IIIB4a - TITLE 
("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental 
OR "induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" OR 
"treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR "surg*-caus*" 
OR "radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* progression" OR 
"caus* accumulation" OR "caus* * accumulation" OR "progression of" OR expos* OR contamina* OR 
chemicals OR abuse* OR induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR 
aggregation OR accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" 
OR "activat* microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR "adverse 
reaction*" OR "adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR "adverse * effect*" 
OR hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR *TOXI* OR "caus* * degrad*" OR 
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"increas* * degrad*" OR "caus* * damag*" OR "increas* * damag*" OR "*toxi* caus* by" OR "*toxi* 
increas* by" OR "*toxi* produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* 
accelerat* by" OR "damag* caus* by" OR "*damag* increas* by" OR deleterious OR deteriorat* OR 
trigger* OR  worsen* OR harm* OR hazard* OR "side-effect*" OR dangerous OR destructive OR 
injurious OR unsafe)  
AND 
MESH HEADING NO EXPLODE 
Lipopolysaccharides OR Malondialdehyde OR Neurotoxicity Syndromes OR Carbon Tetrachloride OR 
Formaldehyde OR 9,10-Dimethyl-1,2-benzanthracene OR Trinitrobenzenesulfonic Acid OR Insecticides 
OR Endocrine Disruptors OR Diethylnitrosamine OR Hydrogen Peroxide OR Benzhydryl Compounds 
OR Chemical Warfare Agents OR Asbestos OR Herbicides OR Organometallic Compounds OR 
Scopolamine Hydrobromide OR Silicon Dioxide OR Polychlorinated Biphenyls OR 1-Methyl-4-phenyl-
1,2,3,6-tetrahydropyridine OR Benzo(a)pyrene OR Fluorocarbons OR Nitrogen Dioxide OR Polycyclic 
Hydrocarbons, Aromatic OR Tetrachlorodibenzodioxin OR Metals, Heavy OR Hydrocarbons, 
Chlorinated OR Chemical Industry OR 1,2-Dimethylhydrazine OR Ethylene Glycol OR Nitrosamines OR 
Benzene OR Fluorides OR Agricultural Workers' Diseases OR Bromodeoxyuridine OR Chromium OR 
Organophosphorus Compounds OR Organic Chemicals OR Carbon Monoxide OR Benzalkonium 
Compounds OR Chlorpyrifos OR Organophosphates OR Organophosphate Poisoning OR Volatile 
Organic Compounds OR Diethylhexyl Phthalate OR Sulfur Dioxide OR Petroleum OR Methylmercury 
Compounds OR Chlorine OR Dichlorodiphenyl Dichloroethylene OR Hydrocarbons OR 
Trichloroethylene OR Carbon Tetrachloride Poisoning OR 3,4-Dihydroxyphenylacetic Acid OR 
Alkanesulfonic Acids OR Plasticizers OR Halogenated Diphenyl Ethers OR Benzene Derivatives OR 
Dinitrofluorobenzene OR Toluene 2,4-Diisocyanate OR Benzopyrenes OR Cyclohexenes OR 
Nitrobenzenes OR Plastics OR Trihalomethanes OR Hydrocarbons, Brominated 
OR 
IIIB4b. TOPIC 
 ("increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* Abeta" OR "increas* senile plaque*" 
OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR 
"increas* phospho-tau" OR "increas* tau protein*" OR "increas* hyperphosphorylated tau" OR "increas* 
neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* Abeta" 
OR "enhanc* senile plaque*" OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR 
"enhanc*total tau" OR "enhanc* phospho-tau" OR "enhanc* tau protein*" OR "enhanc* 
hyperphosphorylated tau" OR "enhanc* neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR 
"stimulat* beta-amyloid" OR "stimulat* Abeta" OR "stimulat* senile plaque*" OR "stimulat* tau 
aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-
tau" OR "stimulat* tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary 
tangle*" OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* Abeta" OR "elevat* senile 
plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR 
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"elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" OR "elevat* 
neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR "induc* Abeta" OR 
"induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR "induc* P-tau" OR 
"induc*total tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR "induc* hyperphosphorylated 
tau" OR "induc* neurofibrillary tangle*" OR "produc* amyloid-beta" OR "produc* beta-amyloid" OR 
"produc* Abeta" OR "produc* senile plaque*" OR "produc* tau aggregat*" OR "produc* T-tau" OR 
"produc* P-tau" OR "produc*total tau" OR "produc* phospho-tau" OR "produc* tau protein*" OR 
"produc* hyperphosphorylated tau" OR "produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" 
OR "accelerat* beta-amyloid" OR "accelerat* Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau 
aggregat*" OR "accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* 
phospho-tau" OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* 
neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "Abeta induc* 
by" OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" OR "P-tau 
induc* by" OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* induc* by" OR 
"hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR "amyloid-beta produc* 
by" OR "beta-amyloid produc* by" OR "Abeta produc* by" OR "senile plaque* produc* by" OR "tau 
aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* by" OR "total tau produc* by" OR 
"phospho-tau produc* by" OR "tau protein* produc* by" OR "hyperphosphorylated tau produc* by" OR 
"neurofibrillary tangle* produc* by" OR "caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive 
decline" OR "caus* brain* decline" OR "caus* functional decline" OR "caus* memory decline" OR 
"caus* cognitive deficit*" OR "caus* language deficit*" OR "caus* memory deficit*" OR "caus* 
plasticity deficit*" OR "caus* behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning 
deficit*" OR "caus* neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular 
impair*" OR "caus* memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological 
impair*" OR "caus* mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" OR 
"caus* executive function impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* 
synaptic loss*" OR "caus* memory loss*" OR "caus* loss of memory" OR "caus* hearing loss*" OR 
"caus* volume loss*" OR "caus* Impair* face recognition" OR "caus* Impair* reasoning" OR "caus* 
Impair* judgment" OR "caus* Impair* problem solving" OR "caus* inflamm*" OR "caus* oxidative 
stress" OR "caus* neuropathology" OR "caus* diabetes" OR "caus* hypertension" OR "caus* high 
cholesterol" OR "caus* hypercholesterolemia" OR "caus* obesity" OR "caus* metabolic syndrome" OR 
"induc* Alzheimer*" OR "induc* dementia" OR "induc* cognitive decline" OR "induc* brain* decline" 
OR "induc* functional decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* 
language deficit*" OR "induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral 
deficit*" OR "induc* saccade deficit*" OR "induc* learning deficit*" OR "induc* neuropsychological 
deficit*" OR "induc* cognitive impair*" OR "induc* vascular impair*" OR "induc* memory impair*" 
OR "induc* neurogenesis impair*" OR "induc* neuropsychological impair*" OR "induc* mind impair*" 
OR "induc* functional impair*" OR "induc* learning impair*" OR "induc* executive function impair*" 
OR "induc* cognitive loss*" OR "induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* 
memory loss*" OR "induc* loss of memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR 
"induc* Impair* face recognition" OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR 
"induc* Impair* problem solving" OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* 
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neuropathology" OR "induc* diabetes" OR "induc* hypertension" OR "induc* high cholesterol" OR 
"induc* hypercholesterolemia" OR "induc* obesity" OR "induc* metabolic syndrome" OR "produc* 
Alzheimer*" OR "produc* dementia" OR "produc* cognitive decline" OR "produc* brain* decline" OR 
"produc* functional decline" OR "produc* memory decline" OR "produc* cognitive deficit*" OR 
"produc* language deficit*" OR "produc* memory deficit*" OR "produc* plasticity deficit*" OR 
"produc* behavioral deficit*" OR "produc* saccade deficit*" OR "produc* learning deficit*" OR 
"produc* neuropsychological deficit*" OR "produc* cognitive impair*" OR "produc* vascular impair*" 
OR "produc* memory impair*" OR "produc* neurogenesis impair*" OR "produc* neuropsychological 
impair*" OR "produc* mind impair*" OR "produc* functional impair*" OR "produc* learning impair*" 
OR "produc* executive function impair*" OR "produc* cognitive loss*" OR "produc* neuronal loss*" 
OR "produc* synaptic loss*" OR "produc* memory loss*" OR "produc* loss of memory" OR "produc* 
hearing loss*" OR "produc* volume loss*" OR "produc* Impair* face recognition" OR "produc* Impair* 
reasoning" OR "produc* Impair* judgment" OR "produc* Impair* problem solving" OR "produc* 
inflamm*" OR "produc* oxidative stress" OR "produc* neuropathology" OR "produc* diabetes" OR 
"produc* hypertension" OR "produc* high cholesterol" OR "produc* hypercholesterolemia" OR 
"produc* obesity" OR "produc* metabolic syndrome" OR "increas* Alzheimer*" OR "increas* 
dementia" OR "increas* cognitive decline" OR "increas* brain* decline" OR "increas* functional 
decline" OR "increas* memory decline" OR "increas* cognitive deficit*" OR "increas* language 
deficit*" OR "increas* memory deficit*" OR "increas* plasticity deficit*" OR "increas* behavioral 
deficit*" OR "increas* saccade deficit*" OR "increas* learning deficit*" OR "increas* 
neuropsychological deficit*" OR "increas* cognitive impair*" OR "increas* vascular impair*" OR 
"increas* memory impair*" OR "increas* neurogenesis impair*" OR "increas* neuropsychological 
impair*" OR "increas* mind impair*" OR "increas* functional impair*" OR "increas* learning impair*" 
OR "increas* executive function impair*" OR "increas* cognitive loss*" OR "increas* neuronal loss*" 
OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" OR "increas* 
hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" OR "increas* Impair* 
reasoning" OR "increas* Impair* judgment" OR "increas* Impair* problem solving" OR "increas* 
inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" OR "increas* diabetes" OR 
"increas* hypertension" OR "increas* high cholesterol" OR "increas* hypercholesterolemia" OR 
"increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* Alzheimer*" OR "exacerbat* 
dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* decline" OR "exacerbat* functional 
decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive deficit*" OR "exacerbat* language 
deficit*" OR "exacerbat* memory deficit*" OR "exacerbat* plasticity deficit*" OR "exacerbat* 
behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning deficit*" OR "exacerbat* 
neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR "exacerbat* vascular impair*" OR 
"exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" OR "exacerbat* 
neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional impair*" OR 
"exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* cognitive 
loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* memory loss*" 
OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR 
"exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* 
judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* 
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oxidative stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* 
obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR 
"trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* 
memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory 
deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade 
deficit*" OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* 
cognitive impair*" OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* 
neurogenesis impair*" OR "trigger* neuropsychological impair*" OR "trigger* mind impair*" OR 
"trigger* functional impair*" OR "trigger* learning impair*" OR "trigger* executive function impair*" 
OR "trigger* cognitive loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* 
memory loss*" OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" 
OR "trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" 
OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* oxidative stress" OR 
"trigger* neuropathology" OR "trigger* diabetes" OR "trigger* hypertension" OR "trigger* high 
cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* obesity" OR "trigger* metabolic 
syndrome" OR "accelerat* Alzheimer*" OR "accelerat* dementia" OR "accelerat* cognitive decline" OR 
"accelerat* brain* decline" OR "accelerat* functional decline" OR "accelerat* memory decline" OR 
"accelerat* cognitive deficit*" OR "accelerat* language deficit*" OR "accelerat* memory deficit*" OR 
"accelerat* plasticity deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR 
"accelerat* learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive 
impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* 
neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind impair*" OR 
"accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* executive function 
impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR "accelerat* synaptic loss*" 
OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR "accelerat* hearing loss*" OR 
"accelerat* volume loss*" OR "accelerat* Impair* face recognition" OR "accelerat* Impair* reasoning" 
OR "accelerat* Impair* judgment" OR "accelerat* Impair* problem solving" OR "accelerat* inflamm*" 
OR "accelerat* oxidative stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR 
"accelerat* hypertension" OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR 
"accelerat* obesity" OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia 
caused by" OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline 
caused by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* 
caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral deficit* 
caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR "neuropsychological 
deficit* caused by" OR "cognitive impair* caused by" OR "vascular impair* caused by" OR "memory 
impair* caused by" OR "neurogenesis impair* caused by" OR "neuropsychological impair* caused by" 
OR "mind impair* caused by" OR "functional impair* caused by" OR "learning impair* caused by" OR " 
executive function impair* caused by" OR "cognitive loss* caused by" OR "neuronal loss* caused by" 
OR "synaptic loss* caused by" OR "memory loss* caused by" OR "loss of memory caused by" OR 
"hearing loss* caused by" OR "volume loss* caused by" OR "Impair* face recognition caused by" OR 
"Impair* reasoning caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused 
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by" OR "inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR 
"diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR 
"hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" OR 
"Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" OR "brain* 
decline induced by" OR "functional decline induced by" OR "memory decline induced by" OR "cognitive 
deficit* induced by" OR "language deficit* induced by" OR "memory deficit* induced by" OR "plasticity 
deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* induced by" OR "learning 
deficit* induced by" OR "neuropsychological deficit* induced by" OR "cognitive impair* induced by" 
OR "vascular impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced 
by" OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional impair* 
induced by" OR "learning impair* induced by" OR " executive function impair* induced by" OR 
"cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* induced by" OR 
"memory loss* induced by" OR "loss of memory induced by" OR "hearing loss* induced by" OR 
"volume loss* induced by" OR "Impair* face recognition induced by" OR "Impair* reasoning induced 
by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR "inflamm* 
induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes induced 
by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia induced 
by" OR "obesity induced by" OR "metabolic syndrome induced by")  
AND 
MESH HEADING NO EXPLODE 
Lipopolysaccharides OR Malondialdehyde OR Neurotoxicity Syndromes OR Carbon Tetrachloride OR 
Formaldehyde OR 9,10-Dimethyl-1,2-benzanthracene OR Trinitrobenzenesulfonic Acid OR Insecticides 
OR Endocrine Disruptors OR Diethylnitrosamine OR Hydrogen Peroxide OR Benzhydryl Compounds 
OR Chemical Warfare Agents OR Asbestos OR Herbicides OR Organometallic Compounds OR 
Scopolamine Hydrobromide OR Silicon Dioxide OR Polychlorinated Biphenyls OR 1-Methyl-4-phenyl-
1,2,3,6-tetrahydropyridine OR Benzo(a)pyrene OR Fluorocarbons OR Nitrogen Dioxide OR Polycyclic 
Hydrocarbons, Aromatic OR Tetrachlorodibenzodioxin OR Metals, Heavy OR Hydrocarbons, 
Chlorinated OR Chemical Industry OR 1,2-Dimethylhydrazine OR Ethylene Glycol OR Nitrosamines OR 
Benzene OR Fluorides OR Agricultural Workers' Diseases OR Bromodeoxyuridine OR Chromium OR 
Organophosphorus Compounds OR Organic Chemicals OR Carbon Monoxide OR Benzalkonium 
Compounds OR Chlorpyrifos OR Organophosphates OR Organophosphate Poisoning OR Volatile 
Organic Compounds OR Diethylhexyl Phthalate OR Sulfur Dioxide OR Petroleum OR Methylmercury 
Compounds OR Chlorine OR Dichlorodiphenyl Dichloroethylene OR Hydrocarbons OR 
Trichloroethylene OR Carbon Tetrachloride Poisoning OR 3,4-Dihydroxyphenylacetic Acid OR 
Alkanesulfonic Acids OR Plasticizers OR Halogenated Diphenyl Ethers OR Benzene Derivatives OR 
Dinitrofluorobenzene OR Toluene 2,4-Diisocyanate OR Benzopyrenes OR Cyclohexenes OR 
Nitrobenzenes OR Plastics OR Trihalomethanes OR Hydrocarbons, Brominated 
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7A - Appendix 2 - Unambiguous MeSH Terms - Streamlined Approach 
("Drug-Related Side Effects AND Adverse Reactions" OR Abnormalities, Drug Induced OR 
Abnormalities, Radiation-Induced OR Agricultural Workers Diseases OR Aids Related Opportunistic 
Infections OR Air Pollutants OR Air Pollutants, Occupational OR Air Pollutants, Radioactive OR Air 
Pollution OR Air Pollution, Indoor OR Air Pollution, Radioactive OR Alcohol Drinking OR Alcohol 
Related Disorders OR Alcoholic Beverages OR Alcoholic Intoxication OR Alcoholism OR Amphetamine 
Related Disorders OR Amphetamines OR Arsenic Poisoning OR Asthma, Aspirin-Induced OR Asthma, 
Exercise-Induced OR Asthma, Occupational OR Behavior, Addictive OR Bullying OR Cadmium 
Poisoning OR Carbon Monoxide Poisoning OR Carbon Tetrachloride Poisoning OR Carcinogenicity 
Tests OR Carcinogens OR Carcinogens, Environmental OR Causality OR Cardiomegaly, Exercise-
Induced OR Chemical Warfare Agents OR Chemically-Induced Disorders OR Child Abuse OR Child 
Abuse, Sexual OR Cholesterol, Dietary OR Ciguatera Poisoning OR Cocaine Related Disorders OR 
Cytomegalovirus Infections OR Dermatitis, Occupational OR Diet, Atherogenic OR Diet, High Fat OR 
Dietary Carbohydrates OR Dietary Fats OR Dietary Fats, Unsaturated OR Dietary Fiber OR Dietary 
Sucrose OR Domestic Violence OR Drug Contamination OR Drug Eruptions OR Drug Hypersensitivity 
OR Drug Overdose OR Drug-Induced Liver Injury OR Dyskinesia, Drug Induced OR Eating Disorders 
OR Environmental Exposure OR Environmental Illness OR Environmental Pollutants OR Environmental 
Pollution OR Environmental Pollution OR Escherichia Coli Infections OR Fast Foods OR Fluoride 
Poisoning OR Food Additives OR Food Contamination OR Food Hypersensitivity OR Foodborne 
Diseases OR Gas Poisoning OR Hazardous Substances OR Hazardous Waste OR Hearing Loss, Noise 
Induced OR Heavy Metal Poisoning, Nervous System OR Hepatitis A, Chronic OR Hepatitis B, Chronic 
OR Hepatitis C, Chronic OR Heroin Dependence OR Herpesviridae Infections OR Htlv I Infections OR 
Hypersensitivity OR Hypersensitivity, Delayed OR Hypersensitivity, Immediate OR Iatrogenic Disease 
OR Inhalation Exposure OR Iron Overload OR Lead Poisoning OR Lead Poisoning, Nervous System OR 
Lead Poisoning, Nervous System, Adult OR Lead Poisoning, Nervous System, Childhood OR Leukemia, 
Radiation Induced OR Manganese Poisoning OR Marijuana Abuse OR Maternal Exposure OR Mercury 
Poisoning OR Mercury Poisoning, Nervous System OR Morphine Dependence OR Mptp Poisoning OR 
Mushroom Poisoning OR Mutagenicity Tests OR Mutagens OR Neoplasms, Radiation Induced OR 
Neurotoxicity Syndromes OR Occupational Diseases OR Occupational Exposure OR Opioid Related 
Disorders OR Opportunistic Infections OR Organophosphate Poisoning OR Paternal Exposure OR Plant 
Poisoning OR Pneumonia, Ventilator-Associated OR Poisoning OR Poisons OR Prenatal Exposure 
Delayed Effects OR Psychoses, Substance Induced OR Radiation Effects OR Radiation Injuries OR 
Radioactive Hazard Release OR Radioactive Pollutants OR Respiratory Hypersensitivity OR Salmonella 
Food Poisoning OR Sedentary Lifestyle OR Shellfish Poisoning OR Sleep Deprivation OR Sleep 
Disorders OR Sodium Chloride, Dietary OR Sodium, Dietary OR Soil Pollutants OR Soil Pollutants, 
Radioactive OR Spouse Abuse OR Staphylococcal Food Poisoning OR Staphylococcal Infections OR 
Streptococcal Infections OR Substance Abuse, Intravenous OR Substance Withdrawal Syndrome OR 
Substance-Related Disorders OR Teratogens OR Tobacco Smoke Pollution OR Tobacco Use Disorder 
OR Toxicity Tests, Chronic OR Virus Diseases OR Vitamin D Deficiency OR Water Pollutants OR 
Water Pollutants, Chemical OR Water Pollutants, Radioactive OR Water Pollution OR Water Pollution, 
Chemical) 
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Chapter 8 
DETAILED AD FOUNDATIONAL CAUSES 
8A. Taxonomy of AD Causes 
 Table 3-1 presented a top-level outline of the taxonomy categories to be used for showing the 
results.  Table 8-1 presents this taxonomy with the categories shown at the next level of detail. 
Table 8-1 - Detailed Taxonomy of AD Foundational Causes  
CODE CATEGORY 
I LIFESTYLE 
I-A Diet 
I-A1 Excesses 
I-A2 Deficiencies 
I-A3 Food Additives/Pollutants 
I-B Activity 
I-B1 Sedentary Lifestyle 
 
I-B2 Sleep 
I-C Substance Abuse 
I-C1 Recreational Drugs 
I-C2 Smoking 
I-C3 Alcohol 
I-D Other 
II IATROGENIC 
II-A Drugs 
II-A1 Anti-Neoplastic Agents 
II-A2 Anti-Infective Agents 
II-A2a Anti-Bacterial/Anti-Fungal/Anti-Parasitical Agents 
II-A2b Anti-Viral/Anti-Retroviral Agents 
II-A3 Anti-Inflammatory Agents 
II-A4 Cardiovascular Agents 
II-A5 Central Nervous System Agents 
II-A5a Analgesics and Pain Relievers 
II-A5b Movement Stabilizers 
II-A5c Depressants/Anti-Depressants and Stimulants 
II-A5d Mood Stabilizers 
II-A6a Immunosuppressive Agents/Immunosuppression 
II-A6b Immunostimulation Agents 
Prevention and Reversal of Alzheimer's Disease               Copyright © 2017               Ronald N. Kostoff et al 
 
85 
 
II-A6b1 Vaccines/Vaccination 
II-A7 Hematologic Agents 
II-A7a Coagulants 
II-A7b Anti-Coagulants 
II-A7c Other 
II-A8 Steroids/Hormones 
II-A9 Anti-Hypertensive Agents 
II-A10 Gastrointestinal Agents 
II-A11 Lipid Regulating Agents 
II-A12 Dermatologic Agents 
II-A13 Anti-Bone-Loss Agents 
II-A14 Anti-Diabetic Agents 
II-A15 Anti-Rheumatic Agents 
II-A16 Anti-Allergic Agents 
II-A17 Anti-Hypotensive Agents 
II-A18 Anti-Thyroid Agents 
II-B Radiotherapy 
II-C Surgery/Invasive Treatments 
II-C1 Transplantation 
II-C2 CardioVascular 
II-C3 Orthopedic 
II-C4 Gastrointestinal 
II-C5 Kidney/Urologic 
II-C6 Brain/Neural 
II-C7 Dental/Oral/Nose/Ear 
II-C8 Gynecologic 
II-C9 Respiratory/Thorax 
II-C10 Liver/Spleen 
II-C11 Ocular 
II-C12 Breast 
II-C13 Dermal/Tissue/Neck 
II-C14 Thyroid 
II-C15 Pancreas 
II-C16 General 
II-C17 Other 
II-D Diagnostic Agents/Procedures 
II-D1 Contrast Media 
II-D2 Radiation 
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II-D2a Ionizing 
II-D2b Non-Ionizing 
II-D3 Invasive 
II-D4 Other 
III BIOTOXIC AGENTS 
III-A Mycotoxins 
III-B Exotoxins 
III-C Bacteria/Fungi/Parasites 
III-D Viruses 
III-E Other 
IV OCCUPATIONAL/ENVIRONMENTAL EXPOSURES 
IV-A Chemicals/Materials 
IV-A1 Industrial/Household Chemicals/Materials 
IV-A1a Hydrocarbons 
IV-A1b Solvents 
IV-A1c Chemical Compounds 
IV-A1d Other 
IV-A2 Agricultural Chemicals 
IV-A3 Materials 
IV-A3a Heavy Metals 
IV-A3b Particulates 
IV-A3c Nanotechnology 
IV-B Physical/Mechanical 
IV-B1 Electromagnetic Radiation 
IV-B1a Ionizing 
IV-B1b Non-Ionizing 
IV-B1b1 Non-Visible 
IV-B1b2 Visible 
IV-B2 Sound 
IV-B3 Temperature; Heat/Cold 
IV-B4 Force/Pressure/Physical Trauma 
IV-C Other 
V PSYCHOSOCIAL/SOCIOECONOMIC 
V-A Psychological 
V-B Sociological 
V-C Economic 
VI GENETICS (Categories Only) 
VI-A Polymorphism/Genotypes/Haplotypes 
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VI-B Mutations 
VI-C Linkages 
VI-D Risk Alleles 
VI-E Genotoxicity 
VI-F Familial 
VI-G Congenital 
  8B.  Effects/Impacts from AD Foundational Causes 
 Table 8-2 presents a taxonomy of effects/impacts from the AD foundational causes.  Its members 
will be used to identify potential links to effects/impacts of the foundational causes identified in the final 
results taxonomy of Table 8-3. 
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Table 8-2  Taxonomy of Effects/Impacts from AD Foundational Causes 
CODE LEVEL 
 CELLULAR LEVEL 
A1 increase neuroinflammation 
A2 increase neurotoxicity 
A3 increase neuronal death 
A4 increase neurodegeneration 
A5 induce DNA damage 
A6 damage mitochondria 
A7 increase neuronal oxidative stress 
 BIOMARKER LEVEL 
B1 increase tau pathology/neurofibrillary tangles 
B2 increase Abeta generation 
B3 increase AGEs 
B4 increase insulin resistance 
B5 reduce brain volume 
B6 produce low tostesterone 
B7 produce tissue lesions 
B8 induce synaptic/neurotransmission dysfunction 
B9 induce hippocampal damage 
B10 induce olfactory dysfunction 
B11 impair glutamate uptake 
B12 compromise BBB integrity 
B13 impair glucose homeostasis 
B14 impair metal homeostasis 
 PERFORMANCE LEVEL 
C1 increase memory loss 
C2 increase seizures 
C3 induce cognitive dysfunction 
 DISEASE LEVEL 
D1 increase AD risk 
D2 increase diabetes risk 
D3 induce hypothyroidism 
D4 induce metabolic syndrome 
D5 increase obesity 
 
 These effects/impacts are divided into four categories: Cellular Level, Biomarker Level, 
Performance Level, Disease Level.  Each lowest-level sub-category was obtained by inspecting visually 
many Abstracts and Titles of records that related cause to effect/impact, and extracting those effects 
mentioned multiple times. 
 The lowest-level sub-categories are not orthogonal; there is some partial overlap and redundancy.  
Much of this is due to the different less-than-precise language of the article authors themselves.  For 
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example, some authors may use neurotoxicity to refer to neural damage, others may use neuro-
degeneration or neuronal death or .....  
 The value of incorporating the members of the above table in the final results is that it conveys (to 
the research community, the medical clinician community, and the consumer community) how the 
research is linked either 1) directly to AD, or  indirectly to AD through 2) strong disease precursors of AD 
(e.g., diabetes), or 3)  strong behavioral precursors of AD (e.g., cognitive decline), or 4) strong biomarker 
precursors of AD (e.g., increase tau hyperphosphorylation), or 5) strong cellular precursors of AD (e.g., 
increase neuronal death).  Why is this important? 
 Consider two potential foundational causes of AD identified in the present study, high-fat diets 
and wireless radiation.  High-fat-diets have been studied for a long time, and there appears to be good 
evidence that such diets are strong contributors to AD.  The long-term data are sufficient to conclude 
there is a direct link between high-fat diets and AD. 
 Wireless radiation (e.g., cell phone radiofrequencies or WiFi frequencies) has been in 
commercial/military use for perhaps thirty years, and in wide-scale use for perhaps ten years.  It might 
take 50-60 years to identify impacts of this radiation on the development of AD.  We have a choice.  We 
can wait many decades for the types of conclusive evidence that would satisfy the statisticians, or we can 
start to take precautions based on the impact of wireless radiation on surrogate endpoints already 
demonstrated.  This is the Precautionary Principle, and the results contained in Table 8-3 provide a 
starting point for implementation of the Precautionary Principle for prevention and reversal of AD. 
8C. Specific Foundational Causes of AD 
 Table 8-3 shows the AD potential foundational causes in this detailed taxonomic structure.  There 
are four columns listed.  The first column on the left (CAT) is the foundational cause category as shown 
in Table 8-1.  The next column is the foundational cause.  To keep the volume of results manageable, in 
some cases only the cause in aggregate was shown, rather than listing all the members (e.g., vegetables).  
The third column is the effect(s) produced by the foundational cause, and the entry tags are those listed in 
Table 8-2.  The fourth column contains relevant references that confirm the foundational cause. 
 In most cases, there were multiple papers linking each foundational cause listed either directly to 
AD or indirectly to one or more surrogate endpoints.  Referencing every single relevant paper for every 
detailed foundational cause would have produced an overly voluminous unreadable table and write-up.  In 
order to balance comprehensiveness with readability, multiple compromises were made. 
 First, one or two representative papers for each foundational cause were selected and referenced.  
Second, foundational causes that had relatively minor differences were aggregated.  Some were listed 
separately under a categorical heading, and others were subsumed within the heading.  Third, the 
effects/impacts of the foundational causes were extracted from at least the papers referenced, and 
sometimes from other relevant papers that were not selected for referencing.  Thus, the effects/impacts 
shown for any potential cause should be viewed as a "floor" of all potential effects, not a "ceiling".   
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 It should also be noted that all the effects/impacts were derived from papers whose central theme 
was AD/dementia, because of the criteria used to extract these records from Medline.  So, a foundational 
cause that, e.g., "damaged mitochondria" (A6) did so within the overall context of relating to AD or 
dementia.  If the four different levels shown, and the items contained in each level, are viewed as 
potential "pathways" to AD, then conventional wisdom implies that the more pathways impacted by a 
potential contributing factor, the greater likelihood that factor would be an important "cause" of AD.  
However, not only are the numbers of pathways impacted important, but the strength of the contributing 
factor's impact on each pathway is important.  This strength of impact is not shown in the table, reflecting 
its ambiguity in the literature. 
 The foundational causes identified are at different levels of importance to AD, and are at different 
levels of verification/validation. In the Medline literature examined, some foundational causes were 
identified through: 1) in vitro cell or tissue tests; 2) animal experiments; 3) epidemiological studies; 4) 
individual case studies; and, 5) trials with large numbers of subjects. Conventional wisdom implies that 
those foundational causes associated with large numbers of papers published and large numbers of test 
subjects would have greater credibility. However, as shown in [1-2], there may be (many) important 
foundational causes being withheld from the literature deliberately, so numbers of papers is not a 
definitive metric for credibility. 
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Table 8-3.  Foundational Causes of AD 
CAT CAUSE EFFECTS REF 
I  
 
LIFESTYLE   
I-A  DIET   
I-A1 EXCESSES   
 High Fat Diet 
-saturated fat 
-dairy fat 
-trans-unsaturated fat 
-hydrogenated fat 
-omega-6 PUFAs 
-n-6/n-3 ratio 
-maternal high fat diet 
A2, B1, B2, C1, C3, 
D1, D4, D5 
[3-12] 
 Diabetogenic diet B2 [13] 
 High calorie diet A1, B1, B12, C3, D1, 
D5 
[14-16] 
 High salt diet B2, C3, D1 [17] 
 High carbohydrate diet 
-refined carbohydrates 
-sugars (fructose/sucrose/glucose/D-galactose) 
-gluten 
-high glycemic index diet 
A1, A3, A4, A7, B2, 
B4, B11, B12, B13, 
C1, C3, D1, D2 
[18-25] 
 High advanced glycation end products diet 
-high temperature food heating  
-food irradiation 
-high glucose 
-high nutrient-bound AGEs 
-animal foods high in fat and protein 
A6, A7, B1, B2, B3, 
C1, C3, D1, D2  
[26-31] 
 
 High cholesterol diet A1, A4 [32] 
 High iron diet 
-high red meat 
-high processed meat 
A1, C3, D1 [33-35] 
 High meat diet D1 [36] 
 High arachidonic acid B1 [37] 
 High methionine diet A1, A2, A7, B1, B8, 
B2, C1, C3 
[38-40] 
 High copper diet C3, D1 [35, 41] 
 High zinc A3, A7, B1, B2 [42-43] 
 High pickle diet D1 [44] 
 High unfermented soy D1 [45] 
I-A2 DEFICIENCIES   
 Vitamin B deficiency 
-myriad B-Vitamin deficiency 
-B2/B6/B12 deficiency 
-folate/folic acid deficiency 
-thiamine deficiency 
A3, A4, A6, A7, B1, 
B2, C1, C3 
[46-49] 
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 Vitamin C deficiency A7, C2 [50] 
 Vitamin D deficiency A1, A4, A6, B1, B2, 
B5, B8, C3, D1 
[51-52] 
 Vitamin E deficiency D1 [53] 
 Vitamin K deficiency 
-fluindone 
C3 [54] 
 Potassium deficiency A1, A3, A7, B1, B2, 
C3 
[55-56] 
 Iron deficiency C3 [57] 
 Zinc deficiency A3, C3, D1 [58] 
 Magnesium deficiency C3 [59] 
 Calcium deficiency A3, A7 [60] 
 Selenium deficiency B2 [61] 
 Starvation B2 [62] 
 Dehydration B5, D1, D2, D5 [63] 
 Malnutrition D1 [64] 
 Early life nutrient restriction B2, D1 [65] 
 Glucose deprivation A3, B1, B2 [66] 
 Glutathione depletion A1, A2, A4 [67] 
 Linoleic acid deficiency A4, D1 [68] 
 Low docosahexaenoic acid A3 [53] 
 Low tryptophan diet B2 [69] 
 Nondrinkers C3, D1 [70] 
 Low cocoa A1, A7, C3 [71] 
 Low coffee C3, D1 [72] 
 Low flavonoids/flavanols: 
acacetin, aminogenistein, apigenin,  kaempferol, 
7,8-Dihydroxyflavone, anthocyanins, atriplex 
laciniata L, blueberries, Curcumin, cyanidin, 
datiscetin, delphinidin, EGCG, epicatechin, 
Epimedium brevicornum, fisetin, genistein, 
Ginkgo, glycitein, icariin,  isoscutellarein 7-O-
[6'''-O-acetyl-beta-D-allopyranosyl-(12)]-beta-
D-glucopyranoside, isovitexin, morin, 
myricetin, Nobiletin, pelargonidin, phloridzin, 
rutin, salvigenin, Scutellaria baicalensis Georgi, 
Sideritis flavonoids, vitexin, xanthomicrol, 
luteolin, morin, PD98059, quercetin,  taxifolin, 
β-naphthoflavone   
A1, A7, B2, C3, D1 [71, 73-74] 
 
 Low fruit: 
low: blackberries, blueberries, strawberries, 
raspberries, cherries, oranges, plums, prunes, 
red grapes, pomegranates, date palm fruits 
A7, B2, B3, B13, C1, 
C3, D1  
[21, 75-76] 
 Low vegetables 
-cruciferous 
-dark and green leafy 
A7, B13, C3, D1  [8] 
 Low fatty fish B2, C3, D1 [77] 
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I-A3 FOOD ADDITIVES/POLLUTANTS   
 Industrialized/preserved food D1 [78] 
 Monosodium glutamate A2, A3, B2, B9 [79] 
 Menadione A3, A7 [80] 
 Cysteine A7 [81] 
 Diacetyl A2, B2 [82] 
I-B ACTIVITY   
I-B1 SEDENTARY LIFESTYLE   
 Physical inactivity/low daily gardening, walking A6, A7, D1 [83-84] 
 Chronic immobilization stress A4, B1, B2, B9, C3 [85] 
 Cognitive inactivity D1 [86] 
 Lack of exercise D1, D2 [23] 
 Low cardiovascular fitness D1 [87] 
I-B2 SLEEP   
 Sleep deprivation C3, D1 [20, 88] 
 Circadian disruption C1, C3 [89-90] 
I-C SUBSTANCE ABUSE   
I-C1 RECREATIONAL DRUGS   
 Amphetamine C3 [91] 
 3,4-Methylenedioxyamphetamine; MDMA; 
Ecstacy 
A2, A7, B1, C1, C3 [92] 
 Cocaine/opiates A2, A4  [93-94] 
 Phencyclidine C3 [95] 
I-C2 SMOKING   
 Tobacco smoke A4 [96] 
 Ethanol/excess alcohol A7, B9, C1, C3, D1 [97] 
II IATROGENIC   
II-A DRUGS   
II-A1 ANTI-NEOPLASTIC AGENTS   
 Chemotherapy A2, A4, B9 [98] 
 Chemical castration C3 [99] 
 Camptothecin A2, A3 [100] 
 Epoxomicin A3, A6 [101] 
 Staurosporine/Etoposide A3, A4 [102-103] 
 Methylmethane sulfonate A5 [104] 
 Paclitaxel/Doxorubicin A3, A4, B1 [105] 
 Doxycyclin B2 [106] 
 Cyclophosphamide/cytophosphane A2, A7 [107] 
 Letrozole B9, C1 [108] 
 Methotrexate B9, C1, C3 [109] 
 Choline mustard Az/Nitrogen mustard B9, C1 [110] 
 Anastrozole B2, B9 [111] 
 d,l-buthionine-S,R-sulfoximine/BSO A3, A6, A7, B14 [112] 
 Fostriecin/Fos B1 [113] 
 carbobenzoxy-Leu-Leu-leucinal/MG132 A2, A4 [114] 
 Streptozocin B14, D1 [115] 
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II-A2 ANTI-INFECTIVE AGENTS   
 Chloroquine(CQ); CQ; lysosomotropic agent B2 [116] 
 Ionomycin A6, B2 [117] 
II-A3 ANTI-INFLAMMATORY AGENTS   
 colchicine A1, A4, C1, D1 [118] 
II-A4 CARDIOVASCULAR AGENTS   
 isoproterenol B1, C1 [119] 
 atropine B2 [120] 
 D-ribose A3, B1, B3 [121] 
 Muscarinic receptor antagonists C1, C3 [122] 
II-A5 CENTRAL NERVOUS SYSTEM AGENTS   
II-A5a Analgesics and Pain Relievers   
 Anesthetics/Opiods 
-acetaminophen 
-barbital 
-barbitone 
-desflurane 
-dexmedetomidine 
-diethylbarbituric acid 
-diethylmalonyl urea 
-enflurane 
-halothane 
-isoflurane 
-ketamine 
-medinal 
-morphine 
-nitrous oxide 
-pentobarbital 
-propofol 
-psychotropic drugs 
-sevoflurane 
-sodium diethylbarbiturate 
-veronal 
 
A2, A3, A4, A6, B1, 
B2, B9, C1, C3, D1 
[123-129] 
II-A5b Movement Stabilizers   
 Anticholinergic medications 
-doxepin 
-chlorpheniramine 
-oxybutynin 
-trihexyphenidyl 
-propiverine 
-L-DOPA/dopamine 
A3, A7, B1, C3, D1 [130-132] 
II-A5C Depressants/Anti-Depressants and Stimulants   
 selective serotonin re-uptake inhibitors D1 [133] 
 benzodiazepine D1 [134] 
 dizocilpine C1, C3 [135] 
 3-quinuclidinyl benzilate C3 [136] 
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II-A5d Mood Stabilizers   
 -clozapine 
-methyllycaconitine 
-dihydro-beta-erythrodine 
 
C1, C3 [137] 
 anisomycin A7, B2 [138] 
II-A6 IMMUNE SYSTEM AGENTS   
II-A6a Immunosuppressive Agents/ 
Immunosuppression 
  
 Cyclosporin B1, C1 [139] 
II-A6b Immunostimulation Agents   
 polyinosinic:polycytidylic acid B2, C3 [140] 
II-A7 Hematologic Agents   
II-A7b Anti-Coagulants   
 Sulfated glycosaminoglycans 
-heparin/heparan sulfate  
-dextran sulfate 
-pentosan polysulfate 
-chondroitin sulfate 
-dermatan sulfate 
B1 [141] 
II-A7c Other   
 mitochondrial toxins 
-1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine/MPTP 
A1, A3, A6, A7 [142] 
II-A8 Steroids/Hormones   
 Corticosteroids 
-methylprednisolone 
-dexamethasone 
A1, A3, A4, B1, B5 [143-145] 
 Anabolic androgenic steroids 
-nandrolone 
-stanozolol 
B8, B9, C1, C3 [146] 
 Corticosterone B1, B2, C3 [147] 
 Wortmannin A7, B1 [148] 
 17beta-trenbolone A3, A4, B2 [149] 
 Salmon calcitonin B2 [150] 
 Human chorionic gonadotropin B2 [151-152] 
 Corticotrophin releasing factor B2 [153] 
 Sex steroid hormones 
-transient testosterone treatment 
-flutamide 
B2 [154] 
 U18666A A3, A7, B2 [155] 
 Allopregnanolone B9, C1, C3 [156] 
 Medroxy-progesterone acetate C3, D1 [157] 
 Androgen deprivation therapy D1 [158] 
 Postmenopausal hormone therapy C3 [159] 
 Testosterone depletion A1, D1, D2 [160] 
 Leptin deficiency B1 [161] 
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 Prenatal sex hormone exposure D1 [162] 
II-A9 ANTI-HYPERTENSIVE AGENTS   
 ACE inhibitor D1 [163] 
 ICI 118,551/Selective beta2AR antagonist B1, B2, C3 [164] 
 Telmisartan/Olmesartan B2 [165] 
 Mecamylamine C3 [166] 
II-A10 GASTROINTESTINAL AGENTS   
 Thiorphan/Phosphoramidon B2 [167] 
 Proton pump inhibitors 
-omeprazole 
-pantoprazole 
-lansoprazole 
-esomeprazole 
-rabeprazole 
B2, D1 [168-169] 
II-A13 ANTI-BONE-LOSS AGENTS   
 PGE2 B2 [170] 
II-A14 ANTI-DIABETIC AGENTS   
 Intralipid and insulin B2 [171] 
 Metformin B2 [172] 
II-A16 ANTI-ALLERGIC AGENTS   
 Anticholinergics 
-first-generation antihistamines  
-tricyclic antidepressants 
-bladder antimuscarinics 
D1 [173] 
II-A18 ANTI-THYROID AGENTS   
 Propythiouracyl A1, B1, B2, B5, B8, 
C1 
[174] 
II-A19 Other   
 Carbachol B8, B14 [175] 
 MDL72974/Mofegiline A3, A7 [176] 
 Pilocarpine A3, B1, B2 [177] 
 Clenbuterol hydrochloride B2 [178] 
 Semagacestat C3 [179] 
II-B RADIOTHERAPY   
 Head radiotherapy C3, D1 [180-181] 
II-C SURGERY/ INVASIVE TREATMENTS   
II-C1 TRANSPLANTATION   
 Liver transplant B2, C3 [182] 
II-C2 CARDIOVASCULAR   
 Cardiac surgery/bypass A1, B1, B2, C3 [183-185] 
II-C5 KIDNEY/UROLOGIC   
 Dialysis C1, C3 [186-187] 
 Gonadectomy B2 [188]  
II-C7 DENTAL/ORAL/NOSE/EAR   
 Olfactory bulbectomy A4, A6, A7, B2, C1 [189-190] 
 Occlusal disharmony B2 [191] 
II-C8 GYNECOLOGIC   
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 Hysterectomy/oophorectomy C3 [192] 
 Premature surgical menopause/Premature 
ovarian failure 
C3 [193] 
II-C17 OTHER   
 Axotomy A3, A7 [194] 
 Cerebral artery occlusion A3, A4, A7, B8, C1, 
C3 
[195-198] 
 Intermittent hypoxia/ischemia A3, A4, A7, B2, B12, 
C1, C3 
[199-202] 
 Brain embolism A4, B1, B2, C1, C3 [203-204] 
 Aortic coarctation A1, B2 [205] 
 Forebrain lesions C1, C3 [206-207] 
 Adrenalectomy B2 [208] 
 Pituitary hormone injections with Abeta B2 [209] 
 Abdominal surgery B2, C3 [210] 
III BIOTOXIC AGENTS   
III-A MYCOTOXINS   
 Mycotoxins 
-ochratoxin A/OTA 
-Fumonisin B1/FB1 
-macrocyclic trichothecenes 
A2, A3, A4, A7, B1, 
C1, C3, D1 
[211-214] 
 3-nitropropionic acid A6 [215] 
III-B EXOTOXINS   
 Excitotoxins 
-kainic acid/ kainate 
-quisqualic acid 
-ibotenic acid 
-domoic acid 
-quinolinic acid/quinolinate 
A1, A2, A3, A4, B9, 
C1, C2, C3,  
[216-220] 
 Phosphatase inhibitor 
-okadaic acid  
B1 [221] 
 Excitatory amino acids D1 [222] 
 Malonate B9 [223] 
 Annonaceaeous acetogenins A2, D1 [224] 
 Cyanobacteria 
-beta-N-methylamino-L-alanine/BMAA 
-saxitoxin 
-anatoxin-a 
-blue-green algae 
-microcystin 
A2, B1, B2, B14 [225-228] 
 Diphtheria toxin B2 [229] 
 Pseudomonas aeruginosa exotoxin Y B1, B12 [230] 
 Saporin 
-192 IgG-saporin 
-p75-saporin 
B1, B2, B13, C3 [231-233] 
 Cycad plant 
-cycasin/methylazoxymethanol 
A2, A4, A5 [234] 
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 Glutamate/Glutamine synthetase A2, A3, A4, A6, B2 [235-237] 
 Mitochondrial inhibitors 
-rotenone 
-3-NPA 
-antimycin 
-KCN 
-oligomycin 
A6 [238] 
III-C BACTERIA/FUNGI/PARASITES   
 Bacteria/bacterial infections 
-bacterial endotoxins 
-bacterial lipopolysaccharide 
-gram-negative bacterium 
-spirochetes 
-Chlamydophyla pneumoniae 
-Helicobacter pylori 
-Escherichia coli 
-Treponema pallidum 
-Tannerella forsythia 
-Treponema denticola 
-T. socranskii 
-T. pectinovorum 
-T. medium 
-T. amylovorum 
-T. maltophilum 
-Fusobacterium nucleatum 
-Prevotella intermedia 
-Chlamydia pneumoniae 
-Porphyromonas gingivalis 
-propionibacterium acnes 
-Treponemas 
-T. lecithinolyticum 
-Borrelia burgdorferi 
Fungi/fungal infection 
-Cryptococcus 
-Coccidioides 
-Aspergillus 
-Histoplasma 
-Blastomyces 
-C. famata 
-C. parapsilosis 
-C. glabrata 
-C. krusei 
-Candida albicans 
-Candida ortholopsis 
-Candida tropicalis 
-Cladosporium 
-Malassezia globosa 
-Malassezia restricta 
A1, A4, A7, B1, B2, 
B3, C3, D1  
[239-253] 
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-Neosartorya hiratsukae 
-Phoma 
-Sacharomyces cerevisae 
-Sclerotinia borealis 
Parasites 
-Trypanosoma brucei rhodesiense 
-Trypanosoma brucei gambiense 
-Acanthamoeba 
-Balamuthia mandrillaris 
-Toxoplasma gondii 
-Taenia solium 
-Toxocara canis 
-T. cati 
-Toxocara ova 
-Leishmania amazonensis 
III-D VIRUSES   
 Viruses/Viral infections/Virulence factors 
Bornaviridae  
-Mammalian 1 bornavirus  
Bunyaviridae  
-Hantavirus  
-La Crosse encephalitis virus  
Coronaviridae  
-Human coronavirus OC43  
-Murine hepatitis virus  
Flaviviridae  
-Hepatitis C virus  
-Japanese encephalitis virus 
-Murray Valley encephalitis virus  
-St. Louis encephalitis virus  
-West Nile virus  
Hepadnaviridae  
-Hepatitis B virus  
Herpesviridae  
-Cytomegalovirus  
-Epstein-Barr virus  
-Herpes simplex virus 1  
-Human herpesvirus 6  
Orthomyxoviridae  
-Influenza A virus (H1N1)  
-Influenza A virus (H3N2)  
-Influenza A virus (H5N1)  
Paramyxoviridae  
-Hendra virus  
-Measles virus  
Picornaviridae  
-Enterovirus 71  
-Theiler's murine encephalomyelitis virus  
A1, A3, A4, B1, B2, 
C3, D1  
[254-260] 
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Polyomaviridae  
-Simian 40 virus large T antigen  
Retroviridae  
-Human immunodeficiency virus 1  
-Human T-cell leukemia virus  
-Moloney murine leukemia virus  
Rhabdoviridae  
-Chandipura virus  
Togaviridae  
-Chikungunya virus  
-Eastern equine encephalitis virus  
-Venezuelan equine encephalitis virus 
III-E OTHER   
 Abeta 
-amyloid precursor protein 
-C31 
-CT105 
-Curli fibrils 
A1, A2, A3, A4, A6, 
B2, B8, B14, C1, C3 
[261-271] 
 Homocysteine/3-Mercaptopropionic Acid B8, B12, C1 [272-273] 
 Lipopolysaccharide A7, B3, C1 [274] 
 Prions/Prion protein fragment A2, A3, B14 [275-277] 
 Cytokines 
-CXCL10 
-IL-1 beta 
-IL-10 
-interferon-alpha 
-interferon-gamma 
-interleukin-6 
-interleukin-18 
-interleukin-8 
-TNF-alpha 
A1, A2, A3, A4, B1, 
B2, B9, C1, C3 
[278-288] 
 Lipoperoxydation proteins 
-advanced lipoperoxydation products 
-oxidized low density lipoprotein 
A1, A2, A3 [289-290] 
 Trophic factor withdrawal A3, A4, B2 [291-293] 
 Amylin A1, A2, A4, A6, A7 [294] 
 Lysophosphatidic acid B2 [295] 
 S100B A1, B1, B2 [296] 
 3-hydroxykynurenine/3-hydroxyanthranilic acid A4, A7, B2 [297] 
 Abscisic acid A1 [298] 
 Phorbol myristate acetate A1 [298] 
 Acid phosphatase D1 [299] 
 2-deoxy-D-glucose B2 [300] 
 3-methylindole/Skatole B10 [301] 
 alpha-amino-3-hydrozy-5-methyl-4-isoxazole 
propionic acid/AMPA 
A2 [302] 
 Asymmetric dimethylarginine A2, A7, B2, C3 [303-304] 
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 Dolichyl phosphate B12 [305] 
 N-(2-chloroethyl)-N-ethyl-bromo-
benzylamine/dsp4 
A1, A3, A4, B2, B13, 
C1 
[306] 
 Galanin C1, C3 [307] 
 GW4869/hydrochloride hydrate B2 [308] 
 Cottonseed B1, B2 [309] 
 Homocysteic acid/Homocysteate A3, A7 [310] 
 Isoprostane B2 [311] 
 Lysophosphatidylcholine A2, A3, A7, B2 [312] 
 Saturated non-esterified fatty acids B2 [313] 
 Palmitic acid A3, C3 [314] 
 Oncostatin M A2, B11 [315] 
 S100A9 A1, B2, C3 [316] 
 Salsolinol A2, A3 [317] 
 Sulfatide A3 [318] 
 Brefeldin A A3, A6, A7 [319] 
 Thapsigargin A3, A6, A7 [319] 
 GF-109203X B1 [320] 
 Isopropyl-1-beta-D-thiogalactopyranoside A3, A6, B1 [321] 
 C2-ceramide A3, A7 [322] 
 dl-threo-1-phenyl-2-decanoylamino-3-
morpholino-1-propanol/PDMP 
B2 [323] 
 (1S,2R-d-erythro-2-N-myristoylamino)-1-
phenyl-1-propanol/DMAPP 
B2 [323] 
 alpha7 nAChR subunit alpha7(1-208) A1, B2, C3 [324] 
 Adenosine triphosphate/ATP B1 [325] 
 Recombinant BiP/GRP78 B2 [326] 
 Bradykinin B1, B14 [327] 
 CD40/CD40L B2 [328] 
 Collagen B2 [329] 
 Cyclic dipeptides A3 [330] 
 D-serine A7 [331] 
 Elastase A7, B1 [332] 
 4-Hydroxyhexenal/HHE A3, B11, B13 [333] 
 High-mobility group box-1/HMGB1 C3 [334] 
 Exogenous amyloidogenic proteins 
-casein 
-fibroin 
-sericin 
-actin 
-islet amyloid polypeptide 
B2 [335] 
 Leukotrienes 
-Leukotriene B4/LTB4 
-Leukotriene D4/LTD4 
A1, B2, C1 [336-337] 
 Myostatin precursor protein B2 [338] 
 N-acetylcholinesterase A3, B1 [339] 
 Secreted phospholipase A2-IIA/sPLA2-IIA A1 [340] 
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 Spermine A2 [341] 
 Xanthine oxidase A3, A7 [342] 
 3-hydroxykynurenine/3-HK A2, A3, A6 [343] 
 Mitochondrial lysates A1 [344] 
 Phytohemagglutinin A3, B14 [345] 
 Angiotensin II B1, B2, C3 [346] 
 3beta-hydroxy-5-oxo-5,6-secocholestan-6-al/ 
ChSeco 
A2, A3, A7, B2 [347] 
 Cholesterol oxidation products/oxysterols 
-27-hydroxycholesterol/27-OHC  
-24-OH 
-7beta-hydroxycholesterol 
-7-ketocholesterol 
-5,6-alpha cholesterol epoxide 
-5,6-beta cholesterol epoxide 
-cholesterol triol 
-lathosterol 
-beta cholesterol epoxide 
-cholesterol triol 
A1, A2, A7 [348-349] 
 Calyculin A A2, A7, B1 [350] 
 Chromogranin A A1 [351] 
 Forskolin B1 [352] 
 N-methyl-D-aspartate A3, B9 [353] 
 PGJ2 A1, A3, B1 [354-355] 
 Quisqualate A3, B9, C2 [356] 
 Tunicamycin A3, B14 [357] 
 2-chloro-2'-deoxyadenosine/2-CDA/ cladribine B2, C3 [358] 
 N-acetylglucosamine A2, B8, B9 [359] 
 Cholinesterase 
-acetylcholinesterase  
-butyrylcholinesterase 
B2 [360] 
 Glycogen synthase kinase 3-beta/GSK3beta B1 [361] 
 HMG-CoA reductase D1 [362] 
 Pam(3)CSK(4) A1 [363] 
 Superoxide dismutase deficiency A1, A7, B1, B2, B3, 
C1 
[364] 
IV OCCUPATIONAL/ENVIRONMENTAL 
EXPOSURES 
  
IV-A CHEMICALS/MATERIALS   
IV-A1 INDUSTRIAL/HOUSEHOLD 
CHEMICALS/MATERIALS 
  
IV-A1a Hydrocarbons   
 20-methylcholanthrene/methylcholanthrene A1 [365] 
IV-A1b Solvents   
 Petroleum-based solvents 
-Mineral turpentine 
D1 [366] 
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-Diesel fuel 
-Fuel oil 
-Kerosene 
 Chlorinated solvents 
-Trichloroethylene 
-Perchlorethylene 
-Trichloroethane 
-Dichloromethane 
-Benzene 
C3 [367] 
 Dimethyl sulfoxide/DMSO B1 [368] 
 Organic solvents 
-Benzene 
-Toluene 
-Phenols 
-Alcohols 
-Ketones 
-Methylmethacrylate 
D1 [369-370] 
IV-A1c Chemical Compounds   
 Neurotoxins 
-6-hydroxydopamine/6-OHDA 
-5,6-dihydroxytryptamine/5,6-DHT  
-5,7-dihydroxytryptamine/5,7-DHT 
A3, A7 [371-372] 
 Type-2 Alkenes/Reactive aldehydes 
-Acrolein 
-4-Hydroxynonenal/HNE 
-Acrylamide 
-Methyl glyoxal 
A2, A3, A4, A7, B1, 
B2, B3, B8 
[373-378] 
 Nitrosamine/N-nitrosodiethylamine A3, A4, B4, C3 [379] 
 Adenosine, 3', 5'-cyclic monophosphate/ cAMP B2 [380] 
 Carbon tetrachloride A1, A4, A7, B4, B13 [381] 
 Chemical warfare agents/nerve agents 
-organophosphates 
-soman 
-sarin 
-ethyl S-2-di-isopropylaminoethyl-
phosphonothiolate 
-VX 
-tabun 
C1, C3 [382] 
 Cyanide 
-Potassium cyanide 
-Sodium cyanide 
A3, A7 [383-385] 
 Formaldehyde B1, C1 [386] 
 Hydrogen Peroxide/H2O2 A2, A3, A6, A7 [387] 
 Lipophilic chemicals 
-persistent organic pollutants 
-bisphenol A 
-phthalates 
C3, D1 [388] 
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-low molecular weight hydrocarbons 
-polynuclear aromatic hydrocarbons 
-endocrine disruptors 
 Sulfur dioxide/ SO2 A2, B8, C3 [389] 
 Phthalates 
-Di-(2-ethylhexyl)-phthalate/DEHP 
-mono-2-ethylhexyl phthalate/MEHP 
-DEHP metabolites  
B1, B4, B14, C3 [390] 
 Brominated flame retardants 
-hexabromocyclo-dodecane/HBCD  
-tetrabromobisphenol-Al/TBBPA  
-decabromodiphenyl ether/DBDE  
-polybrominated diphenyl ethers/PBDEs 
A2, A3, A6, A7, B2 [391-392] 
 Ammonia A1, B2, B8 [393-394] 
 Hypochlorous acid/HOCl A2, A6, B13 [395-396] 
 Methanol A3, B1, C1 [397] 
 Peroxynitrite B1 [398] 
 Sodium azide A3, B1, B2 [399] 
 Acetaldehyde A3, A7 [400] 
 3-Bromopyruvate B13, C3 [401] 
 Vehicular emission oxides 
-nitrogen dioxide/NO2  
-carbon monoxide/CO 
C3, D1 [402] 
 Sodium fluoride C1, C3 [403 
 Membrane-mimicking detergents 
-sodium dodecyl sulfate  
-lithium dodecyl sulfate 
B2 [404-405] 
 Nitric oxide donors 
-sodium nitroprusside 
-DETA NONOate 
B1 [406-407] 
 Amorphous aluminosilicates B2 [408] 
 Sodium nitrite A3, A4, B1, B2, B9, 
B11, C1 
[409] 
 Tert-butyl hydroperoxide/t-BHP A3, A7 [410] 
 Alloxan B1, B2 [411] 
 Ammonium chloride A4, A6 [412] 
 Anionic dyes 
-Congo Red 
-Thiazine Red 
-Thioflavin S 
B1 [413] 
 Aroclor 1254 A3 [414] 
 Cobalt chloride A2, A3, A6, A7, C1, 
C3 
[415] 
 Magnesium chloride B2 [416] 
 2,2'-azobis(2-methylpropionamidine) 
dihydrochloride/AAPH 
A7 [417] 
 Methylglyoxal/Glyoxal A1, A2, A7, B12 [378, 418] 
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 Disuccinimidyl suberate B2 [419] 
 Naphthazarin/5,8-dihydroxy-1,4-
naphthoquinone/5,8-dihydroxy-1,4-
naphthalenedione 
A7 [420] 
 Pyrithiamine B1, B2, C1 [421] 
 Pyrogallol A3, A7 [422] 
 Glyceraldehyde-3-phosphate/GAPDH A3, A6, B2 [423] 
IV-A1d Other   
 Ethylcholine mustard aziridinium ion/ AF64A B8, C1 [424] 
 1-methyl-4-phenylpyridinium ion A2, A3, A6, A7 [425] 
 2,2'-dithiodipyridine B14 [426] 
 Aftin-4 A7, B2, B8, C3 [427] 
 Kaolin B2 [428] 
 Ozone A3, A7, C1, C3 [429] 
 2;3;7;8-tetrachlorodibenzo-p-dioxin A2, D1 [430-431] 
IV-A2 AGRICULTURAL CHEMICALS   
 Pesticides/Insecticides/Herbicides/Fungicides 
-Organochlorine Pesticides 
-Organophosphate Pesticides 
-2,4,5-trichlorophenoxyacetic acid 
-2,4-Dichlorophenoxyacetic Acid 
-Agent Orange 
-Aldrin 
-Alkylphenolpolyethoxylates 
-APEOs 
-Arsenic 
-Beta-hexachlorocyclohexane/beta-HCH 
-Bipyridyles 
-Carbamates 
-Carbofuran 
-Chlorfenvinphos 
-Chlorpyrifos/CPF 
-Cycloheximide 
-Cypermethrin 
-Deltamethrin 
-Dichlorodiphenyldichloroethylene/DDE 
-Dichlorodiphenyltrichloroethane/DDT 
-Dichlorodiphenyldichloroethane/DDD 
-Dieldrin 
-Dimethyl parathion 
-Endosulfan 
-Famoxadone 
-Fenamidone 
-Glyphosate 
-Hexachlorobenzene 
-Hexachlorocyclohexane/HCH 
-Imidacloprid 
-Lindane 
A1, A2, A3, A5, A6, 
A7, B1, B2, B11, B14, 
C1, C3, D1,  
[391, 431-
443] 
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-Maneb 
-Methamidophos 
-Methyl parathion 
-Neonicotinoids 
-Nonylphenol 
-Octylphenol 
-Paraquat 
-Parathion 
-Pyraclostrobin 
-Pyrethroids 
-Trans-nonachlor 
-Trichlorfon/TCF 
-Trifloxystrobin 
IV-A3 MATERIALS   
IV-A3a Heavy Metals   
 Heavy Metals 
-aluminum 
-arsenic 
-cadmium 
-calcium/Ca2/CaCl 
-calcium ionophore/A-23187/calcimycin  
-cobalt 
-copper 
-iron 
-lead 
-manganese 
-mercury  
-methylmercury 
-selenium 
-tin 
-zinc 
A1, A2, A3, A4, A6, 
A7, B1, B2, B14, D1 
[391, 444-
455]  
 
 
IV-A3b Particulates   
 Air pollution 
-fine/ultrafine particles 
-inhalable dust 
-surgical smoke 
A1, A4, A7, B1, B2, 
D1 
[456-458] 
IV-A3c Nanotechnology   
 Nanoparticles 
-iron 
-titanium dioxide 
-CdSe quantum dots 
-diesel exhaust 
-alumina 
-manganese oxide 
-copper 
-silica/silicon dioxide 
-zinc oxide 
-silver 
A1, A2, A3, A4, A7, 
B2, B8, B12; B14 
[459-462] 
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-nickel 
IV-B Physical/Mechanical   
IV-B1 Electromagnetic Radiation   
IV-B1a Ionizing   
 Gamma radiation 
-dental X-ray 
-gamma rays 
A3, B1 [463-464] 
 Particle radiation 
-56Fe-particle radiation 
-cosmic radiation 
-HZE particle radiation 
B2, B8, B9, B12, C3 [465-466] 
 Radionuclide pollutants 
-uranium 
-cesium 
-cobalt 
-radon 
A7, C1, C3, D1 [467-468] 
IV-B1b Non-Ionizing   
IV-B1b1 Non-Visible   
 Electromagnetic fields 
-extremely low frequency/ELF-EMF 
-900 MHz/RFEMR 
-electromagnetic pulse/EMP 
-electroconvulsive shock/ECS 
-UV irradiation 
B1, B2, B8, B9, C1, 
C3, D1 
469-473] 
IV-B1b2 Visible   
 photolysis of 1-(2-nitrophenyl)ethyl sulfate B2 [474] 
IV-B2 SOUND   
 Noise 
-chronic noise exposure 
-short-lasting impulse noise 
-ultrasound sonication 
A1, A4, B2, B3, D1 [475-477] 
IV-B3 TEMPERATURE; HEAT/COLD   
 Heat stress 
-heat shock 
-heating 
-hyperthermia 
A6, A7, B1, B2 [478-481] 
 Cold stress 
-cold water stress 
-cold water hypothermia 
A3, B1, B2, C1, C3 [482] 
IV-B4 Force/ Pressure/ Physical Trauma   
 Traumatic brain injury A4, B2, B9, C1, C3, 
D1 
[483-486] 
 Head trauma 
-history of head trauma 
-closed head injury 
-axonal injury 
 
A1, B1, B8, B9, C1, 
C3, D1 
[487-490] 
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 Spinal cord injury A1, A4, C3 [491] 
 Mechanical stress 
-Valsalva maneuver 
-repetitive heavy lifting 
-repetitive strong cough 
-accumulated mechanical stress 
A1, A3, B1, B2, D1 [492-493] 
IV-C OTHER   
 Oxygen alterations 
-hyperoxia 
-hypoxia 
A1, A3, A4, A7, B2, 
C3 
[494-495] 
V PSYCHOSOCIAL/SOCIOECONOMIC   
V-A PSYCHOLOGICAL   
 Chronic stress 
-repeated stress 
-chronic mild stress 
-chronic psychological stress 
-multiple chronic stresses 
-behavioral stress 
-childhood trauma 
-bereavement 
-chronic restraint stress 
-high job stress 
-low level of job control 
 
A4, A6, A7, B1, B2, 
B9, C1, C3, D1 
[496-503] 
 Low mental activity 
-low cognitively engaging activity 
-low purposeful activities 
-low leisure activities/low hobbies 
--low music/drawing/meditation/reading/arts/ 
crafts 
B5, C3, D1 [504-507] 
V-B SOCIOLOGICAL   
 Social isolation 
-isolation 
-loneliness 
-living alone 
-unmarried 
-maternal separation 
-low social activity index 
-low social support at work 
-constricted life space 
 
A3, B1, B2, B8, C1, 
C3, D1 
[508-513] 
 Low education 
-illiteracy 
D1 [514-516] 
V-C ECONOMIC   
 Early life socioeconomic circumstances C3 [517] 
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8C1.  Analysis of Results in Table 8-3 
 The findings in the Lifestyle, Iatrogenic, Biotoxic Agents, Occupational/ Environmental 
Exposures, and Psychosocial/Socioeconomic categories will now be examined by sub-category.  The sub-
category alphanumerical headings correspond to those in Table 8-3. 
 
I.  Lifestyle 
 Lifestyle includes choices mainly under individual control, and is divided arbitrarily into Diet, 
Activity, Substance Abuse, Other. 
I-A.  Diet 
 Poor diet reflects the adverse effects of excesses and deficiencies of dietary components.  It has 
been used to induce myriad diseases in test animals, and it was a critical disease factor from many 
epidemiological and case studies.   
I-A1. Dietary Excesses 
 Dietary excesses include: high-fat; diabetogenic diet; high-calorie; high-salt; high-carbohydrate; 
high advanced glycation end products (AGEs); high-cholesterol; high-iron; high-meat; high arachidonic 
acid; high methionine; high copper; high zinc; high pickle diet; high unfermented soy; and high-
temperature cooking that results in harmful products (e.g., AGEs, nitrosamines, polycyclic aromatic 
hydrocarbons, and acrylamides). 
 As Table 8-3 shows, high-fat diet (from the specific types of fat listed in the table) had impacts at 
the cellular, biomarker, performance, and disease categories listed in Table 8-2.  These high-fat diets were 
1) directly related to AD, 2) indirectly related to AD through their direct impact on other diseases directly 
related to AD (e.g., metabolic syndrome, diabetes), and 3) indirectly related to AD through their direct 
impact on the pre-disease surrogate endpoints directly related to AD.  High-fats were also a key 
component of the diabetogenic diet listed in the table. 
 High-calorie and high-salt diets had both direct and indirect relationships to AD.  High-
carbohydrate diet, especially refined carbohydrates/sugars, also had full spectrum impacts.  They also 
contributed to the diabetogenic diet. 
 High-AGEs, high-cholesterol, high-iron, and high-meat diets are  intertwined, to a large extent.  
Meat tends to be high-cholesterol, high-iron, and, especially when cooked at high temperatures, 
associated with production of high AGEs.  Most of the articles related to meat consumption and AD 
emphasized adverse effects. Unfortunately, in most of these meat studies, especially epidemiological 
studies on humans, there was no separation of confounding effects. 
 Most meat available to the American public comes from CAFO (confined animal feeding 
operations). These animals are raised confined in very close quarters. To reduce infections from such 
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close confinement, animals are given antibiotics, and to increase growth more rapidly, animals are given 
synthetic growth hormones. Their feed is grain-based, not the grass they would have if pasture-raised.  
Would the  dementia-related diseases associated with meat consumption in the articles be as copious and 
serious for pasture/grass-fed animals not raised under confined conditions, and not given antibiotics and 
synthetic growth hormones? 
 Most meat eaten is cooked, much of it at high temperatures, usually in the presence of 
endogenous and exogenous additional fats. High-temperature cooking, especially of animal foods that are 
high in protein and fat, results in substantial production of AGEs and other harmful substances (e.g., 
nitrosamines, polycyclic aromatic hydrocarbons, and acrylamides).  How are the harmful effects of the 
cooking separated from the harmful effects of the meat?  Separation was not evident in any papers 
examined.  The bulk of the biomedical literature has not demonstrated that meat from 'organic' pasture-
raised grass-fed animals not fed antibiotics and growth hormones and not cooked at high temperatures is 
equally harmful to CAFO meat consumed by the vast majority of the American public, and there is some 
evidence that a moderate amount of high-quality meat may be beneficial. 
 Finally, diets high in arachidonic acid, methionine, copper, zinc, pickles, and unfermented soy 
contribute directly or indirectly to the development of AD. 
1A2. Dietary Deficiencies 
 Many deficiencies listed in the literature may be symptoms of metabolic problems, not 
foundational causes in the present sense.  Thus, a Vitamin A deficiency may be caused by 1) insufficient 
Vitamin A intake (foundational cause), or 2) some metabolic problem that results in reduced Vitamin A 
levels (symptom).   Dietary deficiencies include low: vitamins, especially Vitamins B (B2, B6, B12, 
folate/folic acid, thiamine), C, D, E; minerals, especially potassium, iron, zinc, magnesium, calcium, 
selenium; calories (starvation, malnutrition, early life nutrient restriction); water (dehydration); glucose; 
glutathione; linoleic acid; docosahexaenoic acid; tryptophan; alcohol (nondrinkers); flavonoids/flavanols 
(cocoa, coffee, acacetin, aminogenistein, apigenin,  kaempferol, 7,8-Dihydroxyflavone, anthocyanins, 
atriplex laciniata L, curcumin, cyanidin, datiscetin, delphinidin, EGCG, epicatechin, Epimedium 
brevicornum, fisetin, genistein, ginkgo, glycitein, icariin,  isoscutellarein 7-O-[6'''-O-acetyl-beta-D-
allopyranosyl-(12)]-beta-D-glucopyranoside, isovitexin, morin, myricetin, nobiletin, pelargonidin, 
phloridzin, rutin, salvigenin, Scutellaria baicalensis Georgi, Sideritis flavonoids, vitexin, xanthomicrol, 
luteolin, morin, PD98059, quercetin,  taxifolin, β-naphthoflavone); fruit (blackberries, blueberries, 
strawberries, raspberries, cherries, oranges, plums, prunes, red grapes, pomegranates, date palm fruits); 
vegetables, especially cruciferous, dark and green leafy; fatty fish. 
 A very clear message about the dietary contribution to AD can be extracted from the above 
picture of dietary excesses and deficiencies.  From the macro perspective, the amounts of fat, salt, sugar, 
refined carbohydrates, calories, and meat need to be reduced strongly, along with high temperature 
cooking, and the amounts of vitamin and mineral-laden fruits, vegetables, and fatty fish need to be 
increased substantially to reduce the risk of AD and perhaps contribute to reversal of AD. 
I-A3. Food Additives 
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 Many food additives are accompanied by adverse effects, and these effects may be under-
diagnosed and under-researched.  Many of the excesses and deficiencies mentioned above are the result of 
substances being added to, or removed from, the fresh whole food.   
 Additives include preservatives, monosodium glutamate, menadione, cysteine, diacetylcysteine, 
and diacetyl.  Depending on how one defines "food additives", those additives with the widest impacts 
tend to include the major items listed under excesses above, such as fat, sugar, and salt.  These 
components are typically added to foods for taste enhancement, not nutritional improvement.  The effects 
of these additives appear to be at the cellular and biomarker levels. 
I-B.  Activity 
 The main sub-categories of Activity are exercise, sedentary lifestyle, and sleep.   
I-B1. Sedentary Lifestyle/Lack of Exercise 
 The sedentary lifestyle, including low exercise, low physical activity, low daily gardening, low 
walking, and chronic immobilization, was mentioned quite often, and cognitive inactivity also received 
some mention. The resultant low cardiovascular fitness was also emphasized. 
Sleep 
 Circadian disruption and poor sleep/sleep deprivation were also mentioned, although the main 
foundational components of poor sleep would be 1) choosing to sleep less or 2) not practicing good sleep-
preparation habits.  Other contributing factors to poor sleep, such as excessive pain, anxiety, etc, may be 
less under one's control, and are not regarded as foundational under the definition in the present 
monograph. 
I-C.  Substance Abuse 
 Substance abuse includes "recreational" drugs of all types (cocaine, methamphetamine, etc), other 
substances such as laxatives, common household products not usually identified as recreational drugs 
(such as mothballs), and especially excessive cigarette smoking and alcohol. The main substance abuse 
contributing factors to AD for the present study were 1) recreational drugs (especially cocaine, 
amphetamines/3,4-Methylenedioxyamphetamine (MDMA - Ecstacy), phencyclidine, opioids) and 2) 
excessive smoking and alcohol.  The bulk of the studies showed the recreational drugs' contributions to 
AD surrogate endpoints, such as neurodegeneration markers and cognitive dysfunction. 
Potential Synergies 
 The individual AD foundational causes identified with Lifestyle are usually studied in isolation, 
and synergistic effects are typically not identified.  Given the number of Lifestyle component 
combinations that could potentially be synergistic, and adding in  
1) the foundational causes from the remaining categories (identified in Table 8-3) to the potential 
combinations, and  
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2) potential foundational causes that surface only when operating in synergy but which have not yet been 
identified in Table 8-3 as individual foundational causes, 
it is clear that only the tip of AD foundational causes iceberg is being identified in this study. 
 
II.  Iatrogenic 
 Iatrogenic reflects diseases, symptoms, and injuries resulting from medical treatment, and is 
divided into four sub-categories: Drugs; Radiotherapy; Surgeries/ Invasive Procedures; Diagnostic 
Agents/Procedures.  Iatrogenic is a substantial category, due mainly to the large numbers of drugs and 
surgeries that have side-effects and complications.  The main categories, along with detailed drugs and 
surgeries, are presented in Table 8-3.   
II-A. Drugs 
 While the drug categories have some overlap, each drug is listed in one category only in Table 8-
3 for purposes of brevity when generating the drug categories.  The more frequently a drug is used, or the 
more frequently surgery or invasive treatments are employed, the more opportunity for side-effects and 
complications, and the more opportunity for publications describing these side-effects and complications.  
This study does not provide an indication of how often such side-effects and complications would occur 
as a percentage of use. 
 There were eighteen major drug categories identified in Table 8-3, but only those with substantial 
entries will be discussed in this narrative.  These include anti-neoplastic agents, cardiovascular agents, the 
massive category of central nervous system agents, hematologic agents, steroids/hormones, 
antihypertensive agents, and gastrointestinal agents. 
 What the table does not show is the effect of drug-drug combinations, or drug-other agent 
combinations.  The effects of these combinations could be important, but might not surface in some types 
of studies.  A study on drug-drug combinations concluded that, of approximately 11,000 drug products on 
the US market, trillions of clinical trials would be required to provide an evidentiary basis of safety for all 
combinations of ten drugs [518].  Even for all combinations of three drugs, the number of clinical trials 
required to evaluate safety, or lack thereof, would be astronomical. 
 Thus, there are many ways that 1) a drug that has been shown to contribute to AD in isolation, 
when combined with two other drugs that have not been shown to contribute to AD in isolation, could in 
aggregate have a much stronger contribution to AD, and/or 2) three drugs that have been shown to have a 
modest contribution to AD in isolation, when combined, could in aggregate have a much stronger 
contribution to AD, and/or 3) three drugs that have been shown to have negligible contribution to AD in 
isolation, when combined, could in aggregate have a strong contribution to AD.  Even if there are small 
numbers for any one combination of three drugs, when they are aggregated over the total number of 
potential combinations, this could add up to a large number of strong contributions.  This effect might not 
surface in any epidemiological study because 1) it would fall beneath the statistical radar screen, 2) 
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temporal variation in the combinations would be difficult to assess, and 3) the numbers of clinical trials 
required to assess the impact of drug combinations are astronomical and would be impractical.  For 
combinations of drugs larger than three, which increase for people as they age [518], the numbers of 
combinations and clinical trials to demonstrate safety increase rapidly. 
II-A1. Antineoplastic Agents 
 This is a powerful class of drugs, and they tend to exert toxic/destructive effects on cancer cells.  
It is therefore unsurprising that these drugs would result in surrogate endpoint effects such as 
neurotoxicity/neurodegeneration/apoptoses on some healthy cells as well.  The types of impacts in Table 
8-3 bear this out.  Neurotoxic-type effects are seen for many of the agents, as well as the accompanying 
memory degradation, but direct links to AD are not reported as frequently.  The old dictum "absence of 
evidence is not evidence of absence" should be a warning flag on drawing hard conclusions about direct 
links. 
II-A4. Cardiovascular Agents 
 The impacts of the four agents/agent classes (isoproterenol, atropine, D-ribose, muscarinic 
receptor antagonists) presented in Table 8-3 concentrate on the surrogate endpoints, with emphasis on the 
biomarkers (increase tau, Abeta) and performance (decrease memory, cognition). 
II-A5. Central Nervous System Agents 
 This was by far the largest category of potential contributors to AD.  This should not be 
surprising, since the members of this category act on the central nervous system (and some on the 
peripheral nervous system as well), and the brain is an integral part of the central nervous system.  The 
impacts of the myriad contributing factors in this category differ somewhat by sub-category. 
 The analgesics and pain relievers (anesthetics/opiods) sub-category, consisting of acetaminophen, 
barbital, barbitone, desflurane, dexmedetomidine, diethylbarbituric acid, diethylmalonyl urea, enflurane, 
halothane, isoflurane, ketamine, medinal, morphine, nitrous oxide, pentobarbital, propofol, psychotropic 
drugs, sevoflurane, sodium diethylbarbiturate, veronal, affected all four impact areas.  There was a 
substantial literature on the AD-related impacts of these sub-category members.  One analytic problem 
deriving from this observation is that the relationship between the types of surgery to AD is conflated 
with the relationship between the anesthetic to AD, and it is difficult to separate the two, since anesthetics 
are used almost universally in surgery, especially major surgery. 
 The movement stabilizer sub-category, consisting of the anticholinergic medications doxepin, 
chlorpheniramine, oxybutynin, trihexyphenidyl, propiverine, L-DOPA/dopamine, was less numerous in 
terms of publications than the anesthetic sub-category, but covered the four impact classes as well. 
 The depressant/antidepressant sub-category, consisting of selective serotonin re-uptake inhibitors, 
benzodiazepine, dizocilpine, and 3-quinuclidinyl benzilate, had impact on performance and AD in the 
references shown.  The absence of impact at the cellular and biomarker levels could mean that these 
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classes of impacts were not the objectives of the research that was conducted, or they were reported in 
other papers not presented here. 
 The mood stabilizer sub-category, consisting of clozapine, methyllycaconitine, dihydro-beta-
erythrodine, and anisomycin, impacted across the surrogate endpoints. 
II-A7. Hematologic Agents 
 The main component of this category is the anti-coagulant sub-category, consisting mainly of the 
sulfated glycosaminoglycans heparin/heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin 
sulfate, dermatan sulfate, and fluindione. 
II-A8. Steroids/Hormones 
 The substances in this category include corticosteroids (methylprednisolone, dexamethasone), 
anabolic androgenic steroids (nandrolone, stanozolol), corticosterone, Wortmannin, 17beta-trenbolone, 
salmon calcitonin, human chorionic gonadotropin, corticotrophin releasing factor, sex steroid hormones 
(transient testosterone treatment, flutamide), U18666A, allopregnanolone, medroxy-progesterone acetate, 
androgen deprivation therapy, postmenopausal hormone therapy, testosterone depletion, human chorionic 
gonadotropin, prenatal sex hormone exposure, and the deficiency of leptin.  This class of pharmaceuticals 
(especially the corticosteroids) is used for a wide spectrum of medical conditions, and the broad scope of 
potential impacts is concerning.  While some of the drugs in the larger Iatrogenic category have rather 
narrow applications, the long-term effects on neurodegenerative diseases of widely used drugs such as 
anesthetics and steroids should be cause for serious concern. 
II-A9. Antihypertensive Agents 
 These agents include ACE inhibitors, ICI 118,551/Selective beta2AR antagonists, 
telmisartan/olmesartan, and Mecamylamine.  Some of the anti-hypertensive agents listed are widely used 
because of the prevalence of hypertension, and their long-term effects need to be examined more closely.  
The main impacts listed are those on the surrogate endpoints, although the ACE inhibitors are linked to 
AD.  The referenced papers don't report impacts at the cellular level, although, again, that does not imply 
the absence of such impacts. 
II-A10. Gastrointestinal Agents 
 These agents include thiorphan/phosphoramidon, and the large class of proton pump inhibitors 
(omeprazole, pantoprazole, lansoprazole, esomeprazole, and rabeprazole).  Again, this is disturbing for 
the long-term, because of the almost common-place used of this family of drugs for digestive problems. 
II-B. Radiotherapy 
 Radiotherapy that involves the head region impacts cognition and AD. 
II-C. Surgery/Invasive Treatments 
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 The following categorization is not unique.  Some procedures could be assigned to multiple 
categories.  Surgeries/invasive procedures that contribute to AD tend to involve vessel occlusion, cerebral 
ischemia, broader cardiac surgery, estrogen depletion, and myriad forms of dialysis.   
 One interesting observation is that the surgery impacts are all on AD surrogate endpoints, not on 
AD directly, for the references selected.  This may be due to personal choice of the authors.  Some 
authors identified a number of surrogate endpoints that were impacted, and referred to the aggregate as 
Alzheimer's-like.  Other authors would refer to the aggregate as Alzheimer's Disease.  Since inhalation 
anesthesia seems to be a strong contributing factor, almost any major surgery employing this type of 
anesthesia would have to involve some potential risk for AD, either through the surrogate endpoints, or 
directly.  
 
III.  Biotoxic Agents 
 Biotoxic Agents reflect mainly the biological substances to which we are exposed naturally, but 
sometimes accidentally, and sometimes by design.  This category is divided into five sub-categories: 
Mycotoxins; Exotoxins; Bacteria/ Fungi/ Parasites; Viruses; Other.  Biotoxins contributing to AD include 
some mycotoxins, but mainly exotoxins, bacteria, and viruses. 
III-A. Mycotoxins 
 Only a few mycotoxins were identified, including ochratoxin A, fumonisin B1, and macrocyclic 
trichothecenes.  Their impacts cover all four levels. 
III-B. Exotoxins 
 Many exotoxins were identified, including excitotoxins (kainic acid/kainate, quisqualic acid, 
ibotenic acid, domoic acid, quinolinic acid/quinolinate), phosphatase inhibitors (okadaic acid), excitatory 
amino acids, malonate, annonaceaeous  acetogenins, cyanobacteria (beta-N-methylamino-L-
alanine/BMAA, saxitoxin, anatoxin-a, blue-green algae, microcystin), diphtheria toxin, pseudomonas 
aeruginosa exotoxin Y, saporins (192 IgG-saporin, p75-saporin), cycad plant 
(cycasin/methylazoxymethanol), glutamate/glutamine synthetase, mitochondrial inhibitors (rotenone, 3-
NPA, antimycin, KCN, oligomycin).  Some substances in the Other category could have been assigned to 
the Exotoxin category.  The impacts were heavily weighted toward the cellular and biomarker levels, less 
so toward the performance level, and even less toward the disease level. 
III-C. Bacteria/Fungi/Parasites 
 Myriad bacteria, fungi, and parasites (shown in Table 8-3) are dominant in sub-category III-C.  
The bacteria/bacterial infections include bacterial endotoxins, bacterial lipopolysaccharide, gram-negative 
bacterium, spirochetes, Chlamydophyla pneumoniae, Helicobacter pylori, Escherichia coli, Treponema 
pallidum, Tannerella forsythia, Treponema denticola, T. socranskii, T. pectinovorum, T. medium, T. 
amylovorum, T. maltophilum, Fusobacterium nucleatum, Prevotella intermedia, Chlamydia pneumoniae, 
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Porphyromonas gingivalis, propionibacterium acnes, Treponemas, T. lecithinolyticum, and Borrelia 
burgdorferi.  Bacteria are somewhat ubiquitous, so the flexibility of cause removal for items in this sub-
category is much less than for items in the Lifestyle and Iatrogenic categories.   
 The fungi/fungal infections include Cryptococcus, Coccidioides, Aspergillus, Histoplasma, 
Blastomyces, C. famata, C. parapsilosis, C. glabrata, C. krusei, Candida albicans, Candida ortholopsis, 
Candida tropicalis, Cladosporium, Malassezia globosa, Malassezia restricta, Neosartorya hiratsukae, 
Phoma, Sacharomyces cerevisae, and Sclerotinia borealis.   
 The parasites include Trypanosoma brucei rhodesiense, Trypanosoma brucei gambiense, 
Acanthamoeba, Balamuthia mandrillaris, Toxoplasma gondii, Taenia solium, Toxocara canis, T. cati, 
Toxocara ova, and Leishmania amazonensis. 
III-D. Viruses 
 Myriad viruses (shown in Table 8-3) are dominant in sub-category III-D.  These viruses include 
Bornaviridae (Mammalian 1 bornavirus), Bunyaviridae (Hantavirus, La Crosse encephalitis virus), 
Coronaviridae (Human coronavirus OC43, Murine hepatitis virus), Flaviviridae (Hepatitis C virus, 
Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, West Nile 
virus), Hepadnaviridae (Hepatitis B virus), Herpesviridae (Cytomegalovirus, Epstein-Barr virus, Herpes 
simplex virus 1, Human herpesvirus 6), Orthomyxoviridae (Influenza A virus (H1N1), Influenza A virus 
(H3N2), Influenza A virus (H5N1)), Paramyxoviridae (Hendra virus, Measles virus), Picornaviridae 
(Enterovirus 71, Theiler's murine encephalomyelitis virus), Polyomaviridae (Simian 40 virus large T 
antigen), Retroviridae (Human immunodeficiency virus 1, Human T-cell leukemia virus, Moloney murine 
leukemia virus), Rhabdoviridae (Chandipura virus), Togaviridae (Chikungunya virus, Eastern equine 
encephalitis virus, Venezuelan equine encephalitis virus). 
 Based on the volume of records examined in the bacteria/fungi/viruses categories, linkages to tau 
and Abeta pathologies were mentioned often, as were direct linkages to AD.  Neuroinflammation induced 
by bacterial and viral infections appeared to be responsible for some of the tau pathology.  
III-E. Other 
 The category named Other contains myriad substances, which are listed in Table 8-3.  It includes 
some plant-based contributing factors (e.g., 12-myristate 13-acetate, Forskolin, arecoline hydrobromide, 
quisqualate, etc), and a very substantial number of endogenous substances that were administered 
exogenously (e.g., 27-hydroxycholesterol, acetylcholinesterase, Bradykinin, CD40, etc). 
   Ordinarily, endogenous substances are not foundational causes, but intermediate causes, since 
their harmful effects typically are driven by other foundational causes.  However, for consistency, if an 
endogenous substance was administered exogenously for purposes of experimentation or trial, it was 
considered as an exotoxin or other foundational cause for the purposes of this monograph.  Thus, amyloid 
beta, an endogenous substance, could be viewed as an endotoxin when internal processes are being 
discussed, but also as an exotoxin when administered in laboratory experiments.   
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 Because of the heterogeneity of the myriad substances in this class, specific impact statements 
need to be tailored to the specific members of this class.  However, from an overall perspective, the 
majority of impacts are at the cellular and biomarker levels, much fewer impacts at the performance level, 
and very few impacts at the disease level.  It should be cautioned again that the absence of impacts 
reported should not be interpreted as their non-existence.  They may not exist, they may exist and were 
not an objective of the research, or they may exist and were not reported.  
 
IV.  Occupational/Environmental Exposures 
IV-A. Chemicals/Materials 
IV-A1. Industrial and Household Chemicals/Materials 
 This sub-category is very broad.  There is overlap among the next level  taxonomy elements; for 
example, some of the solvents are hydrocarbons and some of the chemical compounds are hydrocarbons.   
 This sub-category includes hydrocarbons, solvents, chemical compounds, and Other. 
 The hydrocarbons sub-category includes, e.g., methylcholanthrene, polycyclic aromatic 
hydrocarbons, diesel fuel, kerosene, etc. 
 The solvents sub-category includes, e.g., petroleum-based solvents (mineral turpentine, diesel 
fuel, fuel oil, kerosene, etc), chlorinated solvents (trichloroethylene, perchlorethylene, trichloroethane, 
dichloromethane, benzene), organic solvents (benzene, toluene, phenols, alcohols, ketones, 
methylmethacrylate), dimethyl sulfoxide/ DMSO, etc.  The impacts from the members of this sub-
category, as reported in the references selected, tended to focus on performance and disease.  This was 
due to a number of epidemiology studies of occupational impacts, which tend to focus on higher level 
impacts. 
 The chemical compounds/Other sub-categories include a full spectrum of chemical compounds, 
especially chlorine, bromine, nitrogen, sodium, sulfur, and carbon compounds.  Members of these sub-
categories include, e.g., Neurotoxins (6-hydroxydopamine/6-OHDA, 5,6-dihydroxytryptamine/ 5,6-DHT, 
-5,7-dihydroxytryptamine/5,7-DHT, Type-2 Alkenes/Reactive aldehydes (Acrolein, 4-
Hydroxynonenal/HNE, Acrylamide, Methyl glyoxal), Nitrosamine/ N-nitrosodiethylamine, Adenosine, 3', 
5'-cyclic monophosphate/cAMP, Carbon tetrachloride, Chemical warfare agents/ nerve agents 
(organophosphates, soman, sarin, ethyl S-2-di-isopropylaminoethyl-phosphonothiolate, VX, tabun), 
Cyanide (Potassium cyanide, Sodium cyanide), Formaldehyde, Hydrogen Peroxide/H2O2, Lipophilic 
chemicals (persistent organic pollutants, bisphenol A, phthalates, low molecular weight hydrocarbons, 
polynuclear aromatic hydrocarbons, endocrine disruptors), Sulfur dioxide/SO2, Phthalates (Di-(2-
ethylhexyl)-phthalate/DEHP, mono-2-ethylhexyl phthalate/MEHP, DEHP metabolites), Brominated 
flame retardants (hexabromocyclo-dodecane/HBCD, tetrabromobisphenol-Al/TBBPA, 
decabromodiphenyl ether/DBDE, polybrominated diphenyl ethers/PBDEs), Ammonia, Hypochlorous 
acid/HOCl, Methanol, Peroxynitrite, Sodium azide, Acetaldehyde, 3-Bromopyruvate, Vehicular emission 
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oxides (nitrogen dioxide/NO2, carbon monoxide/CO), Sodium fluoride, Membrane-mimicking detergents 
(sodium dodecyl sulfate, lithium dodecyl sulfate), Nitric oxide donors (sodium nitroprusside, DETA 
NONOate), Amorphous aluminosilicates, Sodium nitrite, Tert-butyl hydroperoxide/t-BHP, Alloxan, 
Ammonium chloride, Anionic dyes (Congo Red, Thiazine Red, Thioflavin S), Aroclor 1254, Cobalt 
chloride, Magnesium chloride, 2,2'-azobis(2-methylpropionamidine) dihydrochloride/AAPH, 
Methylglyoxal/ Glyoxal, Disuccinimidyl suberate, Naphthazarin/5,8-dihydroxy-1,4-naphthoquinone/ 5,8-
dihydroxy-1,4-naphthalenedione, Pyrithiamine, Pyrogallol, Glyceraldehyde-3-phosphate/GAPDH, 
Ethylcholine mustard aziridinium ion/AF64A, 1-methyl-4-phenylpyridinium ion, 2,2'-dithiodipyridine, 
Aftin-4, Kaolin, Ozone, 2;3;7;8-tetrachlorodibenzo-p-dioxin. 
 The largest sub-category, by far, is the chemical compounds.  This sub-category is associated 
with roughly even impacts at the cellular, biomarker, and performance levels.  There is much less 
reported direct association at the disease level, for the selected references.  
IV-A2. Agricultural Chemicals 
 This sub-category emphasizes pesticides, herbicides, insecticides, and fungicides, and includes, 
e.g., Organochlorine pesticides, Organophosphate pesticides, 2,4,5-trichlorophenoxyacetic acid, 2,4-
dichlorophenoxyacetic acid, Agent Orange, Aldrin, Alkylphenolpolyethoxylates, APEOs, Arsenic, Beta-
hexachlorocyclohexane/beta-HCH, Bipyridyles, Carbamates, Carbofuran, Chlorfenvinphos, Chlorpyrifos/ 
CPF, Cycloheximide, Cypermethrin, Deltamethrin, Dichlorodiphenyldichloroethylene/DDE, 
Dichlorodiphenyltrichloroethane/DDT, Dichlorodiphenyldichloroethane/DDD, Dieldrin, Dimethyl 
parathion, Endosulfan, Famoxadone, Fenamidone, Glyphosate, Hexachlorobenzene, 
Hexachlorocyclohexane/HCH, Imidacloprid, Lindane, Maneb, Methamidophos, Methyl parathion, 
Neonicotinoids, Nonylphenol, Octylphenol, Paraquat, Parathion, Pyraclostrobin, Pyrethroids, Trans-
nonachlor, Trichlorfon/TCF, Trifloxystrobin, etc. 
 Adverse impacts span the cellular, biomarker, performance, and disease levels.  These chemicals 
impact the larger population through the food supply, and have devastating effects on the agricultural 
workforce.  Given the ubiquitous nature of agricultural chemicals and industrial/household chemicals in 
daily life, eliminating them will be challenging. 
IV-A3. Materials 
 The materials/particulates that constitute this category are broadly-based, and in many cases have 
become part of the average lifestyle.  Some examples include: 
-heavy metals (e.g., aluminum, arsenic, cadmium, calcium/Ca2/CaCl, calcium ionophore/A-
23187/calcimycin , cobalt, copper, iron, lead, manganese, mercury , methylmercury, selenium, tin, zinc, 
etc) 
-particulates (e.g., air pollution, surgical smoke, dust, etc) 
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-nanoparticles (e.g., iron nanoparticles, titanium dioxide nanoparticles, CdSe quantum dots, diesel exhaust 
nanoparticles, alumina nanoparticles, manganese oxide nanoparticles, copper nanoparticles, silicon 
dioxide nanoparticles, zinc oxide nanoparticles, silver nanoparticles, nickel nanoparticles, etc) 
 Impacts of these materials through diverse ingestion pathways cover the full spectrum of levels.  
Both metals and small sized particles have adverse effects.  When the two are combined, the synergy 
becomes problematical.  Metallic particles within the nanoparticle range (<100 nm) are able to cross 
many internal protective barriers, including the blood-brain-barrier (BBB), and cause myriad problems.  
While penetration of the BBB by nanoparticles is sometimes used for drug delivery, unwanted penetration 
(as reflected in the present study's references) can be quite harmful. 
IV-B. Physical/Mechanical 
 This sub-category includes ionizing radiation, non-ionizing non-visible radiation, non-ionizing 
visible radiation, sound radiation, temperature fields, and force fields.   
 The ionizing radiation component includes, e.g., gamma radiation (dental X-rays, gamma rays, 
etc), particle radiation (56Fe-particle radiation, cosmic radiation, HZE particle radiation), radionuclide 
pollutants (uranium, cesium, cobalt, radon).  The main impacts focus on the biomarker and performance 
levels, with some at the cellular levels and much less at the disease level. 
 The non-ionizing non-visible radiation component includes, e.g.,  electromagnetic fields at 
myriad frequencies, such as extremely low frequency/ELF-EMF, 900 MHz radiofrequency (RF), 
electromagnetic pulse/EMP, electroconvulsive shock/ECS, UV irradiation, etc.  The references selected 
emphasize biomarker level impact, then performance level impacts, and some links to AD. 
 The non-ionizing visible radiation component includes e.g., UV irradiation, photolysis of 1-(2-
nitrophenyl)ethyl sulfate, with impacts emphasizing Abeta production. 
 The sound radiation component includes, e.g., short-lasting impulse noise, chronic noise 
exposure, night-time aircraft noise, ultrasound sonication, etc.  While impacts are identified at the 
cellular, biomarker, and disease levels, Abeta generation and exacerbation are emphasized. 
 The thermal component includes, e.g., cold water hypothermia, cold water stress, heat shock, heat 
stress, heating, hyperthermia, etc, and impacts the cellular, biomarker, and performance levels.   
 The physical force component includes, e.g., blasts, blast traumatic brain injury, hippocampal 
injury, accumulated mechanical stress, spinal cord injury, frequent strong Valsalva maneuvers, long hours 
of repetitive heavy lifting, sequences of blows during the playing of a wind instrument, forceful and 
repetitive cough, bearing-down efforts during parturition, history of head trauma, etc.  The impacts cover 
all four levels, with perhaps added emphasis on AD.  
 The main components of this sub-category, the different types of physical fields with which we 
interact (electromagnetic, sound, temperature, pressure, force) are ubiquitous.  Avoiding exposure to these 
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emissions/interactions would require a major change in lifestyle (and probably location) for most people.  
The 'Other' category is small, and contains adverse effects from over- and under-exposure to oxygen. 
 
V.  Psychosocial/Socioeconomic 
 Psychosocial/Socioeconomic are those foundational causes that reflect personal problems, social 
interactions, larger societal interactions, and economic relationships.  Psychological and sociological 
stress were major causative factors; economic types of stress seemed to play less of a direct role.   
V-A. Psychological 
 This sub-category includes, e.g., chronic stress (repeated stress, chronic mild stress, chronic 
psychological stress, multiple chronic stresses, behavioral stress, childhood trauma, bereavement, chronic 
restraint stress, high job stress), low mental activity (low cognitively engaging activity, low purposeful 
activities, low leisure activities/low hobbies, low music/drawing/meditation/reading/arts/crafts), etc.  
Impacts seemed to spread out over all four levels. 
V-B. Sociological 
 This sub-category includes, e.g., social isolation (isolation, loneliness, living alone, unmarried, 
maternal separation, low social activity index, low social support at work, constricted life space), low 
education (illiteracy), etc.  Impacts cover all four levels, with emphasis on the biomarker, performance, 
and disease levels. 
V-C. Economic 
 This sub-category includes, e.g., economic stress (childhood socioeconomic circumstance), etc.  
In this small sub-category, impact focused on cognitive deficits. 
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Chapter 9 
CLASSIC AD PAPERS 
9A. Overview 
 This chapter presents the 500 most cited papers in the AD/dementia literature [1-500], and 
addresses the role of foundational causes research in the context of this highly-cited literature. 
 AD research spans a wide gamut involving mechanisms of pathology, genetics, diagnostics, 
treatments, therapy and maintenance, etc.  What is the role of risk factor identification and prioritization 
in this research spectrum?  In particular, are there objective measures by which importance of "causes" 
research can be estimated, especially foundational "causes"? 
 Citation analysis may offer some useful insights here.  In a citation analysis of three leading 
neuropsychology journals (Cortex, Neuropsychologia, and Brain) [501], it was shown that as citations 
increased in absolute amounts, the study type transitioned from the clinically oriented behavioral focus 
("soft" technology) to the correlates with more objective measurements ("hard" technology, such as non-
invasive diagnostics).  Similarly, in a study of highly and lowly cited Lancet articles [502], it was shown 
that clinical drug trials, especially large-scale, and high-technology analytic techniques dominated the 
highly-cited group.   
 For the present chapter, a Medline query was generated to identify the most highly cited AD 
papers.  The query focused on papers with AD or dementia in the Title and MeSH terms.  About 150,000 
papers were retrieved, arranged in descending order of times cited, and the 500 most cited papers were 
downloaded [1-500].   
 A taxonomy of types of papers was generated manually, and the 50 most cited papers were 
assigned to the different categories in the taxonomy.  Some interesting patterns were identified from these 
category distributions.    
9B. Results of Taxonomy Analysis 
 Three main categories covered ~95% of the papers.  Diagnosis/Assessment/ Testing and 
Mechanisms/Pathology were the two largest categories, followed by Genetics.  As article publication 
dates became more recent, higher technology was employed more frequentlyin diagnosis, chemical and 
physical analysis, and treatments.  This was true not only in the fifty most cited papers, but throughout the 
list of most highly cited. 
 In the 250 most highly cited papers, only two had determination of non-genetic risk factors as 
their central theme.  Reference [58] focused on correlation of plasma homocysteine levels with dementia, 
which would not be considered a foundational cause by our definition.  Reference [146] concluded that 
statins were associated with lower risk of dementia, which would place them more into the treatment 
category rather than foundational cause category.   
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 Further down the list, reference [302] concluded that high blood pressure and serum cholesterol 
were associated with increased AD risk, but these are not foundational factors.  Reference [437] showed 
the seed of the neurotoxic plant Cycas circinalis L played an important role in the etiology in the high 
incidence of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer-type dementia among the 
Chamorro population of the western Pacific islands of Guam and Rota.  This reference is the first among 
the highly-cited papers whose main theme was identification of a foundational cause of AD, and, even so, 
addressed a rare (and low technology) contributing factor globally. 
 There were a few references among the 500 most highly cited papers whose main themes allowed 
foundational causes to be "backed out" of the findings.  Reference [448] showed higher education levels 
were associated with lower dementia/AD risk, reference [452] showed similar results for leisure activities, 
reference [468] showed similar results for a socially integrated lifestyle, and reference [495] showed 
similar findings for physical activity. 
 What's wrong with this picture?  Of the five papers (in the 500 cited most highly) that could in 
any way be construed as having their main theme focused on identifying foundational causes of 
AD/dementia, one focused on a rare neurotoxic plant and four focused on "soft" behavioral technologies.  
Yet, the central findings of the present monograph are that the introduction of modern technology ("hard"  
technology) and its lack of regulation constitute a large share of the foundational causes of AD/dementia, 
especially in the Occupational/Environmental, Iatrogenic, and portions of the Lifestyle categories.  What 
is the reason for this disconnect? 
 There are myriad reasons for why papers are highly cited.  Two obvious reasons are the numbers 
of researchers in allied fields who are available to cite related research in their own published papers, and 
the papers that pass the review process and end up in the literature available to be cited.  In the latter case, 
the papers that are published in the journals with higher circulation would be seen by more readers, and 
would thus be more available for citation. 
 As was concluded in [503], research areas that receive strong funding from government and 
industry would attract more researchers.  And, it was concluded in [503] that journals would be more 
prone to accept papers (all else being equal) that had the prospect of garnering more citations, and thereby 
increasing the journal Impact Factor.  Thus, to some degree, there is a mutually re-inforcing sponsor-
journal-performer system at work that amplifies the importance of those research areas that receive strong 
government and industry sponsorship, and, at the same time, reduces the importance of research areas that 
receive weak support. 
 As was also concluded in [503], industry, and to some degree government as well, have little 
motivation to advertise potential adverse effects of modern technologies.  Thus, there is little motivation 
for government and industry to sponsor research in these areas.  There are few incentives for research 
performers to focus on adverse effects from (mainly) modern technologies, and strong incentives to focus 
either on the adverse effects from "soft" technologies or on the positive effects enabled by modern 
technologies.   
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 One can examine the medical approach to AD through two pathways: research and clinical.  The 
research pathway should have the following structure: cause--->research on pathology/mechanisms---
>research on treatments to exploit mechanisms.  The clinical pathway should have the following 
structure: diagnosis--->cause--->elimination of cause and/or treatment--->therapy--->maintenance.  
Unfortunately, from the perspective of what the research community views as most important, as 
evidenced by high citations, the research community downplays foundational causes relative to 1) 
research on mechanisms/pathology and 2) research on treatments.  Again, based on citations, this implies 
the clinical community places less emphasis on identification and elimination of causes, especially 
foundational causes, relative to emphasis on diagnosis, treatments, and therapy/maintenance.  Both the 
sponsor and performer communities need to re-orient research and clinical priorities, and place much 
larger emphasis on identifying and eliminating foundational causes, especially those related to adverse 
effects from modern technologies, as part as an overall AD prevention and reversal strategy.   
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